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Abstract
This thesis presents an investigation of ﬂuorescence resonance energy
transfer (FRET) as a reporting signal for protein-protein interactions. Quan-
titative optical assays to measure protein binding, conjugation and deconju-
gation are developed and results validated by conventional biochemical tech-
niques. The optical techniques developed provide fast, cheap, quantitative
and accurate alternatives to conventional methods. Fluorescent protein ﬂuo-
rophores ECFP and Venus-EYFP were chosen as they are a non-interfering
FRET pair and provide an inexpensive and convenient cloning-based labelling
method. The small ubiquitin-like modiﬁer SUMO and the SUMOylation path-
way leading to its conjugation to target proteins is investigated as a model
system. These assays are hence particularly relevant to research on post-
translational modiﬁcation and ubiquitin systems.
In protein-protein binding assays we utilise both steady-state and time-
resolved FRET detection to measure the equilibrium binding constant of the
well-characterised pair SUMO1 and Ubc9. An assay in multi-well plate format
is also presented, which uniquely enables repeat measurements under varying
conditions and under the addition of further substances. The multi-protein
binding interactions of the SUMOylation pathway including RanBP2 are anal-
ysed in binding inhibition assays. Our results clarify the role of RanBP2: a
covalent SUMO1-Ubc9 link is required for the formation of a trimeric complex,
although mutual binding sites are present on all three proteins. Furthermore,
the binding of SUMO1 and Ubc9 is disrupted by RanBP2, which may be an
essential step in transferring SUMO1 to its target protein. A FRET-based
kinetic study of this conjugation process to RanGAP1 is presented.
An assay to monitor the deconjugation of SUMO1 by speciﬁc proteases
is established using a doubly-tagged SUMO construct. This enables a quanti-
tative analysis of protease and substrate speciﬁcity based on real-time kinetic
data, a characterisation of crude cell extracts and a high-throughput screen
for protease inhibitors using FRET. A screen of the National Cancer Insti-
tute (NIC) diversity set for SenP1 inhibition reveals nine suitable compounds,
which are potential anti-cancer drugs.
The results of two further projects, the study of protein-protein binding
by measuring small refractive index changes and the autoﬂuorescence of normal
and neoplastic cervical tissue models are also presented. In the latter, principal
component analysis was used to systematically identify emission regions of
signiﬁcant variation between samples, enabling discrimination between healthy
and pre-cancerous tissue models.
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Introduction
Biophotonics, science at the interface of optics and biology, breaks down the
boundaries between traditional disciplines and is increasingly establishing itself
as an exciting ﬁeld in its own right. Limitations of currently available working
methods for cutting-edge research in biology provide the inspiration to look
beyond commercial systems, innovate, design and apply new assays. In this
thesis I set out to investigate, develop and apply techniques based on methods
commonly used by physicists in the characterization of organic semiconduc-
tors, such as absorbance, ﬂuorescence, energy transfer, spectral analysis and
fast time-resolved measurements. Many of these are already in use in speciﬁc
biological assays, however it is their continuous development which will aid the
1
vast research eﬀort of modern biology.
In this work, ﬂuorescence resonance energy transfer (FRET) between
ﬂuorescent proteins is exploited as a research tool in molecular biology. In the
last decade, FRET has gained popularity particularly in microscopy, as well as
in in vitro studies to back up data from conventional biochemical assays such
as Western blots. FRET is however most commonly used to conﬁrm binding
without the attempt of further quantiﬁcation. The assays we develop in this
work provide fast, cheap, quantitative and accurate alternatives for researchers
studying protein-protein interactions.
The ﬁrst investigation focussed on whether FRET between EYFP and
ECFP-tagged proteins provides a signal suitable for the quantiﬁcation of protein-
protein binding. Fluorescent proteins were chosen as they are minimally inva-
sive and provide an inexpensive cloning-based labelling method, which is con-
venient for molecular biologists using these assays. SUMO1 and Ubc9, a well
characterised binding pair, were used as model proteins in this blind study,
presented in chapter 4. Initially, a titration layout was chosen, as used in
isothermal titration calorimetry (ITC), and emission spectra recorded. FRET
results in an increase in the EYFP emission intensity, which we utilised as
a binding signal. A more versatile small-volume version in multi-well plate
format is presented in the same chapter. In chapter 5, time-correlated single
photon counting measurements of the ﬂuorescence lifetimes of the ﬂuorophores
are presented. FRET was detected as a decrease in ECFP lifetime, which was
used as a measure of binding.
The advantage of FRET as a reporter for a speciﬁc protein pair dur-
ing multi-protein interactions was used in chapter 6 to study the sequence
of binding events between SUMO1, Ubc9 and RanBP2 during the conjuga-
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tion of SUMO1 to target proteins. The inhibition of binding was evaluated
quantitatively and the role of RanBP2 investigated.
The conjugation of SUMO1 to target proteins is an essential step towards
their post-translational modiﬁcation and correct cellular function. In chapter
7 we present a conjugation assay modelled with ECFP-SUMO1 and EYFP-
RanGAP1, which enables the collection of real-time kinetic reaction data at
a high temporal resolution, and is a signiﬁcant improvement on conventional
gel-based techniques.
Following modiﬁcation, SUMO1 is deconjugated from the target protein
and recycled with the help of speciﬁc proteases. These cleave four amino
acids oﬀ SUMO1's C-terminus. Deconjugation and protease activity was in-
vestigated using a doubly-tagged EYFP-SUMO1-ECFP substrate in chapter
8. Furthermore, conformational changes in SUMO1 upon binding the inactive
protease dSenP1 were studied.
An exciting application of the deconjugation assays builds on the fact
that ﬂuorescence is an ideal high-throughput screening signal. In chapter 9,
EYFP-SUMO1-ECFP was used as a substrate to screen 2500 potential drugs
for inhibition of the protease SenP1, which has been found to be over-active
in prostate tumours.
Further work on protein-protein binding by optical methods was carried
out in a collaboration with Vanderbilt University, and is described in chapter
10. This study aimed to use refractive index changes as binding signals instead
of FRET, and enable a comparative study of the binding aﬃnity of proteins
with and without attached ﬂuorescent protein labels. A microchannel and
interferometer was built for this purpose and interference fringes analysed to
detect refractive index changes as small as 10−7.
3
An alternative use of ﬂuorescence, investigated in a collaboration with
the Bute Medical School, is presented in chapter 11. This work started as
an undergraduate project to investigate the ﬂuorescence signature of cervical
pre-cancer using cultured cells in epithelial raft models, which are free from
the variation observed in patients but provide a robust model of tissue changes
associated with cancer formation. Rafts modelling normal and neoplastic skin
were screened at a range of UV excitation wavelengths. Principal component
analysis was used to systematically identify emission regions of signiﬁcant vari-
ation between rafts.
The work described in this thesis was made possible by the Biophotonics
Platform Grant funded by the EPSRC for interdisciplinary work at the Uni-
versity of St Andrews. Research was carried out at the Bute Medical School
and the Division of Biomolecular Science, University of St Andrews, the Sir
James Black Centre for Interdisciplinary Research, University of Dundee, and
the Department of Chemistry, Vanderbilt University, Nashville, Tennessee.
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Background Literature and Theory
2.1 Fluorescence
Luminescence is the emission of light from an electronically excited substance
[2]. Excitation generally occurs by the absorption of a photon, but may occur
as a result of a chemical reaction in some molecules. Electronic excitation
takes place from the ground singlet state to a higher excited state, the na-
ture of which determines the occurrence of ﬂuorescence or phosphorescence
subsequently: from a singlet excited state, rapid decay to the ground state is
spin-allowed, leading to ﬂuorescence emission typically with lifetimes of 10−8
seconds, whereas from a triplet excited state transitions to the ground state
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are forbidden, leading to phosphorescence and lifetimes of up to seconds or
more [2].
Fluorescence is hence deﬁned as the rapid singlet-state emission of a pho-
ton by a molecule or atom, also called ﬂuorophore, activated by the absorption
of a photon, usually of shorter wavelength.
2.1.1 Application in Biology
One of the ﬁrst applications of ﬂuorescence in biological research was in envi-
ronmental sensors, for example ﬂuorescein which was used as a pH indicator.
Today, ﬂuorescence is central to a wide variety of intricate and commercially
available biotechnology assays.
During the cloning of recombinant proteins for instance, DNA is fraction-
ated in agarose gels and bands are routinely detected by the ﬂuorescence of
ethidium bromide contained in the gel, which is greatly enhanced upon binding
nucleic acids [2]. The exact sequence of bases in the DNA obtained is deter-
mined by means of functionalized ﬂuorescent tags that enable the automated
distinction between C, T, A and G bases [3, 4]. Subsequently, gene expression
can be monitored with ﬂuorescence by fusion of a green ﬂuorescent protein
(GFP) gene to the gene to be studied [5]. Speciﬁc detection technologies of
both DNA and protein fragments have been developed in ﬂuorescence-based
assays, where complementary fragments and antibodies are used on chips to
adsorb speciﬁc molecules in arrays. Further to the mere detection of ﬂuores-
cence, a vast variety of spectroscopy-based indicator tests have been developed
for quantitative measurements. Among those in common use are glutathion
and caspase assays [6].
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Scaling up from the molecular to the cellular level, ﬂow cytometry and
ﬂuorescence-activated cell sorting (FACS) have enabled the diﬀerentiation of
cell lines with signiﬁcant impact in immunology research and diagnostic testing
[7]. Here, the distribution of two distinctly labelled molecules in a collective of
cells allows the distinction between diﬀerent cell types and, accordingly, their
sorting.
The most obvious impact of ﬂuorescence in biology however has been in
microscopy. Particularly the speciﬁc labelling during live-cell imaging [8] has
contributed fundamental information about cell structure formation. Striking
examples include the visualisation of the actin skeleton, cell membranes and the
formation of chromosomal spindles during mitosis. An example is presented
in ﬁgure 2.1.1. Furthermore, the expression and subsequent cellular location
of speciﬁc proteins can only be monitored by in vivo ﬂuorescent tagging (see
section 2.5). This provides the unique opportunity to literally watch proteins
of interest wander around the cell and go about their business.
Cell death by apoptosis or necrosis is routinely monitored using ﬂuo-
rescence microscopy. Ethidium bromide and propidium iodide are membrane
impermeable dyes which enter cells only after cell death and stain the nu-
cleus red. Conversely, cell vitality is monitored with the green ﬂuorescent
carboxy-ﬂuorescein-di-acetate (CFDA) [10], which is membrane permeable and
quenched by the di-acetate group until activated by intra-cellular proteases,
which only operate when alive. In combination these two methods enable the
clear distinction between live and dead cells during toxicity tests.
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Figure 2.1: Nature cell of the month [9]: Two telophase HeLa cells express-
ing GFP-tagged human Aurora B. Microtubules are shown in red, inner-
centromere protein (INCENP) in blue, AuroraB-GFP in green and DNA in
white. The image is a maximum-intensity projection of a deconvolved 3D
data set acquired on a DeltaVision Restoration microscope (Applied Precision
LLC). Scale bar represents 5 µm.
2.1.2 Autoﬂuorescence of Tissue
The ﬂuorescence signature of tissue is of great interest but currently poorly un-
derstood due to a multitude of contributing ﬂuorophores, all of which are sensi-
tive to their immediate and often variable environment in vivo. The molecules
described below however dominate tissue autoﬂuorescence.
Fluorescence occurs naturally in proteins due to the aromatic amino
acids tryptophan, tyrosine and phenylalanine [2]. Tryptophan is sensitive to
quenching in its immediate environment (e.g. by disulphide groups, iodide,
acrylamide) and can hence be used to monitor conformational changes in pro-
teins [11]. The other two are quenched in the presence of tryptophan which
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is an abundant aminoacid and are hence less frequently observed. Further ﬂu-
orophores which contribute to the autoﬂuorescence of tissue include NADH,
which becomes non-ﬂuorescent upon oxidising, and increases in ﬂuorescence
emission upon binding certain proteins. Flavins on the other hand are ﬂuores-
cent only in the oxidised state and are quenched when binding adenine, while
derivatives of pyridoxal are pH sensitive [2].
The best characterized tissue components are collagen and elastin. The
main issue concerning research on tissue samples is not its autoﬂuorescence
but the high levels absorption due to DNA around 260 nm, protein around
280 nm and haemoglobin and melanin below 650 nm, leaving a small optical
window up until water absorption becomes signiﬁcant in the near infrared
range. Since tissue ﬂuorescence outside the optical window is re-absorbed
within millimetres, wavelength-matched probes are continuously developed for
in vivo studies. Furthermore, irradiation with light below 400 nm may lead to
irreparable tissue and DNA damage, such as erythema, also known as sunburn,
which can lead to neoplasia and cancer.
2.1.3 Fluorescent Probes
A signiﬁcant number of every-day items are ﬂuorescent. Among the better
known ones are the antimalarial drug and tonic water constituent quinine,
which was the ﬁrst description of a ﬂuorescent substance [12], and ﬂuorescein
which is routinely used by opticians to detect scratches to the cornea, and also
gives a green glow to antifreeze. Numerous ﬂuorescent probes are used in sci-
entiﬁc research and range from chemical dyes such as rhodamine to ﬂuorescent
proteins and semiconductor quantum dots [13]. Furthermore, companies such
as Invitrogen have developed a patented range of dye-based probes for speciﬁc
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applications which span the spectrum from UV to IR [14].
Clearly ﬂuorescence is not the only characteristic a material required to
make a successful ﬂuorescent probe with application in biological research.
Further important qualities are:
1. a high quantum yield providing a high ﬂuorescence intensity
2. spectral distinctiveness from background ﬂuorescent materials
3. resistance to photobleaching,
4. insensitivity to the solvent environment (unless this is to be studied),
5. speciﬁcity for labelling the molecule of interest, such as the sulphydryl
group of cysteine
6. non-interference with conformation and function of the tagged molecule
7. non-invasive introduction to the experiment
8. non-toxic properties when used in live cells.
These criteria are met by the careful engineering of eﬃcient ﬂuorophores
in a range of colours and for speciﬁc labelling strategies. As for biocompat-
ibility, encapsulation and surface coating of for example quantum dots are
common strategies [13]. However the extra layer comes at a cost of label size
- as a result "dots" can be as large as 500 nm.
Labelling with dyes such as the common cyanine Cy3 and Cy5 [15] re-
quires just one exposed cysteine residue at the position where the protein
under study is to be tagged. Any others must be substituted with serines
by site-directed mutagenesis prior to chemical labelling, which can be a time-
consuming and potentially detrimental process. Furthermore, if a compound is
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to be doubly tagged with two diﬀerent cysteine dyes to generate a FRET sub-
strate, several puriﬁcation steps are necessary to ensure complete labelling by
both dyes. Fluorescent proteins such as GFP mutants however can be directly
expressed as fusions with the proteins of interest, tagged on either or both
terminae. Fluorescent proteins are also naturally biocompatible, as discussed
in section 2.5.
2.1.4 Absorption of Electromagnetic Radiation
Absorption of electromagnetic radiation in the ultraviolet and visible ranges
results in the electronic excitation of molecules, i.e. an intramolecular charge
shift from the lowest energy ground state. The wavelength of absorbed photons
depends on the structure of the molecule and the energy required to shift to an
excited state. Absorption of certain wavelength ranges of the visible spectrum
by materials and scattering of the non-absorbed light leads to our observation
of colour.
The eﬃciency of absorption is also a molecular property, which is quanti-
ﬁed by the wavelength-dependent molar extinction coeﬃcient ε(λ) inM−1cm−1.
The extinction coeﬃcient ε(λ) is hence quoted for a speciﬁc wavelength in liter-
ature. In bulk measurements at low optical densities, the fraction of absorbed
illumination is proportional to the concentration of the absorbing substance.
Excitation is also possible by the simultaneous absorption of two photons of
lower energy, however the probability of simultaneous absorption is very small.
In a cuvette of optical path length d, the light intensity dI absorbed per
path length dx will depend on the intensity of incident light I0, the concen-
tration of the solution c (in M , or mol cm−3) and the extinction coeﬃcient ε
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[2].
dI
dx
= −Iεc (2.1)
which, integrating within the limits I = I0 at x = 0 and I at x = d, gives the
Beer-Lambert law [2]:
log
I0
I
= εcd = A (2.2)
The absorbance A is hence a measure of optical density, and relates the
illumination intensity incident on the cuvette I0 to the transmitted intensity
I. According to the Beer-Lambert law, the optical density is linearly propor-
tional to the concentration of the absorbing molecules. This proportionality
however breaks down at high optical densities, when second-order terms be-
come signiﬁcant and the linear approximation breaks down. Hence, samples
of optical densities below 0.1 should be used to achieve accurate absorbance
readings and also avoid the saturation of ﬂuorescence detectors.
2.1.5 Emission
A Jablonski diagram of energy levels and the processes of excitation and emis-
sion is presented in ﬁgure 2.2. Here, irradiation by blue light of frequency hν
leads to excitation from the ground state energy level s0 to a higher excited
state. A very rapid decay to the lowest vibrational level of this state is followed
by a return to the electronic ground state, accompanied by the emission of a
photon. Return to the ground state generally occurs with a lifetime of 10−9
- 10−8 s [2]. Fluorophores have characteristic absorption and emission energy
bands that are deﬁned by the energy gaps between their ground and excited
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states.
Figure 2.2: Jablonski diagram showing ﬂuorescence excitation and emission
(vertical arrows). The ground state energy level (s0) and the ﬁrst excited sin-
glet state (s1) are depicted with vibrational sub-levels as parallel lines. Life-
times are indicated where appropriate.
Electronic excitation and subsequent relaxation can lead to the accession
of low energy, long-lived "dark" states from which repeated excitation is not
possible. This leads to characteristic blinking behaviour of single molecules,
which is particularly observed in ﬂuorescent proteins [16, 17]. The non-ﬂuorescent
state of a molecule can last for minutes, and this property can be used to re-
searchers' advantage: molecules can be selectively switched oﬀ and on again
[18, 19].
Repeated electronic excitation eventually leads to photobleaching and
destruction of molecules. The tolerance to irradiation varies, however stable
organic dyes will typically absorb and re-emit up to 100 photons per millisec-
ond and photodestruct after 105 − 106 absorption-emission cycles. Unwanted
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photobleaching will not aﬀect bulk measurements under low illumination as
the relative number of aﬀected molecules is very small. Photobleaching how-
ever is utilized as technique in its own right to monitor the ﬂux of ﬂuorescent
probes in ﬂuorescence recovery after photobleaching (FRAP) microscopy of
cells [20].
2.1.6 Lifetime and Quantum Yield
A further characteristic is the ﬂuorescence lifetime, a measure of the typical
time interval between the absorption of a photon and its re-emission. The
lifetime τ is inversely proportional to the radiative ﬂuorescence emission rate
κr and the sum of the rate constants of all other non-radiative relaxation
processes ∑κnr:
τ =
1
κr +
∑
κnr
(2.3)
.
Fluorescence emission is hence only one of several potential pathways for
the loss of excitation energy. Excited ﬂuorophores can be deactivated by a
number of competing processes with diﬀerent, but not necessarily independent
decay rates:
1. radiative ﬂuorescence emission (at a rate κr)
2. loss as heat by internal conversion (κIC)
3. transfer to a quencher (κQ)
4. triplet state formation through intersystem crossing (κISC)
5. ﬂuorescence resonance energy transfer (κFRET )
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Details of these processes can be found in Lakowicz [2], while ﬂuorescence
resonance energy transfer (FRET) is described in detail in section 2.2.
Fluorescence emission is less eﬃcient at higher temperatures, where rates
of other processes (κIC , κISC , etc.) are increased. Diﬀusional collisions with
quencher molecules (such as oxygen and acrylamide) also lead to a decrease
in emission intensity. The quantum yield, the ratio of the number of emitted
photons to the number of absorbed photons is a further characteristic:
Q =
Nemittedphotons
Nabsorbedphotons
=
κr
κr +
∑
κnr
(2.4)
where Q is the quantum yield, κr is the ﬂuorescence emission rate constant and∑
κnr is the sum of the rate constants of all other energy decay processes. The
quantum yield hence has a theoretical maximal value of Q = 1.0 and provides
a measure of ﬂuorescence eﬃciency and an estimate of losses discussed above.
2.2 Fluorescence Resonance Energy Transfer (FRET)
2.2.1 FRET Basics
Fluorescence involves the absorption of light by a ﬂuorophore molecule and
its re-emission, generally following vibrational losses, at a longer, lower energy
wavelength. If this emission overlaps the absorption spectrum of a second
molecule in close proximity, radiationless transfer of energy may occur instead
of emission. This near-ﬁeld dipole-dipole interaction is called ﬂuorescence res-
onance energy transfer (FRET), and is observed as a decrease in emission
intensity from the higher energy, bluer "donor", and an increase in emission
from the lower energy, redder "acceptor" ﬂuorophore. For any given donor-
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acceptor pair, the energy lost by the donor is gained by the acceptor.
In a comprehensive review, DosRemedios [21] lists the advantages of using
FRET in biomolecular research: experiments are relatively quick, ﬂuorimeters
comparatively inexpensive; it is more sensitive than most other methods of
examining molecular structure, and can detect distance changes as small as 2
nm in proteins, using a wide range of solvent conditions and concentrations.
Figure 2.3: Jablonski diagram showing FRET between CFP and YFP. All
radiative energy transfers are shown in solid colour; conventional absorption
and emission that do not occur with FRET are semi-transparent; lifetimes of
energy transfer are indicated where appropriate.
Figure 2.3 illustrates the vibrational energy states and transitions of two
individual ﬂuorescent molecules and energy transfer [2].
2.2.2 FRET Eﬃciency
The classical derivation of the eﬃciency of FRET outlined here is based on
the publication by Hans Kuhn [22]. Treating the dye molecules as classical
linear harmonic oscillators, energy transfer may be described by examining
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the absorption of an acceptor A at a rate bA in the radiation ﬁeld of a donor D
absorbing at a rate bD. Assuming the contribution of A to the radiation ﬁeld
of D is negligible, the amount of quenching of the ﬂuorescence of D by A can
be described as a decrease in ratio of the initial quantum yield of D, (Q0) to
that with A present at a distance R (QR).
Q0
QR
=
bD + bA
bD
(2.5)
Equation 2.5 can be re-expressed in terms of the power loss of D when A is
absent (L0) and the power absorbed by A when it is present at a distance R
(LR):
Q0
QR
=
L0 + LR
L0
(2.6)
L0 is a function of the donor's frequency νD, dipole moment µD and
quantum yield Q0, the refractive index n and the speed of light in vacuum c:
L0 = (2piνD)
4µ2Dn/3Q0c
3, (2.7)
and
LR = aF
2
0 (2.8)
where a = 3(ln10/NA)(cn/8pi)εA(νD) is a function of the extinction coeﬃcient
of A at the oscillator frequency εA(νD) and NA is Avogadro's constant. F0 is
the amplitude of the donor electric ﬁeld component in the direction of A. In
the near ﬁeld, when r < λ/(2pin), the emission of a Hertzian dipole takes
the form F0 = µDκ/R3n2, where κ is a geometrical factor which provides a
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measure of the orientation of the dipole moments of A and D with respect
to the direction of R. Theoretically, values of κ2 can range between 0 and
4, but if the probes possess full rotational freedom, κ2 = 2/3. In this work,
the ﬂuorescent proteins are attached to ﬂexible terminae, which enable some
mobility. The exact value of κ2 is however only required in experiments where
FRET is used to determine distances.
Combining equations 2.7 and 2.8 in equation 2.6 gives
Q0
QR
= 1 + (
R0
R
)6 (2.9)
with R60 = (9ln10/128pi5)(κ2 εA(νD)cQ0/NAν4Dn4) for radiationless energy trans-
fer in the case of a narrow ﬂuorescence band of frequency νD.
The rate of energy transfer from a donor D to an acceptor A at distance
R can be derived from equation 2.9 by substituting expressions of the quantum
yields in terms of the radiative decay rate of the donor (κr), the non-radiative
decay rate (κnr) and energy transfer rate (κFRET ). The quantum yields are
Q0 =
κr
κr + κnr
(2.10)
and
QR =
κr
κr + κnr + κFRET
(2.11)
which gives
Q0
QR
= 1 +
κFRET
κr + κnr
= 1 + κFRET · τD (2.12)
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where τD is the donor lifetime. Equating equations 2.9 and 2.12 gives the rate
of energy transfer as a function of donor lifetime and distance:
κFRET =
1
τD
(
R0
R
)6 (2.13)
The eﬃciency of energy transfer is the fraction of photons absorbed by
the donor that are transferred to the acceptor [2], which is given by
E =
κFRET
κFRET + τ
−1
D
(2.14)
and, by substituting with equation 2.13
E =
R60
R60 +R
6
(2.15)
The eﬃciency of energy transfer for a given pair of ﬂuorophores is hence highly
sensitive to the distance between them.
The constant R0 and the R−6 dependency were ﬁrst derived by Theodor
Förster in 1948, naming R0 the Förster Radius, the distance at which the
eﬃciency of transfer is by deﬁnition 50% [23]. Equation 2.15 is plotted in
ﬁgure 2.4. Reported R0 values range from 0.34 to 9 nm, indicating the scale
at which FRET can be exploited [21].
For the more general case of an arbitrary ﬂuorescence distribution the
overlap integral Jda of the donor emission with the acceptor absorption spec-
trum replaces ε/ν4D in the narrow-band derivation outlined above. The spectral
overlap integral Jda is deﬁned as
Jda =
∫
FD(λ)εA(λ)(λ)
4dλ∫
FD(λ)dλ
(2.16)
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Figure 2.4: Graph showing the energy transfer eﬃciency as a function of dis-
tance for a Förster radius R0 of 5 nm, the literature value for ECFP and Venus
YFP [24].
where FD(λ) is the donor ﬂuorescence per wavelength unit and εA(λ) is the
extinction coeﬃcient of the acceptor at wavelength λ. The units are M−1cm−1
when λ is expressed in cm.
The FRET eﬃciency can be determined experimentally from the ﬂuores-
cence intensity I using
E = 1− IA
I0
(2.17)
where IA and I0 is the emission intensity of a given concentration of donor in
the presence and absence of acceptor respectively.
2.2.3 Time-resolved FRET
The ﬂuorescence lifetime of the donor ﬂuorophore is inversely proportional to
the rate of decay from the excited state back to the ground state by emission of
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a photon, and also depends on the rates of further non-radiative energy losses
such as FRET:
τ =
1
κr + κFRET + κnr
(2.18)
where κr is the rate of radiative emission, κFRET is the rate constant of energy
transfer to an acceptor as described by equation 2.13 and κnr is the sum of
rate constants of non-radiative energy loss processes as described in section
2.1.6. As a result, the time-resolved trace can be ﬁtted by exponential decays.
The occurrence of FRET leads to the additional κFRET decay rate and hence
a change in the lifetime of the donor ﬂuorophore τD. FRET can hence be
quantiﬁed by measuring the donor lifetime in the presence and absence of an
acceptor. The FRET eﬃciency can subsequently be calculated from ﬂuores-
cence lifetimes as follows:
E = 1− τDA
τD
(2.19)
where τDA and τD are the ﬂuorescence lifetimes of the donor in the pres-
ence and absence of the acceptor respectively.
The distribution of acceptors around a donor molecule can be determined
from time-resolved measurements by ﬁtting to the 3-dimensional Förster Equa-
tion [25]
I(t) = I(0)exp[− t
τ0
− 2γ[ t
τ0
]1/2] (2.20)
where γ = [A]/CA is the ratio of acceptor concentration [A] and the critical
acceptor concentration CA = 3/(2pi3/2NAR30 and τ0 is the unquenched donor
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lifetime. In a similar expression for a 2-dimensional case of a planar distribu-
tion of acceptors the square root term is replaced by a cube root.
Time-resolved measurements are performed by repeatedly exciting the
solution of molecules, for example with a short pulsed laser, and measuring the
time intervals after which photons are emitted from the sample. This method is
limited by the available pulse duration; only ﬂuorophores with lifetime values
similar or greater than the response time of the experimental setup can be
measured. A major advantage of ﬂuorescence lifetime measurements is that, as
opposed to emission intensities, the lifetime is not aﬀected by the ﬂuorophore
concentration. This feature makes time-resolved measurements particularly
attractive for in vivo studies [26]
2.2.4 Applications of FRET in Biology
The eﬃciency of energy transfer between two probes is strongly distance-
dependent in a range up to 10 nm. This scale makes it an ideal signal for the
study of biomolecules, since it is comparable to the dimensions of many pro-
teins, the thickness of biological membranes and short DNA strands. Hence,
conformational changes and interactions of two labelled biomolecules which
result in donor-acceptor distance changes modify the transfer eﬃciency and
generate measurable signals. The unique ability of FRET to answer questions
in molecular biology has led to a research boom and a plethora of publications.
Numerous reviews provide good overviews of the ﬁeld [2, 27, 28], and some key
concepts and applications are well worth a concise description here.
The ﬁrst conceived biological application of FRET was as a "spectro-
scopic ruler" to measure distances between sites in proteins [29, 30], using
equation 2.15 and the R0 value of speciﬁc probes as well as assumptions about
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their rotational freedom. Subsequent research has been extensively reviewed
[31, 32, 33]. As a result, structural information about proteins as well as
their conformational changes have been resolved [34, 35], and similar methods
applied to measurements of RNA and DNA molecules [36, 37, 38]. The devel-
opment of equipment such as multi-well plate readers and probes have enabled
integration of FRET-based techniques in genomics [39] and immunoassays [40]
and have made FRET a popular signal for high-throughput screening (HTS)
assays [41, 42, 43, 44]. The advantages of ﬂuorescence-based techniques in
HTS are clearly the speciﬁc, real-time signals and hence the possibility to de-
velop small-volume assays with instantaneous readout of quantitative results.
Screening systems based speciﬁcally on time-resolved FRET have also been
developed [45], reviewed [46, 36, 47, 48, 49, 45] and marketed (CysBio [50],
Wallac Oy [51], LANCETM [52]). Most assays are based on long lifetime lan-
thanide donors [53, 54, 55, 56], which carry the advantage that time-gating of
the long-lived donor and acceptor signals achieves high sensitivity by reducing
background in cell-based assays.
FRET has been similarly popular in microscopy since the development
of genetically encoded ﬂuorescent proteins, enabling studies of protein expres-
sion, localization and interaction in live cells [57, 58, 59, 60] and speciﬁcally
in cellular membranes [61, 62]. Fluorescence lifetime imaging microscopy
(FLIM) is the time-resolved equivalent. Since the lifetime is not inﬂuenced
by scattering in biological matter, images from greater depths can be obtained
[63]. FRET and FLIM have been successfully combined in cell imaging stud-
ies [64, 65, 66]. Furthermore, technical advances in ﬂuorescence microscopy
and spectroscopy have enabled measurements of single labelled biomolecules
[67, 68, 69]. The main techniques used are wide-ﬁeld epiﬂuorescence or total
internal reﬂection excitation, confocal and near-ﬁeld optical scanning micro-
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scopies [70]. Notable experiments include the quantiﬁcation of FRET on sin-
gle DNA [71] strands, followed by studies of structural changes in biomolecules
[67, 72, 73], ﬂuorescent-protein-based protease assays using two-photon excita-
tion [74] and ﬂuorescence-aided molecule sorting (FAMS) by alternating-laser
excitation [75].
All applications of FRET rely on the complete labelling of all molecules
at the correct sites. This is not trivial during chemical labelling, particu-
larly when dual-tagging molecules. Furthermore, the ﬂuorescent probes must
not interfere with the activity of the biomolecule, since labelling may cause
disruption ranging from steric hindrance to denaturation and complete loss
of functionality. If FRET is to be routinely used by molecular biologists, a
straightforward, non-invasive labelling method is essential, such as enabled by
the use of ﬂuorescent proteins 2.3.
2.3 The Green Fluorescent Protein GFP
2.3.1 Origin and Applications of GFP
The green ﬂuorescent protein (GFP) [76] has been a major contributor to
the integration of optical techniques into biomolecular research over the last
decade, and has become indispensable in live cell studies of protein localiza-
tion [77] and interaction [78]. GFP stems from the colourless hydromedusa
Aequorea Victoria, an abundant deep-sea jellyﬁsh. Bioluminescence occurs
only at the rim of the bell, and appears as a string of green lights when the an-
imal is disturbed. It is not known what biological function the bioluminescent
capabilities serve. Blue luminescence is actually produced by Ca2+-stimulation
of aequorin , but energy transfer leads to emission by GFP [79].
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While the protein was initially extracted together with aequorin in 1962
[80], it was not until the corresponding gene was identiﬁed thirty years later
[81] and expressed in bacteria [5] that its potential as a non-invasive, non-toxic
intracellular marker could be exploited. The wild-type GFP is only weakly
ﬂuorescent, and also dimerizes and photobleaches. However, several mutants
of GFP with improved ﬂuorescence eﬃciency and stability have been devel-
oped and new ﬂuorescent proteins based on other organisms are continuously
discovered.
Figure 2.5: GFP ribbon structure [82], ﬂuorophore sequence and chemical
structure [83]
GFP is a barrel-shaped protein made of 236 amino acids and molecular
weight 26592 kDa. It is made up of a sheet of 11 β-strands [84] enclosing
a ﬂuorophore composed of 6 post-translationally modiﬁed amino acids [85]
as shown in ﬁgure 2.5. Ultrafast ﬂuorescence lifetime measurements suggest
that proton transfer is involved in the formation of the excited state, and that
several intermediate states are involved in the relaxation process [83, 86, 17].
Peculiarly enough, it is the non-ﬂuorescent intermediate states that are of
advantage in microscopy [16], and the further development of photoactivatable
[18] and photoswitchable [87] proteins has enabled the selective tracking of
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proteins in live cell microscopy.
2.3.2 GFP Mutants: ECFP and Venus-EYFP
The use of GFP has been signiﬁcantly extended through the development of
mutants with improved stability and quantum yield, but also diﬀerent spectral
properties [88, 89]. An initial aim was to tune GFP to excite at available laser
wavelengths. Mutants of GFP as well as a multitude of ﬂuorescent proteins
derived from corals (see ﬁgure 2.6) have subsequently enabled multi-colour
microscopy and FRET experiments [6, 40, 90, 91, 92]. Numerous reviews
describe the development of ﬂuorescent proteins and a wide variety of their
applications, as well as their suitability as FRET pairs [8, 24, 93].
The enhanced cyan ﬂuorescent protein ECFP [24, 90] and yellow ﬂuores-
cent protein Venus EYFP [94, 95] used in this work are a common FRET pair,
with a literature Förster radius of 5nm. The ECFP gene contains six amino
acid substitutions. The Tyr-66 to Trp substitution deﬁnes the double-peaked
ECFP ﬂuorescence excitation (435 nm, 453 nm) and emission (478 nm, 501
nm). The other ﬁve substitutions (Phe-64 to Leu; Ser-65 to Thr; Asn-146 to
Ile; Met-153 to Thr; and Val-163 to Ala) enhance the brightness and solubility
of the protein, primarily due to improved folding properties and eﬃciency of
chromophore formation. Similar substitutions apply to Venus-EYFP (Phe-46
to Leu; Phe-64 to Leu; Met-153 to Thr; Val-163 to Ala; Ser-175 to Gly) which
lead to excitation and emission maxima of 515 nm and 528 nm. The literature
extinction coeﬃcient of ECFP is 28750 M−1cm−1 and its quantum yield 0.4
[90]. The values for Venus EYFP are 92200 M−1cm−1 and 0.61 respectively
[94].
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Figure 2.6: Photographs in white light (top) and UV-excited ﬂuorescence (bot-
tom) of ﬂuorescent proteins [96]: mHoneydew, mBanana, mOrange, tdTomato,
mTangerine, mStrawberry, mCherry.
2.4 Introduction to Protein Research
2.4.1 Protein Basics
Proteins are linear polymers made up of up to nineteen distinct amino acids
and one imino acid. They are assembled in cells by ribosomes in a speciﬁc
sequence which is determined by the corresponding gene and covalently linked
by peptide bonds to form the -NCCNCC- protein backbone. Amino acids
diﬀer in attached side-chains. Their sequence deﬁnes the primary structure
of the protein and determines the folding into alpha helix and beta sheet
domains. This secondary structure further folds into the three-dimensional
tertiary structure which represents the most thermodynamically stable confor-
mation for the molecule in solution, and results from non-covalent interactions
between the various amino acid side-chains. Speciﬁc exposed surfaces are in-
volved in interactions with other molecules including proteins. While proteins
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are assembled by ribosomes following the translation of RNA, the formation
of their functional structure and speciﬁc cellular localization often requires
post-translational modiﬁcation by other proteins, known as modiﬁers [97]. In-
deed, a variety of modiﬁcations may occur between synthesis and degradation,
which may include cleavage of the protein chain or the attachment of molecular
groups to speciﬁc aminoacids.
Ubiquitin is the most heavily researched of the protein modiﬁers [98, 97,
99]. Its known substrates include regulators of cell division, growth regulators,
tumor suppressors, surface receptors, ion channels and transcription regula-
tors. The physiological consequence of such a diverse substrate speciﬁcity is
that ubiquitin inﬂuences a huge spectrum of basic cellular processes, including
regulation of cell response to stress and extracellular modulators, cell mor-
phogenesis, neuronal network activity, membrane permeability, DNA repair,
biogenesis of organelles, and the regulation of immune and inﬂammatory re-
sponses. Consequently, post-translational modiﬁcation pathways are essential
to cell viability, while their malfunction is life-threatening, with pathological
manifestations including rheumatoid arthritis, Alzheimer's disease, diabetes
and cancer.
2.4.2 Protein-Protein Binding
Protein molecules in solution are in constant motion and frequently collide
with one another when in physiological concentrations. Molecules with closely
matched surfaces can potentially form more stable associations. These are
mediated by non-covalent interactions which form at close range, such as:
• Lipophilic interactions of exposed hydrophobic amino acids of proteins,
which will tend to cluster together and repell the hydrogen bonded ae-
28
2.4. INTRODUCTION TO PROTEIN RESEARCH
queous solvent.
• Ionic bonds, which form due to attraction between oppositely charged
groups
• Hydrogen bonds, which form between electronegative and electropositive
atoms, such as when the hydrogen of an amino group is shared with an
oxygen atom
• Van der Waals forces, which are weak attractions between atoms at close
range
In water these non-covalent bonds are at least an order of magnitude
weaker than the covalent peptide bonds which hold amino acids together.
Many of these bonds must form in order to overcome random thermal motions
and facilitate binding. This requirement leads to the speciﬁcity of interactions
between proteins via distinctive binding surfaces.
A measure of the strength of association can be derived from the law of
mass action for a reversible, bimolecular reaction of the form [A]+ [B]
 [AB]
with association and dissociation rate constants of k+ and k− with dimensions
of M−1s−1 and s−1 respectively [100]. The number of association and dissoci-
ation events per unit time are N+ = k+[A][B] and N− = k−[AB], where [A]
and [B] are the free concentrations of each protein. Equilibrium is reached
when N+ = N−, i.e. when the rate at which AB complexes are formed equals
the rate at which they dissociate and k+[A][B] = k−[AB].
The equilibrium binding constant is deﬁned as
Kd =
k−
k+
=
[A][B]
[AB]
(2.21)
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From equation 2.21 follows that when [B] = Kd, then [A]/[AB] = 1 and 50%
of species A is bound in the form [AB]. The fraction of species B bound in
the form AB as a function of A is hence given by
FB =
[AB]
[B] + [AB]
(2.22)
which, when combined with equation 2.21 gives
FB =
[A][B]/Kd
[B] + [A][B]/Kd
=
[A]
Kd + [A]
(2.23)
Hence, the concentration of bound complex can be expressed as a function of
[A]:
[AB] =
[Bmax][A]
Kd + [A]
(2.24)
where Bmax is the maximum concentration of bound complex, which in a titra-
tion of species A into species B will be limited by the ﬁxed initial concentration
of [B]. Equation 2.24 is plotted in ﬁgure 2.7.
An interaction will follow equilibrium binding relations providing that
• all A and B are equally accessible
• proteins are in either bound or free states - partial binding is not ac-
counted for
• A and B share a single binding site
• binding is fully reversible; proteins are not altered
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Figure 2.7: Hyperbolic binding curve for one binding site from which the
binding constant Kd can be determined as indicated. The saturation level is
indicated as Bmax [100]
Equation 2.24 may be linearized to give
[AB]
[A]
= − 1
Kd
[AB] +
[Bmax]
Kd
(2.25)
.
which gives a Scatchard plot of bound/free versus free protein concen-
trations and the binding constant from the inverse gradient. However ﬁtting
experimental data is not advised in the linear form as a linear ﬁtting procedure
will weigh data points unevenly and result in large errors [100].
In order to measure the aﬃnity of proteins, a detectable signal of as-
sociation is required. This is not trivial considering the molecular scale of
this interaction: the proteins under investigation here are approximately 2
nm in length. The technique most accepted as a standard of measurement of
binding in free solution is isothermal titration calorimetry (ITC)[101]. ITC
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Figure 2.8: Scatchard plot of the data from ﬁgure 2.21 from which the binding
constant Kd can be determined as indicated. [100]
relies on measurements of heat change upon binding as a small volume of con-
centrated binding partner is titrated into a ﬁxed amount of the other. High
concentrations (10 - 200 µM) are required in order to achieve an acceptable
signal-to-noise ratio for quantitative analysis.
Other methods for measuring binding aﬃnity rely on the immobilization
of at least one binding partner and include surface plasmon resonance (SPR)
[102], for which one species is immobilised on the resonant surface, and scin-
tillation binding assays [103] where binding partners are tagged radioactively
or attached to scintillating beads. More traditional biochemical methods such
as glutathion aﬃnity chromatography rely on the fractionation of samples by
polyactrylamide gel electrophoresis (PAGE) which is both laborious and diﬃ-
cult to quantify. Fluorescence-based approaches fair better [102] with real-time
signals from tryptophan quenching upon binding [104] or polarized measure-
ments of the anisotropy of a single label which changes upon binding when
the increased size of the bound complex aﬀects the rotational mobility of the
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tag. Pioneering anisotropy experiments studied myosin light-chain kinase ac-
tivation by calmodulin [105] and binding of the tryptophan repressor protein
to DNA [106].
2.4.3 Competitive Binding and Inhibition
Protein-protein binding commonly involves the simultaneous or sequential
binding of several proteins in a biochemical pathway. In an example of the
case of sequential binding, protein C may disrupt the AB complex due to a
strong aﬃnity to a shared binding site on either A or B, or just by providing
steric hindrance to their interaction at a diﬀerent site on either protein. The
concentration [C] at which 50% of the AB complex is dissociated is called the
inhibitory concentration IC50. The inhibition constant Ki provides a measure
of the interaction and is equivalent to the binding constant of the AB complex
(with binding constant Kd) with protein C. Ki is readily derived from the
IC50 value with the following relation [100]:
Ki =
IC50Kd
[AB] +Kd
(2.26)
.
2.4.4 Enzyme Activity: Michaelis-Menten Kinetics
Processes which modify the covalent bonds of the protein backbone by ex-
tension or cleaving are commonly catalyzed by enzymes. In bulk, enzyme-
dependent modiﬁcation of the initial substrate S to the ﬁnal product protein
P occurs at a rate that depends on the relative concentrations of enzyme and
substrate, but also on temperature and solvent properties. A useful method of
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determining the characteristic activity of an enzyme with respect to a speciﬁc
substrate is the analysis of initial reaction rates at diﬀerent substrate concen-
trations [S], while keeping all other variables constant, using the Michaelis-
Menten relation [100]:
[P ] =
[vmax][S]
Km + [S]
(2.27)
Figure 2.9: Michaelis-Menten analysis from which the constant Km can be
determined as indicated. The saturation level is indicated as Vmax [100]
2.5 The SUMO Pathway
2.5.1 SUMO
The small ubiquitin-like modiﬁer SUMO1 (101 amino acids, 11558Da molecu-
lar weight, also known as sentrin1, UBL1, PIC1, GMP1, SMT3c) is a human
post-translational modiﬁer which shares 18% of its primary sequence with
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Figure 2.10: Schematic diagram of SUMOylation representing the matura-
tion, conjugation, and deconjugation reactions for ubiquitin and SUMO1 [99].
SUMO1 precursor requires the removal of an inhibitory C-terminal extension
(indicated by scissors). The mature modiﬁer is attached to a substrate by
a three-step mechanism. In the ﬁrst step, the speciﬁc activating enzymes
SAE1/2 form ATP-dependent thiolester bonds between cysteine residues and
the conserved C-terminal glycine of SUMO1. In the second step, the speciﬁc
conjugating enzyme Ubc9 accepts the activated modiﬁer via a transesteriﬁca-
tion reaction to a cysteine residue. The ﬁnal step involves the formation of
an isopeptide bond between the -amino group of the target substrate lysine
and the terminal glycine of the modiﬁer. The conjugation of some substrates
is known to require an additional E3 ligase protein such as RanBP2. The
deconjugation reactions are catalyzed by speciﬁc isopeptidases that cleave the
bond between the substrate and the modiﬁer, also indicated by scissors.
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ubiquitin. The SUMO1 pathway has been an intensively researched ﬁeld over
the last decade, owing to its importance in a diverse range of cellular functions
including subcellular transport, nuclear structure formation, protein stability
and transcriptional regulation. Two further SUMO1 homologues, SUMO2 and
SUMO3 have also been identiﬁed, but their requirement in mammals is cur-
rently poorly understood. SUMOylation has been extensively summarized and
reviewed [107, 108, 109, 97, 110, 99, 111]. A book dedicated to the topic of
SUMOylation has also been published [98].
A unique feature of ubiquitin and ubiquitin-like proteins such as SUMO
and NEDD8 is that they all contain a diglycine sequence at the C terminus
that is capable of conjugating to other proteins, but which is initially extended
by inhibitory peptides. C-terminal hydrolase proteases cleave these peptides
to reveal the active diglycine motif, a process called maturation. A further
similarity is revealed in the pathways, as they are conjugated by homologous
enzymes, have similar conjugation chemistry, and share the same tertiary fold
known as the ubiquitin superfold. In contrast to other common modiﬁcations
by covalent attachment and removal of small chemical moieties such as phos-
phoryl, methyl, and acetyl groups, the modifying groups here are polypeptide
chains.
The conjugation process for all ubiquitin-like modiﬁers can be broken
down into three steps, as depicted in ﬁgure 2.10 for SUMO1: In the ﬁrst,
a speciﬁc activating enzyme E1 (SAE1/SAE2 for SUMO1), forms an ATP-
dependent adenylate intermediate with the modiﬁer before forming a thiolester
bond between a cysteine residue in E1 and the carboxy group of the C-terminus
of the modiﬁer. In the second step, a transesteriﬁcation reaction results in the
transfer of the thiolester bond from the E1 enzyme to a cysteine residue on
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a speciﬁc E2 enzyme (Ubc9 for SUMO1). In the third step, the modiﬁer is
attached to the target protein via an isopeptide bond between the C-terminal
carboxyl group of the modiﬁer and the -amino group of a particular lysine
residue on the substrate. This third step requires an E3 ligase protein or
complex in some cases. A small fragment of RanBP2 has been identiﬁed as an
E3 ligase in the SUMOylation of the substrates RanGAP1 and P53 [112].
The SUMOylation pathway is a good model system for the study of
ubiquitin-like post-translational modiﬁcation and biochemical cascades in gen-
eral. All proteins are readily expressed in bacteria and puriﬁed for in vitro stud-
ies. The relatively small substrates and the individual conjugation of SUMO1
proteins (as opposed to that of poly-ubiquitin chains) allow the quantiﬁcation
of the conjugation by both biochemical and, most recently, ﬂuorescence-based
methods.
2.5.2 E2: The Role of Ubc9
The SUMO-speciﬁc E2 enzyme Ubc9 (158 amino acids, 18008Da molecular
weight) is found both in the cytoplasm and nucleus. Ubc9 contains a ΦKxE
recognition sequence, where Φ is a hydrophobic residue, K is a lysine, x is
any amino acid and E is a glutamic acid. This sequence is present in SUMO1
substrates, and its recognition by Ubc9 facilitates SUMOylation.
The interaction of SUMO1 and Ubc9 is well characterized. The sequence
regions which form the binding interface of Ubc9 and SUMO1 have been iden-
tiﬁed using site-directed mutagenesis to alter residues in Ubc9 and compare the
aﬃnity of mutants using isothermal titration calorimetry and biochemical anal-
ysis [113]. The binding interface has also been mapped by NMR chemical shift
perturbation [114], shown in ﬁgure 2.11. These studies show that the binding
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interfaces of Ubc9 and SUMO1 are highly complementary in their electrostatic
potentials and hydrophobicity with the positively charged N-terminal region
of Ubc9 interacting with the negatively charged main β-sheet in SUMO1. The
non-covalent interaction of SUMO1 and Ubc9 is important for initiating the
formation of the thioester bond required for SUMOylation.
Figure 2.11: Connolly surfaces and corresponding ribbon structures [82] of
Ubc9 (left) and SUMO1 (right) [114]. Connolly surfaces are coloured by elec-
trostatic potentials: the spectrum from red to blue corresponds to changes
from negative to positive potentials over a range of 25 to 15 KB/electron. In
addition, the surface hydrophobic side chains are indicated in yellow.
2.5.3 E3: The Role of RanBP2
Among other tasks, the Ran-binding protein 2 (RanBP2) stimulates the SUMOy-
lation of RanGAP1 and has been shown to bind both RanGAP1 and Ubc9 in
the internal repeat regions IR1 and IR2 [98]. Furthermore, RanBP2 can itself
be SUMOylated. The discovery of SUMO-speciﬁc E3-like proteins like RanBP2
has opened the scope for structural and kinetic analysis of the interactions of
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these proteins and the characterization of their role in the SUMOylation path-
way. Both the Ubc9 binding site on SUMO1 and the SUMO1 binding site on
Ubc9 can bind other proteins, leading to potential competition between bind-
ing sites. The similarity of the ubiquitin and ubiquitin-like modiﬁer pathways
indicates that such binding events are likely to have similar functions and are
important features of the conjugation and modiﬁcation processes.
2.5.4 SUMOylation of Proteins
A large number of proteins contain the ΦKxE consensus sequence, and a
fraction of these have so far proven to be SUMO substrates [98]. Just some
substrates of recognized signiﬁcance are the nuclear promyelitic leukaemia pro-
tein PML, the shuttling protein IκBα and the tumor supressor p53. The ﬁrst
substrate however to be discovered was the GTPase activating cytoplasmic pro-
tein RanGAP1. The SUMOylation of RanGAP1 targets it to the nuclear pore
complex of proteins, where it facilitates import of speciﬁc proteins through the
nuclear envelope. New substrates are continuously identiﬁed and summarized
in reviews [108].
2.5.5 SUMO Proteases
Eight human proteases were initially identiﬁed as speciﬁc to the SUMO cycle
and denoted SenP1 to SenP8, short for sentrin-speciﬁc protease [98]. SenP1
and SenP2 are the most thoroughly characterised, whereas SenP8 was found
actually to be NEDD8-speciﬁc and SenP4 not to be relevant. The importance
of the step following the SUMOylation of a substrate, namely the deconju-
gation of SUMO by these speciﬁc cysteine proteases has been demonstrated
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by genetic studies where the deletion of SUMO proteases produced abnor-
mal or even nonviable cells, hypersensitive to DNA damage. In fact, recent
studies link the overexpression of SenP1 (648 amino acids) to prostate tumor
growth [115, 116]. All SenP proteases have an active C-terminal domain of 200
residues in common. A conserved cysteine residue in this sequence is required
for activity, as well a histidine residue, the deletion of which decreases the ac-
tivity. While SUMO proteases are inhibited by N-ethylmaleimide as expected
for cysteine proteases, no speciﬁc inhibitors are known.
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Materials and Methods
The proteins I cloned, expressed and puriﬁed for this work (unless otherwise
stated) were SUMO11−97∗, ECFP-SUMO11−97, EYFP-SUMO11−97, EYFP-
SUMO11−101-ECFPx, ECFP-SUMO11−101-EYFPx, Ubc9∗,
ECFP-Ubc9, EYFP-Ubc9, ECFP-RanGAP1418−587x, EYFP-RanGAP1418−587x,
RanBP2(l)2532−2767∗, ECFP-RanBP2(l)2532−2767, EYFP-RanBP2(l)2532−2767,
RanBP2(s)2633−2762∗, SAE1/2∗, SenP1415644, dSenP1415644, ECFP and EYFP.
Asterisks ∗ denote laboratory stocks and x denotes proteins cloned by Mike
Tatham. SenP1 and the inactive dSenP1 mutant were a kind gift from Linnan
Shen, University of St Andrews. Proteins were cloned, expressed and puri-
ﬁed as described below. All proteins include N-terminal 6-His-TEV tags for
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puriﬁcation by nickel aﬃnity. Chemicals were purchased from Sigma unless
otherwise stated.
3.1 Bacterial Strains and Preparation
E.coli DH5α (genotype: φ80dlacZ∆M15, rec A1, end A1, gyr A96, thi-1, hsd
R17 (rk-, mk+), sup E44, rel A1, deoR, D(lacZYA-argF) U169) was used for
DNA preparation. E.coli BL21 DE3 (F-, ompT, hsdSB, (rB-, mB+), gal, dcm,
(DE3)) was used for protein expression of all ﬂuorescent protein constructs
except those of RanBP2 which were expressed in B834 DE3 (F-, ompT, hsdSB,
(rB-, mB+), dcm, gal (DE3)). Bacteria were grown in Luria-Bertani (LB)
broth supplemented with kanamycin.
Bacteria were prepared for transformation by spreading on an LB agar
plate, picking a single colony approximately 12 hours later and incubating in
10 ml LB (no antibiotic) for 12 hours at 37◦C with agitation. Then 500 ml LB
was added before incubating at 25◦C with agitation until the optical density
(OD) at 600 nm reached 0.4 - 0.7. The culture was then chilled on ice for
1 hour before centrifuging for 15 min (2500·g, 4◦C). The bacterial pellet was
resuspended in ten pellet volumes sterile 50 mM CaCl2, 20 mM MgSO4 at 4◦C,
centrifuged as before, and the pellet resuspended in four pellet volumes of 50
mM CaCl2, 20 mM MgSO4, 10% glycerol at 4◦C. Aliquots were snap frozen in
liquid nitrogen and stored at -80◦C.
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3.2 cDNA Cloning
3.2.1 Plasmids
pHIS-TEV-VENUS (a kind gift of Atsushi Miyawaki, RIKEN, Japan), pHIS-
TEV-ECFP (a kind gift of Tony Vaughan, University of St Andrews), pHIS-
TEV-30a-VENUS-ECFP and pHIS-TEV-30-ECFP-VENUS (subcloned by Mike
Tatham as described in [117]) plasmid vectors were used to produce ﬂuorescent
protein fusions. These encode the enhanced cyan ﬂuorescent protein ECFP [90]
and the yellow ﬂuorescent protein Venus EYFP [94] described in chapter 2.3.2.
3.2.2 DNA Preparation
DNA insert templates (pGEX2T-SUMO11−97, pGEX2T-SUMO11−101, pGEX2T-
Ubc9, pGEX2T-RanGAP1418−587, pGEX2T-RanBP1(l)2532−2767) were subcloned
or polymerase chain reaction (PCR) ampliﬁed from existing stocks. All prepa-
rations (minipreps, maxipreps and gel extractions) were performed using Quia-
gen kits and instructions. Restriction enzymes (BamH1, EcoRI, HindIII) and
vent DNA polymerase for PCR were purchased from New England Biolabs
(NEB) and primers from Eurogentec. DNA concentrations were checked by
absorbance at 260 nm on a Hitachi U-1100 Spectrophotometer.
3.2.3 Plasmid Constructs
pGEX2T-SUMO11−97 was used as template DNA with the primers
5'-GTCAGGATCCATGTCTGACCAGGAGGCCAAAC-3' (5' primer contain-
ing a BamHI restriction site) and
5'-TGACAAGCTTCTAACCCCCCGTTTGTTCCTG-3' (3' primer contain-
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ing a HindIII restriction site) to generate the insert for pHIS-TEV-ECFP-
SUMO1 and pHIS-TEV-VENUS-SUMO1 plasmids.
Double-tagged full-length SUMO1 and SUMO2 were generated by insert-
ing SUMO11−101 or SUMO21−103 into pHIS-TEV-30a-VENUS-ECFP. pGEX2T-
SUMO11−101 was used as template DNA with primers
5'-ACAAACGGATCCATGTCTGACCAGGAGGCCAAA-3' (5' BamHI) and
5'-GTCAAAGCTTGAACTGTTGAATGACCCCC-3' (3' HindIII). pGEX2T-
SUMO21−103 was used as template DNA with primers
5'-TCCCCGCGCCGCTCGGGATCCATGTCCGAG-3' (5' BamHI) and
5'-GTCAAAGCTTGGAAACTGTGCCCTGCCAGGCTGC-3' (3' HindIII).
Ubc9 was sub-cloned from pGEX-2T-Ubc9 by digestion with BamHI and
EcoRI enzymes to generate the insert for pHIS-TEV-ECFP-Ubc9 and pHIS-
TEV-VENUS-Ubc9 plasmids.
pGEX2T-RanBP2(l)2532−2767 was used as template DNA with the primers
5'-GCGCGGATCCCCATTTGCATTCGGCAACAGTTCAGCC-3') (5' BamHI)
and
5'-GCGCAAGCTTCTACTGAGATTTTTGAGCTTCCTGAACTTTTTGAAGC-
3' (3' HindIII) to generate the insert for pHIS-TEV-ECFP-RanBP2(l) and
pHIS-TEV-VENUS-RanBP2(l) plasmids.
pGEX2T-RanGAP1418−587 was used as template DNA with the primers
5'-GTCAGGATCCATGACTGTAAAGACAGAAACG-3' (5' BamHI) and
5'-GTCAGTCAAAGCTTCTAGACCTTGTACAGCGTCTG-3' (3' HindIII) to
generate the insert for pHIS-TEV-ECFP-RanGAP1 and pHIS-TEV-VENUS-
RanGAP1 plasmids.
The PCR mix volume of 100 µl comprised of 1 µM of each primer, 1
ng/µl template DNA, Vent DNA polymerase, dNTP mix and buﬀer (NEB).
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PCR products were gel extracted before digestion with the appropriate restric-
tion enzymes (BamHI, EcoRI or HindIII) and cloning into similarly digested
plasmids by ligation with a T4 DNA ligase at 16◦C over night.
3.2.4 Transformation
Bacteria were transformed by mixing 100 µl bacterial suspension with 10 µl
(approximately 100 ng) plasmid DNA and incubating on ice for 30 min. Subse-
quent heat shocking at 42◦C for 2 minutes and cooling on ice again for 30 min
leads to plasmid intake. The solution was resuspended in 900 µl LB, incubated
at 37◦C for 30 min and spread on LB-agar plates with kanamycin. A single
colony was picked approximately 12 hours later and incubated again over night
in 10 ml LB with kanamycin. DNA was extracted using the Quiagen miniprep
protocol.
Transformation with plasmids containing complete inserts was veriﬁed
by digesting 8.4 µl of miniprepped DNA with suitable primers for 2 h before
fractionating on a 1% agarose gel with plasmid and insert wells as controls.
3.2.5 DNA Sequencing
DNA constructs were veriﬁed by automated DNA sequencing on an ABI Prism
377 DNA Sequencer (St Andrews University DNA sequencing unit). RanBP2
constructs were veriﬁed on an ABI 3730 capillary DNA sequencer (University
of Dundee sequencing service). Resulting sequences were aligned and analysed
using ClustalX software.
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3.3 Expression and Puriﬁcation
Proteins were expressed in E.coli strains BL21 DE3 or B834 DE3 (see section
3.1. Bacteria were transformed by mixing 100 µl bacterial suspension with 5
µl plasmid DNA and incubating on ice for 30 min, heat shocking at 42◦C for
2 minutes and cooling on ice again for 30 min. The solution was resuspended
in 900 µl LB, incubated at 37◦C for 30 min, spun down (1 min at 5000 rpm)
and spread on LB-agar plates with kanamycin. A single colony was picked
approximately 12 hours later and incubated again over night in 10 ml LB with
kanamycin. 30% glycerol stocks were made from this culture and stored at
-80◦C.
For expression, 8 ml culture was added to 1 l kanamycin-supplemented
LB and and incubated at 37◦C with agitation until the optical density reached
0.6 at 600 nm (after approximately 3 h). Expression was induced with 1 ml
ﬁlter sterilized 0.1 g/ml IPTG before incubating at 25◦C for 4 h and spinning
down at 5000 rpm for 15 min. The bacterial pellet was washed in 30 ml
PBS before spinning down at 4000 rpm for 20 min. Protein was extracted by
sonicating in 10 ml lysis buﬀer (0.3 M NaCl, 20 mM imidazole, 1mM DTT,
EDTA free in PBS) three times for 60 seconds before pelleting at 18000 rpm
for 30 min.
The 6HISTEV-tagged protein contained in the supernatant was puriﬁed
using an Ni-NTA agarose column. The supernatant was ﬁltered (0.2 µm) onto
a 4 ml column preequilibrated with lysis buﬀer and washed (0.3 M NaCl, 30
mM imidazole, 1mM DTT, 1 mM PMSF, 1 mM benzamidine in PBS) before
eluting (0.3 M NaCl, 250 mM imidazole, 1mM DTT, 1 mM PMSF, 1 mM
benzamidine in PBS). This produced approximately 10 ml elute of 20 - 100
µM protein concentration. Purity of elutes was veriﬁed by fractionation by
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electrophoresis on polyacrylamide gels and protein masses were veriﬁed by
MALDI TOFF mass spectrometry (University of St Andrews). Furthermore
absorption and emission spectra of proteins were recorded as described in the
following two sections. It was found that the spectra of ECFP and Venus-
EYFP resemble published data, while the SUMO family proteins are non-
ﬂuorescent in this wavelength range. The spectra of tagged protein constructs
were identical to those of the ﬂuorescent proteins. Normalised absorption and
emission spectra of ECFP an EYFP are shown in ﬁgure 3.1.
Figure 3.1: Normalised absorption (dashed lines) and emission spectra (solid
lines) of ECFP (cyan) and EYFP (yellow).
Elutes were dialyzed twice against 2 l assay buﬀer prior to determining
concentrations and snap freezing in aliquots for storage at -80◦C.
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3.3.1 Quantiﬁcation of Protein Concentration
Protein concentrations were determined by Bradford's assay (performed by
Mike Tatham) and by absorbance using the extinction coeﬃcients of ECFP
(28750 M−1cm−1 at 435 nm [90]) and VENUS-YFP (92200 M−1cm−1 at 515
nm [94]) on a Cary Eclipse Spectrophotometer or a Hitachi U-1100 Spec-
trophotometer. Assuming the proteins are correctly folded and ﬂuorescent,
this method is more accurate than Bradford's assay which relies on the la-
belling of speciﬁc residues with Bradford's reagent (Biorad), the occurence of
which however varies between proteins. Several dilutions were measured and
the concentration estimated from the slope of a plot of absorbance versus di-
lution factor. Bradford's assay results were found to be consistently 20 - 30 %
higher than absorbance values.
3.4 Steady-State Fluorescence
Steady-state excitation and emission measurements were performed on a Cary
Eclipse Spectrophotometer (Varian Inc) supplied with Scan software. The
machine was calibrated using the validation software and data were spectrally
corrected using the ﬁles supplied. The spectral correction was veriﬁed by
comparing rhodamine 6G and ﬂuorescein 27 spectra from the Cary eclipse with
spectrally corrected data for the same samples from a Fluoromax spectrometer.
Samples were contained in 10 mm path length quartz cuvettes (Hellma) held
at 21◦C by a water peltier system. Parallel measurements were performed in
multi-cell mode.
Multi-well plate measurements were performed on a Novostar reader
(BMG Labtech) in Cornig 3711 black, clear bottom 384-well plates using
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bottom excitation and collection. Filters used were 405-20 (405 nm central
transmission, 20 nm bandwidth) for excitation and 480-10 and 530-10 for dual
emission collection. The gain factor was set to 1500 for both wavelengths. 50
ﬂashes were averaged for each data point (1 s measurement time) unless spec-
iﬁed otherwise. The plate was held at 30◦C by the integrated incubator and
solutions dispensed using the integrated and automated pipettor. The repro-
ducibility of the pipettor function was tested by the repeated dispensing and
measuring of a ﬂuorescent solution. The dispensing depth was set to 10.5 mm
below the well plate edge - just above the bottom - to avoid bubble formation
upon mixing by aspiration.
3.5 Time-Correlated Single-Photon Counting Flu-
orescence Detection
A custom built time-resolved detection system was used for time-correlated
single-photon counting (TCSPC) ﬂuorescence detection of ﬂuorescent protein
lifetimes [118, 119]. A pulsed laser LED at 393 nm with a pulse duration of 60
ps was used to excite a thin line within a cuvette of sample with a repetition
rate of 5 MHz. Lifetime traces were recorded at 475nm, 498nm and 530nm, by
setting the emission monochromator (slit width 8 nm). A ﬁlter ensured that
scattered excitation light did not reach the photon counting detector (Hama-
matsu microchannel plate-photomultiplier tube, situated at 90◦ to the excita-
tion system). The system achieves precise timing by charge build-up following
the excitation pulse within the time-to-amplitude converter (TAC). Photons
emitted from the ﬂuorescent sample and detected at the photomultiplier tube
lead to the charge build-up being stopped. The potential diﬀerence is sent
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as a pulse to a multi channel analyser (MCA A65-BI) where it is allocated a
channel related to its magnitude. The signal from the MCA is displayed in a
Maestro 3.10 for Windows software interface, where the output is the number
of pulses as a function of channel number. The time interval that corresponds
to one channel width was calibrated using a 50 ns delay line which shifted the
excitation peak by 2046 channels, giving 24.4 ps per channel. The instrument
response was recorded using scattering solutions (diluted milk and LUDOX)
at 393 nm, without ﬁltered emission. The data was analysed by deconvolution
and ﬁtting with exponential decays and the Förster Equation using IBH DAS6
decay analysis software.
3.6 Polyacrylamide Gel Electrophoresis
To determine the approximate molecular weights and relative quantities of
protein in a sample, solutions were fractionated by electrophoresis on 8%-
12% polyacrylamide gels (mini-gel, BioRad), assembled following the manu-
facturer's instruction. Samples were denatured in gel loading buﬀer (20 mM
Tris/HCL pH 6.8, 2 % SDS, 5 % β-mercaptoethanol, 2.5 % bromophenol
blue) and fractionated at 180 V for up to 1 hour alongside protein molecu-
lar weight markers (NEB). Gels containing ﬂuorescent proteins were digitally
photographed under UV illumination. All gels were stained with Coomassie
brilliant blue (0.2 % Coomassie brilliant blue R250, 50 % methanol, 10 %
glacial acetic acid) for 30 minutes and destained (20 % methanol, 10 % glacial
acetic acid). Gels were photographed with white light transmission illumina-
tion and analysed by densitometry (Image Gauge V3.45).
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3.7 Isothermal Titration Calorimetry (ITC)
A VP-ITC MicroCalorimeter (MicroCal) was used for free-solution binding
measurements. Proteins were dialysed three times against an ITC-compatible
buﬀer (20 mM NaCl, 0.5 mM DTT, PBS). The third dialysis buﬀer was used
for diluting samples and washing the machine. Dialysed samples were spun at
13000 rpm for 10 min before checking concentrations by absorbtion and de-
gassing using a ThermoVac degasser (MicroCal) while stirring at 30◦C. Experi-
ments were performed following manufacturer's instructions and data analysed
with the supplied routine in Origin 7. Sample quantities were 2.5 ml at 5 or
10 µM in sample chamber and 0.5 ml at 100 or 200 µM injectant. Runs were
performed at 30◦C.
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A Steady-State FRET Protein-Protein
Binding Assay
Protein-protein binding is fundamental to the speciﬁcity of biochemical path-
ways, the quantiﬁcation of the strength of the association of any two binding
proteins is essential in the study of cellular function. The equilibrium binding
constant Kd provides a measure of the strength of non-covalent interactions
(see chapter 2.4.2 for the deﬁnition and derivation of relevant equations). A dif-
ferent approach - measuring binding by detecting bulk refractive index changes
- is discussed in chapter 10.
Here we set out to measure the binding aﬃnity of a protein-protein inter-
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action using optical signals. Since the dimensions of the proteins studied lie two
orders of magnitude below the diﬀraction limit, we utilize ﬂuorescence-based
signals that enable the detection of binding. Binding may lead to quenching
(see chapter 2.1.2) or energy transfer between two probes (see chapter 2.2.4.
Fluorescence resonance energy transfer (FRET) results from the proximity of
two suitably tagged proteins upon binding. The method we develop here for
the quantitative analysis of protein-protein binding is based on FRET between
ﬂuorescent protein tags. This is a novel approach in protein research: while
binding is commonly detected in vivo using energy transfer, to our knowl-
edge it has not been used quantitatively as an in vitro signal to derive the
binding constant of protein interactions. FRET studies of DNA triple helix
formation have been published [120], however these involve chemical labelling
and molecules of DNA fragments up to 50 base pairs, while we investigate the
binding of proteins of tens of kilodaltons molecular weight, using genetic fusion
and ﬂuorescent protein tags.
The technique most accepted as a standard measurement of the binding
constant in free solution is isothermal titration calorimetry (ITC) (see chapter
2.4.2 for details and a discussion of further techniques). The FRET-based
method presented here also enables the quantitative determination of Kd in
free solution and has several advantages over ITC, the main ones being the
high speciﬁc signal, the small amounts of sample required and the versatility
of alternative assay formats such as the use of multi-well plates.
Firstly we present as a proof of principle an assay resembling the titration
that is performed during a microcal ITC experiment, but using a tenth of the
concentrations and recording the steady-state spectra following each titration
step. In parallel we run three controls for non-speciﬁc interactions and signals.
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For the analysis we use the acceptor emission and ﬁt the resulting binding
curve with the one-variable hyperbola derived in chapter 2.4.2. We validate the
results in comparison to published ITC data and contrast the two techniques.
Finally we modify the format of the assay to a multi-well plate dilution
series, which requires 5% of the material of the equivalent ITC run and enables
the repeated collection of binding data under addition of further molecules.
The materials used in this section are ECFP-SUMO1, EYFP-Ubc9 and
ECFP buﬀered in 20mM NaCl, 50mM Tris HCL 7.5, 5mM β-mercaptoethanol.
4.1 FRET Binding Assay in Titration Format
The experimental system to examine the use of a FRET signal to measure
binding resembles the setup used in isothermal titration calorimetry (ITC).
This involves a titration beginning with one donor-tagged protein at low con-
centration, and adding in small volumes of its acceptor-bound binding partner
at higher concentration. After each addition emission spectra are recorded to
monitor the energy transfer between the protein tags.
Spectral shifts occur due to energy transfer, though other eﬀects may
also contribute:
• Non-speciﬁc binding, quenching or non-speciﬁc energy transfer (e.g. at
very high protein concentrations).
• Direct excitation of the acceptor in addition to its emission as a result
of energy transfer,
• The overall emission intensity will decrease as the samples are diluted
during the titration
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To estimate these eﬀects accurately, three controls are run in parallel to
the main titration. The setup is shown in ﬁgure 4.1.
Figure 4.1: Experimental setup of the FRET binding experiment in cuvettes:
ECFP-SUMO1 with addition of EYFP-Ubc9 (binding experiment), ECFP
with addition of EYFP-Ubc9 (control for potential non-speciﬁc interactions),
buﬀer with addition of EYFP-Ubc9 (control 1 recording the direct excitation
of EYFP), ECFP-SUMO1 with addition of buﬀer (control 2 recording the
decrease in ECFP emission as the solution is diluted).
Four 3.5 ml quartz cuvettes (Hellma Scientiﬁc, 10mm path length) ini-
tially holding 3ml of sample each are set up in a Cary Eclipse Spectropho-
tometer and maintained at 21C by a PCB Peltier system. The details of the
titrations performed are as follows:
• Adding 10 µl increments of 55 µM EYFP-Ubc9 to 3 ml of 1.1 µM ECFP-
SUMO1
• Adding 10 µl of 55 µM EYFP-Ubc9 to 3 ml of 1.1 µM ECFP (control
for non-speciﬁc interactions)
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• Adding 10 µl of 55 µM EYFP-Ubc9 to 3 ml buﬀer(EYFP emission fol-
lowing 400 nm excitation)
• Adding 10 µl buﬀer to 3ml of 1.1 µM ECFP-SUMO1(dilution of ECFP-
SUMO1)
Following each addition and mixing by inversion, spectra were recorded
from each cuvette in turn. The titration step sizes were increased towards the
end as the changes in the spectra decreased. The spectra recorded during the
titration are shown in ﬁgure 4.2 and the data analysis presented in the next
section.
4.1.1 Analysis and Results of Steady-State FRET Assay
In the analysis we resolve the FRET component of the acceptor spectrum,
which is linearly proportional to the amount of protein in bound complexes
undergoing FRET. This is demonstrated experimentally in chapter 8.4. The
concentration of the acceptor-tagged protein increases during the titration,
binding successively larger amounts of the already present donor-tagged bind-
ing partner, up until all of it is bound. The FRET signal increases correspond-
ingly up to a saturation level. The points between the minimum and maximum
FRET signal are now easily converted to the relative amount of donor-tagged
protein in the bound state. In this case, the binding stoichiometry of 1:1
means that this is equal to the amount of acceptor-tagged protein in bound
state. From this we determine the amount of free acceptor-tagged protein
after each titration step by subtraction. The data is presented in the classic
bound protein versus free ligand binding curve and ﬁtted with a hyperbola as
described in chapter 2.4.2.
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Figure 4.2: Initial spectra of each cuvette (black) and spectral change asso-
ciated with each titration (various colours). a) red: 1.1 µM ECFP-SUMO1
with addition of EYFP-Ubc9. This is the FRET binding experiment, where
we expect emission from the acceptor beyond direct excitation upon binding.
b) blue: 1.1 µM ECFP with addition of EYFP-Ubc9. This is the control for
potential non-speciﬁc interactions. c) yellow: buﬀer with addition of EYFP-
Ubc9. This is control 1 recording the direct excitation of EYFP. d) green: 1.1
µM ECFP-SUMO1 with addition of buﬀer. This is control 2 recording the
decrease in ECFP emission as the solution is diluted.
The emission spectra of the steady-state binding assay titration of EYFP-
Ubc9 into 1.1 µM ECFP-SUMO1 are shown in ﬁgure 4.2. As EYFP-Ubc9 is
added and Ubc9 and SUMO1 bind, energy is transferred from ECFP to EYFP
and, as a result, the ECFP emission at 480nm decreases while the EYFP
emission at 530 nm increases. The 530nm signal is proportional to the number
of molecules undergoing FRET 8. The 530 nm peak intensity is plotted as a
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Figure 4.3: Fluorescence emission of EYFP-peak (around 530nm) as a function
of added EYFP-Ubc9 (except for the ECFP-SUMO1 + buﬀer series (green)).
function of EYFP-Ubc9 concentration in ﬁgure 4.3. The peak data from the
three parallel controls is also shown:
• The titration of EYFP-Ubc9 into 1.1 µM ECFP (not fused to SUMO1)
leads to a linear increase in 530 nm emission (slope 7.56 µM−1)
• The same titration into buﬀer gives a measure of direct excitation of
EYFP and is also linear (8.95 µM−1)
• The dilution of 1.1 µM ECFP-SUMO1 by an identical titration of buﬀer
leads to a linear decrease (-1.97 µM−1)
The sum of the dilution and direct excitation controls is plotted on the same
graph (6.97 µM−1).
A plot of the binding data with the dilution and direct excitation controls
subtracted is presented in ﬁgure 4.4. The saturation level is determined by a
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Figure 4.4: Fluorescence emission of ECFP-SUMO1+EYFP-Ubc9 minus con-
trols 1 and 2 as a function of total EYFP-Ubc9 concentration. The dashed
line indicates the estimated saturation level of this curve used in the analysis.
single exponential ﬁt and gives the FRET signal that corresponds to 1.1 µM
of bound protein complex since this is the total ECFP-SUMO1 present. Every
data point is converted from the FRET signal into the corresponding relative
amount of bound complex. The free EYFP-Ubc9 is calculated in a subtraction
for each point and the axis rescaled to give the bound protein versus free
EYFP-Ubc9 binding curve shown in ﬁgure 4.5, ﬁtted with the hyperbola [100]
Y =
Bmax ·X
Kd +X
(4.1)
Fitting with Bmax = 1.1 µM (the maximum concentration of bound pro-
tein) givesKd = 0.59 µM± 0.09 µM. This is in the same range as the value from
isothermal titration calorimetry (ITC), Kd ITC = 0.25 µM with a quoted error
of 0.07 µM [20]. The measurement errors associated with both measurements
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are however relatively small, and results do not agree within error limits. The
accuracy of the ITC measurement is disputed due to the measurement method
of protein concentrations of the solutions used. This may signiﬁcantly impact
on the result without appearing as a measurement error. Similarly, the value
from FRET may be an overestimate if the ﬂuorescent tags hinder binding.
These points are discussed further in section 4.3.
Figure 4.5: Binding curve of EYFP-Ubc9 to ECFP-SUMO1, displaying free
EYFP-Ubc9 versus bound protein, ﬁtted with a single hyperbola.
4.2 FRET Binding Assay in Well Plate Format
Multi-well plate format assays have revolutionised biomedical research: this
material eﬃcient µl reaction scale is particularly convenient since thousands
of parallel reactions are readily automated in robotic systems. A quantitative
analysis of binding based on FRET is ideally suited to multi-well plate format.
The high speciﬁc FRET signals established in 4.1 allow for small-volume and
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low concentration analysis, and there is an abundance of ﬂuorimeters either
adapted to or speciﬁcally designed for multi-well plate reading.
4.2.1 Well-plate Setup
In this section we describe the re-scaling of the assay presented in section 4.1.
We convert the ratios of concentrations achieved by means of a titration in the
assay described previously to a dilution series spread over 28 wells of a 384-well
plate. Similarly, a set of controls is performed to check for non-speciﬁc signals.
Reactions are set up in triplicate.
Measurements were performed in black, clear bottom 384 well plates
(Greiner 3811) using bottom excitation and collection on a BMG Labtech
NOVOstar ﬂuorimeter using excitation 405-20 nm and emission 530-10 nm
ﬁlters. Three identical dilution series of EYFP-Ubc9 were dispensed in trip-
licate in 28 wells of 15 µl, to be topped up to 20 µl. The ﬁnal concentration
ranges were 0.0 µM - 7.5 µM in 15 steps of 0.1 µM followed by 12 steps of 0.5
µM. They were topped up using the automated pipettor with 5 µl of 4 µM
ECFP-SUMO1 (1), 4 µM ECFP (2) or buﬀer (3). The emission at 530 nm
was recorded, standard deviations of the emission of triplicate wells calculated
and the average emission used in the analysis.
4.2.2 Well-plate Analysis and Results
The acceptor emission at 530 nm from wells containing ECFP-SUMO1 and
increasing concentrations of EYFP-Ubc9 are shown as the red trace in ﬁgure
4.6. The increase in signal due to FRET is evident in contrast to the non-
binding control of ECFP with increasing concentrations of EYFP-Ubc9 (blue).
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Figure 4.6: Emission at 530 nm from wells containing 1 µM ECFP-SUMO1 +
increasing concentrations of EYFP-Ubc9 (red) and 1 µM ECFP + increasing
concentrations of EYFP-Ubc9 (blue).
In order to isolate the FRET signal and calculate the concentration of
bound species from it, the non-binding control has to be checked for linearity
and hence the absence of non-speciﬁc binding of strength of the order of the
interaction to be measured. This is examined more closely in ﬁgure 4.7.
Following this veriﬁcation, the linear non-binding data was subtracted
from the ECFP-SUMO1 + EYFP-Ubc9 data and the binding curve analysed
as discussed in section 4.1.1. The asymptotic maximum was determined with
a single exponential ﬁt giving the FRET signal that corresponds to 1 µM
ECFP-SUMO1 bound to 1 µM EYFP-Ubc9. The amount of bound species in
each well of the dilution series was expressed as a fraction of this maximum on
the basis of its FRET signal. The free amount of EYFP-Ubc9 was calculated
from this and knowledge of the total amount of EYFP-Ubc9 in the dilution
series and the results presented in the binding curve plot of bound versus free
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Figure 4.7: Fluorescence emission at 530 nm of ECFP + EYFP-Ubc9. This is
the control for non-speciﬁc interactions. Data shown is the average from trip-
licate experiments, the error bars show the corresponding standard deviation.
EYFP-Ubc9 in ﬁgure 4.8.
The hyperbolic ﬁt to the multi-well plate format binding assay results in
Kd = 0.56 ± 0.11 µM for EYFP-Ubc9 and ECFP-SUMO1, which is close to
Kd = 0.59 µM ± 0.09 µM for the titration and in the same range as the ITC
result, KdITC = 0.25 µM ± 0.07 µM [113].
4.3 Validation and Discussion of Steady-State
Binding Assays
The FRET binding assays presented here exploit the decrease in the average
distance between the ﬂuorescent tags of a protein pair as they bind in free
63
4.3. VALIDATION AND DISCUSSION OF STEADY-STATE BINDING
ASSAYS
Figure 4.8: Binding curve of EYFP-Ubc9 to ECFP-SUMO1, displaying free
EYFP-Ubc9 versus bound protein, ﬁtted with a single hyperbola.
solution. Binding brings the tags into the range required for energy transfer
(typically <10nm).
We demonstrate FRET due to the speciﬁc binding of SUMO1 to Ubc9
using the ﬂuorescent protein tags ECFP and EYFP. In contrast, a solution
of EYFP-Ubc9 and non-binding ECFP does not exhibit spectral changes at-
tributable to energy transfer. Instead, the changes in emission run closely
parallel to the contributions of dilution and direct excitation. With this estab-
lished, we utilise the increase of the acceptor emission at 530 nm as a direct
measure of the amount of tagged proteins forming a bound complex and pro-
ceed to compute the equilibrium binding constant Kd from these data. We
validate the method by comparing the Kd for tagged SUMO1 and Ubc9 by
steady-state FRET to results from the conventionally used isothermal titra-
tion calorimetry (ITC). The ﬁt to the cuvette assay data shown in ﬁgure 4.5
gives Kd = 0.59 µM ± 0.09 µM which is in the same range as the ITC result,
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Kd ITC = 0.25 µM ± 0.07 µM [113]. The good ﬁt conﬁrms again that the 530
nm signal is a valid measure of the number of molecules undergoing FRET.
The well-plate format assay results in Kd = 0.56 ± 0.11 µM which is very close
to the result obtained from the cuvette assay.
In addition to producing accurate and precise quantitative results, the
FRET assays presented here have a range of advantages over ITC:
1. Concentrations of proteins are measured by means of the peak absorbance
of the ﬂuorophores, using the established extinction coeﬃcients [90] [94].
This signiﬁcantly increases the accuracy of the concentrations input into
the calculations over colourimetric chemical assays such as Bradford's as-
say, which are commonly inaccurate for small proteins or for those with
unusual amino-acid sequences.
2. FRET occurs when suitable ﬂuorophores are brought into close proxim-
ity, and hence produces a high speciﬁc signal when tagged protein pairs
bind in solution. In ITC, the binding signal measured is the heat freed
due to the decrease in free energy upon binding. This requires large
amounts of sample at high concentration to achieve the sensitivity re-
quired for a reliable analysis. The sensitivity of FRET however enables
measurements at lower - and closer to physiological - concentrations, in
smaller volumes and alternative formats such as multi-well plates. While
the amount of sample required for the ITC measurements was 125 nmol
[113], the cuvette assay was performed with 27 nmol. This is readily
reduced to just 6 nmol in a multi-well-plate format dilution series, in
triplicate and including three controls.
3. Heat change upon binding is a transient signal measured in the ﬁrst
seconds of the addition of each titration step. Repeat measurements in
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ITC require a new set of samples. FRET occurs as soon as tagged protein
partners bind and remains until they dissociate, and is hence a stable
signal that can be measured repeatedly . This is of particular interest in
multi-well plate format, which enables the repeat measurement of wells
and hence the re-acquisition of the data points of a binding curve while
varying the temperature or before and after the addition of potential
drugs which inﬂuence the Kd of a protein pair.
4. Calorimetric techniques require a thermally stable reaction chamber.
Most systems achieve this by raising the temperature of the insulated
reaction chamber to >5◦C above room temperature. This limits the
range of temperatures at which measurements can be performed.
5. For best results, ITC is performed with samples in plain buﬀers such
as PBS. The presence of stabilising constituents like β-mercaptoethanol
interferes with the heat signal. This not only restricts a range of buﬀer
ingredients - often requiring a dialysis step prior to measurements - but
also complicates experiments with further interacting molecules such as
drug candidates. Since FRET produces a signal speciﬁc to the proximity
of two selected proteins, these assays provide a convenient method for
screening drug candidates which modify protein interactions and a pow-
erful tool for the study of biochemical cascades in which several proteins
bind competitively. Multi-protein binding experiments are presented in
chapter 6.
The ECFP and EYFP ﬂuorescent proteins provide convenient ﬂuorescent
tags, since they are a spectrally well suited FRET pair, possess enhanced
quantum yields and are fused to the proteins of interest during the cloning
stage. This not only renders further mutations and complex chemical labelling
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superﬂuous, but also simpliﬁes the puriﬁcation procedure since the brightly
coloured solution is clearly visible during washing and elution steps.
The presence of ﬂuorescent protein tags could conceivably increase the Kd
of protein pairs determined by FRET by reducing the functionality of proteins
or by providing a steric hindrance to binding partners. However ﬂexible linkers
between the non-interacting ﬂuorescent protein tags and the proteins minimise
this risk. The results above and comparative experiments presented in chapter
8.4 conﬁrm that the inﬂuence of tags is not limiting, since results from tagged
and untagged measurements lie in a similar range.
When applied to other systems, the size of the proteins and the location
of the binding surfaces will impact on the eﬃciency of energy transfer and
hence the dynamic range of the assay. Since FRET has an R−6 dependency on
the distance between the loosely attached ﬂuorescent tags, the bulk monitored
energy transfer is a weighted average dominated by the closest tags. The
detection limit is 0.4 nM of bound complex based on the 3σ noise level of the
spectra, the dynamic range shown in ﬁgure 1b and the amount of bound protein
in this equimolar solution determined from the binding curve. This detection
limit is speciﬁc to the binding of SUMO1 to Ubc9 for the reasons mentioned
above. In a multi-well-plate format dilution series, the FRET binding assay
gives a similar Kd, validating the use of this small and versatile format.
4.4 Conclusion
In this work we investigated the potential of ﬂuorescence resonance energy
transfer (FRET) as a signal for the quantitative study of protein-protein bind-
ing. We succeeded in developing a free-solution equilibrium binding assay
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based on steady-state FRET between tagged proteins of the SUMO family.
The resulting binding constants calculated from measurements based on the
EYFP emission peak compare well with published ITC data for SUMO1 and
Ubc9. This suggests that the the presence of ﬂuorescent protein tags does
not aﬀect binding. Further results presented in chapter 8 conﬁrm that even
doubly-tagged SUMO1 is fully functional and processed by proteases at the
same rate as untagged SUMO1. With this established, the use of FRET as
a binding signal actually carries several advantages over label-free techniques.
Firstly, concentrations can be determined accurately by absorption and using
known extinction coeﬃcients, thanks to the presence of ﬂuorescent tags. Fur-
thermore, comparably small amounts of sample are required, enabling the use
of a versatile mutli-well-plate format. This technique also enables the study of
the binding of two proteins in the presence of further interacting substances,
as demonstrated in chapter 6. This is of particular interest in multi-well-plate
format, where the repeated study of the same binding experiment under vary-
ing conditions and under addition of further compounds is now possible. This
method of measuring binding is applicable to a wide range of protein systems
that can be expressed for in vitro studies.
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A Time-Resolved FRET
Protein-Protein Binding Assay
FRET can be measured as a spectral shape change as described in chapter
4, or as a change in donor lifetime when using time-resolved detection. As
energy is transferred, the additional decay rate κFRET leads to a decrease in
the lifetime of the donor ﬂuorophore as described in chapter 2.2.3. This sec-
ond method of FRET detection is used to measure protein-protein binding in
this chapter. Unlike steady-state emission intensities, lifetime measurements
are independent of concentration, which decreases the number of controls nec-
essary to just one, testing for non-speciﬁc binding. Changes in the emission
69
5.1. TIME-RESOLVED FRET BINDING ASSAY SETUP
lifetime can be used as a dynamic signal to construct a binding curve in a
similar manner as in the steady state experiments described previously. This
experiment also serves as an independent validation of the use of the 530 nm
peak values as a direct measure of bound protein in section 4.1.1.
The materials used in this section are ECFP-SUMO1, EYFP-Ubc9 and
ECFP buﬀered in 20mM NaCl, 50mM Tris HCL 7.5, 5mM β-mercaptoethanol.
5.1 Time-Resolved FRET Binding Assay Setup
A time-correlated single photon counting (TCSPC) system was used for time-
resolved measurements (see chapter 3.5 for experimental details). The instru-
ment response was recorded using scattering solutions (LUDOX) at 393 nm
(without ﬁlter). A pulsed laser diode at 393 nm with a pulse duration of 60
ps was then used to excite a thin line within a cuvette containing 1 ml of 2
µM ECFP-SUMO1 solution. EYFP-Ubc9 was added in increments: six at
0.5 µM and four at 1 µM. Following each addition and mixing by inversion,
lifetime traces were recorded with the monochromator set to 475 nm at 8
nm slit width. The collection time was around 2 minutes for each trace. A
control was performed by the subsequent addition of ECFP-SUMO1 to check
whether the changes in lifetime were reversible. The experiment was repeated
with substituting ECFP-SUMO1 with ECFP to check for non-speciﬁc binding
signals.
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Figure 5.1: Lifetimes recorded at 475 nm during the titration of EYFP-Ubc9
into ECFP-SUMO1. The excitation pulse is shown in grey and the time-
resolved photon count traces of the progressing titration are presented in a
series of colours from dark red through to purple.
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5.2 Analysis and Results of the Time-Resolved
FRET Assay
The time-resolved ﬂuorescence traces recorded after each titration step are
shown in ﬁgure 5.1. Four selected traces are presented on a logarithmic scale
in ﬁgure 5.2 and clearly demonstrate the decrease in lifetime upon addition of
EYFP-Ubc9. From the logarithmic scale plots we can deduce that the traces
can be closely ﬁtted with a single exponential since they are close to linear
on this scale. We proceed with four ﬁtting approaches: a single exponential,
a double exponential to determine whether short-lifetime components vary
during the experiment, and ﬁts to the 2D and 3D Förster Equation (equation
2.2.3).
Figure 5.2: Four representative lifetimes recorded at 475 nm during the titra-
tion of EYFP-Ubc9 into ECFP-SUMO1. The excitation pulse is shown in
grey and the time-resolved photon count traces are presented as stated in the
legend.
72
5.2. ANALYSIS AND RESULTS OF THE TIME-RESOLVED FRET
ASSAY
The traces were ﬁtted using iterative deconvolution in the IBH DAS6
decay analysis software (functions 1,2 and 9). A single exponential resulted in
a reasonable and consistent ﬁt throughout with an average χ2 value of 1.43.
The single-exponential lifetime of ECFP-SUMO1 was found to be 2.49 ± 0.01
ns in the absence of EYFP-Ubc9. As a result of the titration his lifetime
decreased to 2.01 ± 0.01 ns as shown in ﬁgure 5.3.
Figure 5.3: Single-exponential ﬁt: lifetimes as a function of EYFP-Ubc9 added
to 2 µM ECFP-SUMO1.
The double-exponential ﬁt revealed a weak short component at 0.58 ±
0.03 ns, 17 % relative amplitude, which did not vary signiﬁcantly, and a dom-
inant longer component (83 % relative amplitude) that decreased from 2.81
± 0.01 ns to 2.38 ± 0.01 ns during the titration. The relative amplitudes
remained constant during the experiment. The lifetimes are shown in ﬁgures
5.2 and 5.4. The average χ2 value for this ﬁt was 1.31.
The observed decreases in donor lifetime are fully attributable to FRET
since the values were restored as more ECFP-SUMO1 was added and the
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Figure 5.4: Double-exponential ﬁt: Short and long lifetime components as a
function of added EYFP-Ubc9.
relative concentration of bound complex was decreased. The reversibility of the
experiment is important since lifetime decreases could also have been a result
of radiation quenching by surrounding molecules at higher concentrations.
As the titration progresses the decrease in lifetime levels oﬀ, as can be
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seen in ﬁgure 5.3. The saturation lifetime corresponds to the total amount of
ECFP-SUMO1 undergoing FRET in bound state. The range of values between
this and the lifetime of the initial free ECFP-SUMO1 can be expressed as the
amount of bound ECFP-SUMO1 and EYFP-Ubc9. Subsequently the amount
of free EYFP-Ubc9 is calculated by subtraction and the data presented in
a bound versus free EYFP-Ubc9 curve. The binding curve from the single-
exponential lifetimes is shown in ﬁgure 5.5 and results in the binding constant
Kd = 0.73 ± 0.15 µM. Using the longer lifetime component of the double
exponential ﬁt gives the binding curve in ﬁgure 5.6 and Kd = 0.63 ± 0.11 µM.
Figure 5.5: Bound versus free EYFP-Ubc9 binding curve based on single-
exponential lifetime data from the time-resolved FRET binding assay. The
hyperbolic ﬁt gives Kd = 0.73 ± 0.15 µM.
The 2D Förster Equation provided a slightly improved ﬁt to the data in
comparison to the double-exponential, with an average χ2 value of 1.27, while
the 3D equation resulted in no improvement. However the γ value was found
not to vary with acceptor concentration. The Förster Equation model predicts
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Figure 5.6: Bound versus free EYFP-Ubc9 binding curve based on the long
component of double-exponential lifetime data from the time-resolved FRET
binding assay. The hyperbolic ﬁt gives Kd = 0.63 ± 0.11 µM.
an increase in γ in materials densely packed with acceptors as their concen-
tration increases. Our result is however not surprising, as we expect energy
transfer to occur solely as a result of two proteins binding, which in this case
leads to just one eﬀective acceptor per donor. Even the highest concentration
of EYFP-Ubc9 of 8 µM leads to a mean distance between acceptors of 60 nm,
which is over an order of magnitude higher than the Förster Radius. The ef-
fective number of acceptors per donor does hence not depend on the acceptor
concentration.
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5.3 Validation and Discussion of the Time-Resolved
FRET Assay
The single exponential lifetime of ECFP was measured as 2.49 ns, which is
in close agreement with the published value 2.53 ns [121]. Consistently with
our FRET measurements, during which the lifetime decreases to 2.01 ns, this
value is 1.95 ns for an ECFP-EYFP fusion protein. Literature values for other
GFP mutants range from 2.7 to 3.8 ns [86, 122, 123, 124].
The binding constants from the time-resolved FRET assay presented
here are very close to the results from the steady-state assay presented and
validated in chapter 4. Indeed these results serve as an independent validation
of the steady-state analysis based on the 530 nm emission peak.
Time-resolved FRET detection is a promising assay for the quantitative
study of protein-protein binding. A major beneﬁt is the fact that FRET,
measured as the decrease in donor lifetime, is purely a measure of binding and
is hence only a function of the relative protein concentrations and their binding
aﬃnity. This is validated experimentally by adding more ECFP-SUMO1 at the
end of the titration and recovering the lifetimes previously measured at that
ECFP-SUMO1/EYFP-Ubc9 ratio. Direct excitation and dilution during the
titration do not obscure the FRET signal, greatly simplifying the experiments.
The sensitivity of this measurement depends on the collection time for each
lifetime trace which in turn impacts on the precision of the ﬁtting procedure.
However, speciﬁc equipment is required to perform measurements at this
short timescale at photon-counting sensitivity. Several systems are available
commercially, however these are not likely to be as proliﬁc in bioscience labo-
ratories as steady-state ﬂuorimeters.
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5.4 Conclusion
In this time-resolved FRET assay to quantify protein-protein binding we mea-
sure the ﬂuorescence lifetime of a ﬁxed amount of donor ECFP-tagged protein
solution using a TSCPC setup. The concentration of the EYFP-tagged binding
partner in this solution is gradually increased in a titration, and the resulting
energy transfer measured as a decrease in the ECFP lifetime at 475 nm. Life-
times computed from deconvolution and both single and double exponential
ﬁts are used as binding data. Fitting with hyperbolas gives binding constants
that compare well with the results obtained in steady state measurements in
chapter 4. Together with the comparison to ITC results this validates the
use of FRET as a quantitative binding signal, and its use for determining the
equilibrium binding constant of a protein pair.
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Multi-Protein Interactions Analysed by
FRET
A major advantage of monitoring binding by means of FRET is that the eﬀect
of third molecules on the binding of two selected proteins can be measured.
This provides a convenient method for screening drug candidates which may
modify protein interactions and a powerful tool for the study of biochemical
cascades within which several proteins bind competitively.
To illustrate this we investigate binding and competition of proteins dur-
ing the SUMOylation of substrates, and present a method of quantifying com-
petitive binding by determining the inhibition constant Ki.
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It requires the concerted eﬀorts of multiple proteins to catalyse the for-
mation of a covalent bond between the small ubiquitin-like modiﬁer SUMO1
and a variety of diﬀerent protein targets as discussed in chapter 2.5. The ﬁnal
step of this conjugation involves the binding of RanBP2 to a covalently linked
Ubc9-SUMO1 complex, and the formation of a trimeric bound complex. The
covalent Ubc9-SUMO1 link is essential for SUMOylation to occur, although
in its absence, a bound trimeric complex could still be formed due to mutual
binding sites on the three proteins. The exact mechanism of this ﬁnal stage
is unknown, but studying the mutual binding aﬃnity of the three proteins by
FRET can shed light on the cascade of interactions.
Materials used here were ECFP-SUMO1, EYFP-Ubc9, ECFP-RanBP2(l),
EYFP-RanBP2(l), SUMO1, RanBP2(l) and RanBP2(s).
6.1 Multi-Protein Experiments
Multi-protein binding was quantiﬁed by tagging the two proteins to be mea-
sured with a donor ECFP and an acceptor EYFP respectively and making up
an equimolar solution of the two. The eﬀect of a third, untagged molecule is
measured during a titration into this solution, while spectra are recorded as in
chapter 4.
Firstly, experiments were performed to determine the eﬀect of two RanBP2
fragments on the bound SUMO1-Ubc9 complex. The longer RanBP2(l) binds
Ubc9 but its SUMO1 binding site is concealed [125]. The shorter RanBP2(s)
was shown to bind both SUMO1 and Ubc9 individually in GST pulldown ex-
periments. The following titrations in 3.5 ml quartz cuvettes were monitored
in a Cary Eclipse Spectrophotometer:
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• RanBP2(s) was titrated into 1 ml of 1 µMECFP-SUMO1 + 1 µMEYFP-
Ubc9, in 17 x 5 µl additions up to 3.1 µM ﬁnal concentration
• RanBP2(l) was titrated into 1 ml of 1 µM ECFP-SUMO1 + 1 µM EYFP-
Ubc9
Next, controls were performed with untagged SUMO1 to contrast the
competition of SUMO1 for its tagged counterpart with that of the RanBP2
fragments. This reveals the relative binding aﬃnity of the proteins for Ubc9.
• SUMO1 was titrated into 1 ml of 1 µM ECFP-SUMO1 + 1 µM EYFP-
Ubc9 in 20 x 5 µl additions up to 3 µM ﬁnal concentration (control for
substitution of ECFP-SUMO1 with SUMO1)
Furthermore, the eﬀect of Ubc9 titrated into ECFP-SUMO1 + EYFP-
RanBP2(l) and that of SUMO1 on the ECFP-RanBP2(l) + EYFP-Ubc9 com-
plex were monitored during the following titrations:
• Ubc9 was titrated into 1 ml of 1 µM ECFP-SUMO1 + 1 µM EYFP-
RanBP2 in 20 x 5 µl additions up to 3 µM ﬁnal concentration
• SUMO1 was titrated into 1 ml of 1 µM ECFP-SUMO1 + 1 µM EYFP-
Ubc9 in 20 x 5 µl additions up to 3 µM ﬁnal concentration
• The last titration was repeated with more SUMO1, in 5 µl additions in
7 increments of 30 µM, up to 210 µM ﬁnal concentration.
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6.2 The Eﬀect of RanBP2 on SUMO1 and Ubc9
binding
In chapter 4 we demonstrated the spectral detection of the binding of ECFP-
SUMO1 and EYFP-Ubc9. In three further experiments we now add interacting
proteins to equimolar solutions of these two tagged proteins and record spectra
during the titration. The resulting spectra are presented in ﬁgure 6.1.
The additions of RanBP2(l), RanBP2(s) and SUMO1 lead to a decrease
in the FRET acceptor emission at 530 nm in all three cases as the bound ECFP-
SUMO1 + EYFP-Ubc9 complex is disrupted. In the case of the RanBP2
fragments, the acceptor peak vanishes, indicating that dissociation of all the
initially bound complex has taken place. The donor emission at 475 nm de-
creases slightly as the solution is diluted during the titration.
The 530 nm peak clearly decreases at diﬀerent rates in the three experi-
ments. This is readily visualised by plotting the 530 nm / 480 nm ratio of the
ﬂuorescence emission, as shown in ﬁgure 6.2. Using this ratio isolates spectral
changes due to energy transfer from an overall decrease in emission intensity
due to dilution. The ratio is hence a convenient method of presenting FRET
changes on a scale from about 0.6 (no FRET) to approximately 1.1 (maximum
FRET) in this case. It is however not linearly proportional to the number of
molecules undergoing FRET as it is the ratio of two rates of energy transfer
(the donor decrease at 475nm and acceptor increase at 530nm).
The FRET change due to the dissociation of the ECFP-SUMO1 and
EYFP-Ubc9 complex is shown in ﬁgure 6.2 as a function of added RanBP2(l),
RanBP2(s) and SUMO1. RanBP2(l) demonstrates stronger inhibition than
RanBP2(s), however in both titrations the signal eventually saturates at the
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Figure 6.1: Spectra recorded during the titration of RanBP2(l), RanBP2(s)and
untagged SUMO1 into 1 µM ECFP-SUMO1 and EYFP-Ubc9. The FRET
acceptor emission at 530 nm decreases during the titrations as a result of
binding of the tagged proteins being disrupted. The donor emission at 475 nm
decreases and the solution is diluted during the titration.
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Figure 6.2: FRET emission ratio as RanBP2(l), RanBP2(s) and SUMO1 are
added to 1 µM ECFP-SUMO1 and EYFP-Ubc9. The plots summarise spectral
data presented in ﬁgure 6.1.
same level (530 nm / 480 nm ratio of 0.63). Competition for the binding site
is tested in a control, adding SUMO1, which competes with its tagged and
monitored counterpart ECFP-SUMO1. The decrease in FRET here is smaller
than for either RanBP2 type, and demonstrates its weaker aﬃnity for binding
Ubc9. These aﬃnities can be quantiﬁed by means of the inhibition constant
Ki (see section 2.4.3).
6.2.1 The Inhibition Constant Ki from FRET data
As in chapter 4, the 530 nm peak is used in the quantitative analysis in this
section. The method is illustrated for the titration of RanBP2(l) into ECFP-
SUMO1 + EYFP-Ubc9. The peak at 530 nm decreases due to both decreasing
energy transfer and dilution during the titration. The data from a dilution
control was subtracted from the emission peak to give the contribution of
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Figure 6.3: Competition curve of RanBP2(l) inhibiting ECFP-SUMO1 +
EYFP-Ubc9 binding, ﬁtted with a single exponential rise. The 50% point
is deﬁned as the IC(50).
FRET. Using the initial FRET signal and the saturated end point, the data was
scaled in terms of % of ECFP-SUMO1 and EYFP-Ubc9 complex dissociated.
The curve was then ﬁtted with an exponential function, as presented in ﬁgure
6.3. From this ﬁt, the amount of RanBP2(l) required in order to achieve 50%
inhibition is IC50 = 0.68 µM ± 0.06 µM.
The inhibition constant Ki is the binding constant relating to the in-
teraction of the bound complex of binding constant Kd with the inhibiting
molecule and can be derived from the IC50 value with the following relation
[100]:
Ki =
IC50 ·Kd
[S] +Kd
(6.1)
Using IC50 = 0.68 ± 0.06 µM, Kd = 0.59 ± 0.09 µM and [S] = 1.0 ±
0.05 µM (the equimolar concentration of the initial proteins) gives Ki=0.25 ±
0.06 µM.
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The inhibition constant computed for RanBP2(s) is IC50 = 1.04 ± 0.08
µM, and the resulting Ki = 0.38 ± 0.09 µM.
6.3 Further Multi-Protein Interactions
Spectra recorded during two further titrations are presented in ﬁgure 6.4.
Firstly, Ubc9 was titrated into an equimolar solution of ECFP-SUMO1 +
EYFP-RanBP2(l).
Figure 6.4: Spectra recorded during the titrations of
a. Ubc9 into 1 µM ECFP-SUMO1 and EYFP-RanBP2(l).
b. SUMO1 into 1 µM ECFP-RanBP2(l) and EYFP-Ubc9.
The spectra display the double-peaked emission of the ECFP donor ﬂuo-
rophore at 475 nm, but no acceptor emission peak at 530nm. We can conclude
that the tagged proteins have not bound. Furthermore, the spectral shape does
not change upon the addition of Ubc9, indicating that it does not facilitate the
formation of a trimeric bound complex through its binding sites for both the
tagged proteins. From the results of section 6.2.1 we can also conclude that
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Ubc9 preferably binds EYFP-RanBP2(l) in this conﬁguration.
In contrast, the spectra of the equimolar solution of ECFP-RanBP2(l)
+ EYFP-Ubc9, shown in ﬁgure 6.4, show a decreased emission at 475 nm and
a peak at 530 nm as a result of FRET due to RanBP2(l) and Ubc9 binding.
The spectra do not change shape upon the addition of SUMO1 up to 3 µM,
although the overall emission decreases due to dilution.
Figure 6.5: FRET emission ratio as a function of added protein. The plots
summarise spectral data presented in ﬁgure 6.4. Diﬀerence plots demonstrating
linearity are inserted.
Figure 6.5 summarises the results in graphs of FRET ratio as a function
of added protein. This visualises the constant low or high level of FRET
respectively. The last titration was subsequently repeated taking the SUMO1
concentration up to 210 µM, and the ratio graph shown in ﬁgure 6.6
Since RanBP2(l) binds Ubc9 and not SUMO1, the Ki of RanBP2(l)
inhibiting the SUMO1-Ubc9 interaction is equivalent to the Kd of RanBP2
and Ubc9. The Kd for RanBP2(l) binding Ubc9 was determined by FRET
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Figure 6.6: FRET emission ratio as a function of SUMO1 added to 1 µM
ECFP-RanBP2 + EYFP-Ubc9. This is a repeat experiment of that presented
in ﬁgure 6.5 with higher concentrations of SUMO1.
which gave Kd = 0.17 ± 0.04 µM. This validates the Ki calculation, since the
calculated Ki is close to the Kd but not smaller in value.
We can conclude that while SUMO1 may provide some hindrance to
RanBP2(l) binding to Ubc9, the binding constant is not signiﬁcantly decreased
and SUMO1 does not bind Ubc9 strongly enough to compete with RanBP2 in
the same concentration range.
The inhibition constant of SUMO1 in this reaction is IC50 = 69.2 ± 4.0
µM, resulting in Ki = 10.05 ± 3.43 µM (using [S]= 1.00 ± 0.05 µM and Kd
= 0.17 ± 0.04 µM). This Ki is considerably lower than the one determined
for RanBP2(l), demonstrating that RanBP2 binds strongly to Ubc9 and that
SUMO1 competes minimally with a high Ki.
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6.4 Discussion of Multi-Protein Experiments
The eﬀect that other molecules have on the binding of two labelled proteins is
readily studied by monitoring the change in FRET signal from a solution of
tagged proteins during the addition of a third, untagged sample. In the case of
RanBP2(l) titrated into ECFP-SUMO1 + EYFP-Ubc9, we observe the FRET
signal decrease to zero. This is due to a separation of the tags well beyond the
Förster Radius (>10nm), implying that the binding of the two tagged proteins
has been disrupted. Furthermore, RanBP2(l) is shown to bind Ubc9 but not
SUMO1, as shown schematically in ﬁgure 6.7.
Figure 6.7: Schematic diagram of RanBP2 inhibiting SUMO1-Ubc9 binding.
Accordingly, FRET decreases as the concentration of RanBP2 is increased.
We can quantify the interaction of RanBP2(l) with the SUMO1-Ubc9
complex using inhibition relations. The resulting inhibition constant Ki is
moderately larger than the binding constant for RanBP2(l) and Ubc9 deter-
mined by FRET, indicating that binding to Ubc9 may be slightly weakened
in the presence of SUMO1. The same titration with RanBP2(s), which binds
both SUMO1 and Ubc9, also interestingly results in a FRET signal decrease
to zero although multiple mutual binding sites are present [125]. The results
show that binding is disrupted, although these three proteins are theoreti-
cally able to form a trimeric complex. Indeed they have been shown to do so
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when SUMO1 and Ubc9 are covalently linked in the ﬁnal conjugation stage of
SUMO1 in a crystal structure [126]. The formation of this complex was shown
to catalyse SUMOylation, and these results emphasise the necessity of the co-
valent SUMO1-Ubc9 link for substrate conjugation. The eﬀect of SUMO1 on
the binding of ECFP-RanBP2(l) to EYFP-Ubc9 was shown to be signiﬁcantly
weaker. This is in accord with the binding constants which show a stronger
aﬃnity of Ubc9 to RanBP2(l) over SUMO1, impeding the binding of SUMO1
to Ubc9 in the presence of RanBP2(l).
6.5 Conclusion
The major beneﬁt of FRET that distinguishes it fundamentally from ITC is
that we can adapt assays to resolve information on speciﬁc proteins within a
complex of several interacting molecules. Using FRET as a binding signal, we
can quantify the eﬀect of further substances on the binding of tagged protein
partners. Binding in an equimolar solution typically results in a FRET signal
and hence a 530 nm / 475 nm emission ratio of >1. We now monitor changes
in binding through spectral changes as a third interacting molecule is added.
This may bring the tagged proteins together in a trimeric complex, or compete
with one (or both) of them for an exclusive binding site and act as an inhibitor.
In this case, we can compute the inhibition constant Ki, which relates to the
Kd of the interaction of the inhibiting molecule with the bound complex.
Our results show that neither of the two RanBP2 fragments used in the
study of SUMOylation facilitates the formation of a stable trimeric bound com-
plex with SUMO1 and Ubc9 although several mutual binding sites are present.
This appears to be because RanBP2 competes with SUMO1 for an overlap-
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ping binding site on Ubc9 in spite of its ability to bind Ubc9 and SUMO1
independently. This implies that SUMO1 has to be covalently linked to Ubc9
for RanBP2 to bind in trimer formation and catalyse SUMOylation. However
following the SUMOylation of substrates, and the loss of the covalent link to
SUMO1, Ubc9 can strongly bind to RanBP2. This complex may facilitate the
deconjugation of Ubc9 from the SUMOylated substrate and act as a ﬁrst step
towards recycling Ubc9.
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Post-Translational Modiﬁcation
Monitored by FRET
SUMOylation of substrates ultimately requires the conjugation of SUMO1 to
target proteins to initiate their post-translational modiﬁcation. The conjuga-
tion of proteins is generally detected by immunoblotting or autoradiography,
which both require samples to be fractionated on SDS electrophoresis gels.
This requires the manual removal of sample from the reaction for each mea-
sured time point. Kinetic analysis by this method is not ideal - temporal
resolution and, as a result, the detectable kinetic range are limited, and quan-
titative analysis of gel fractions from photographs is diﬃcult. Furthermore,
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neither technique is a suitable high-throughput format assay.
In chapters 4-6 we presented FRET-based methods to quantify non-
covalent binding interactions, based on a thermodynamic association and dis-
sociation that facilitate the ﬁxed covalent conjugation of SUMO1 to its targets.
We now demonstrate the potential of FRET in the quantitative kinetic analysis
of post-translational modiﬁcations. We illustrate this with the SUMOylation
of RanGAP1, during which an isopeptide bond is formed between the carboxy
group on the activated SUMO1 C-terminus and the ε-amino group of a lysine
residue in RanGAP1. Ubc9 catalyses this reaction, and is recycled following
each conjugation. As in chapter 6 we examine a complex interaction, this
time using the FRET signal between ECFP-SUMO1 and EYFP-RanGAP1 as
a measure of time-dependent conjugation.
Materials used in this chapter are EYFP-RanGAP1, ECFP-SUMO1,
SAE1/2, Ubc9, ATP and MgCl2.
7.1 SUMOylation Assay Setup
We begin with 800 µl solution containing 2 µM ECFP-SUMO1 and 1 µM
EYFP-RanGAP1 in a 3.5 ml quartz cuvette. Spectra are monitored during
the reaction in 2 minute cycle mode on a Cary Eclipse Spectrophotometer,
with a scan time of 80 s, 1 nm intervals, 0.5 s integration time and a spectral
detection range of 440 to 600 nm. The reaction cuvette is held at 21C with
a PCB peltier system. After recording the ﬁrst spectrum, 200 µl solution
is added containing 500 nM Ubc9, 140 nM SAE1/2, 2 mM ATP and 5 µM
MgCl2. We expect a FRET signal to appear and increase linearly as Ubc9
conjugates increasing numbers of EYFP-RanGAP1 to ECFP-SUMO1. As all
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RanGAP1 is conjugated the signal is expected to plateau, since no further
product is formed. We increase the concentration of ECFP-SUMO1 to ensure
that only the availability of EYFP-RanGAP1 limits the reaction. This ensures
that the plateau occurs when all EYFP-RanGAP1 is conjugated, rather than
when ECFP-SUMO1 is depleted.
When the plateau is reached and the reaction completes, we add 10 mM
inhibiting EDTA to deactivate Ubc9 as well as 0.02 µM SENP1 protease, which
cleaves the C-terminus of SUMO1 and hence deconjugates the RanGAP1-
SUMO1 complex. The FRET signal is consequently expected to decrease as
a function of SENP1 activity. Deconjugation at the SUMO1 C-terminus is
further explored in chapter 8.
In addition to ﬂuorescence measurements, 6 x 20 µl samples of the reac-
tion were removed at a range of time points, added to protein loading buﬀer,
fractionated by electrophoresis on an 8% polyacrylamide gel containing SDS
and stained with Coomassie Brilliant Blue.
7.2 FRET Signals of SUMOylation
The FRET signal resulting from the Ubc9-mediated conjugation of ECFP-
SUMO1 to EYFP-RanGAP1 is shown in ﬁgure 7.1. Here, the EYFP peak at
530 nm is plotted as a function of time - following the injection of the Ubc9
mixture the reaction took 7.25 hours to complete. This slow rate is due to the
low concentrations and the low temperature chosen for this initial experiment.
Deconjugation by SenP1 on the other hand occurred within 20 s - the
FRET signal vanished by the time the spectrum following the addition of the
protease was recorded. We can conclude that SenP1 has a very high catalytic
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Figure 7.1: FRET peak intensity at 530 nm as a function of time during the
conjugation of ECFP-SUMO1 to EYFP-RanGAP1, induced by the addition
of Ubc9, SAE1/2 and ATP at t = 0. More ECFP-SUMO1 was added after t =
240 min. At t = 422 min, EDTA and the protease SenP1 was added, leading
to deconjugation. The jumps at 18 and 244 minutes are due to a change in
cuvette position. The numbers in circles indicate the points at which samples
were removed and run on a gel, which is shown in ﬁgure 7.2
activity.
In addition to the FRET experiment, samples were removed at various
stages during the reaction, preserved and fractionated by electrophoresis in
a polyacrylamide gel containing SDS, followed by staining with Coomassie
Brilliant Blue. A labelled photograph is shown in ﬁgure 7.1). Samples were
taken at t = (1) 2 min, (2) 239 min, (3) 242 min (after the addition of more
ECFP-SUMO1), (4) 300 min, (5) 423 min and (6) 430 min (after adding EDTA
and SENP1). A pre-stained protein marker solution (A), EYFP-RanGAP1 (B)
and ECFP-SUMO1 (C) were also analysed.
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Figure 7.2: Photograph of an SDS polyacrylamide gel showing bands of ECFP-
SUMO1 and EYFP-RanGAP1 individually and as a conjugated complex at
various stages of the Ubc9-catalysed reaction. The numbers in circles corre-
spond to those in ﬁgure 7.1. A pre-stained protein marker indicates molecular
weights on the left, while EYFP-RanGAP1 and ECFP-SUMO1 were run in two
further wells. The faint lines above the labelled proteins are due to species mi-
grating more slowly in the EYFP-RanGAP1 and EYFP-SUMO1 preparations
as a result of translational readthrough in the bacteria.
Indeed, the gel shows the expected decrease in EYFP-RanGAP1 between
(1) and (5), and in parallel to that an increase in the conjugated ECFP-SUMO1
+ EYFP-RanGAP1 complex. The added ECFP-SUMO1 is clearly visible in
well (3), as is complete deconjugation in well (6). This gel supports the FRET
data, and also shows that even after seven hours (well (5)) not all EYFP-
RanGAP1 is conjugated. Complete conjugation will appear as a plateau in
the FRET graph - this was not quite reached in this experiment. The rate of
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conjugation under these conditions was calculated from the linear sections of
the FRET graph to be 2.55 ± 0.05 nM/min.
7.3 Discussion of FRET in Post-Translational
Modiﬁcation
This is a beautiful example of the precision, simplicity and versatility of using
FRET for quantitative studies. The FRET-based post-translational modiﬁ-
cation assay is ideal for the detection of further SUMO-modiﬁed substrates.
As shown in previous experiments, the format is easily adapted to multi-well
plate and high-throughput screening formats.
The high temporal sensitivity and the quantitative nature of the detec-
tion by FRET can not only lead to new insights into substrate speciﬁcity, but
also characterise the conjugation process as a function of the concentration of
catalysing molecules such as Ubc9 and RanBP2. Buﬀer constituents, ATP con-
centration and temperature are further variables of interest. Initial conjugation
rates, determined for a range of substrate concentrations form the basis of the
analysis of Michaelis-Menten kinetics. Similar to the binding curve hyperbola
in chapter 4, this analysis yields the constant Km, the substrate concentration
at which the initial reaction rate is half the maximum rate. Monitoring reac-
tion rates by FRET gives a set of data ideal for advanced analysis. This can
give valuable input to models of pathways, and enable predictions concerning
in vivo interactions.
Following this proof of principle, we planned further work to explore
the options discussed above, consolidate the analysis techniques and present a
comprehensive method. However these plans were shelved when similar work
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was published by Bossis et al [1].
Figure 7.3: Figures 2 A and 2 B from Bossis et al [1]:"(A) Unprocessed emission
data. Twenty-ﬁve microliter reaction mixes containing YFP-SUMO1, CFP-
GAPtail, Aos1/ Uba2, and Ubc9 were incubated in a 384-well plate at 30C
in the absence or presence of 1 mM ATP. Fluorescence after excitation at 430
nm was measured every minute at 485 and 527 nm. (B) Processed data. The
rate of conjugation correlates directly with the change in the ratio of emissions
(527 nm/485 nm). The value observed in the absence of ATP is due to the
ﬂuorescence of CFP at 485 and 527 nm (YFP is not excited to signiﬁcant levels
at 430 nm) and reﬂects 0% modiﬁcation. After the addition of ATP, the ratio
of emissions increases linearly until it reaches a stable plateau. This reﬂects
100% modiﬁcation[...]"
In a very similar experiment, presented in well-plate format, they demon-
strate the conjugation of YFP-SUMO1 to a version of CFP-RanGAP1. They
expand the initial experiment to include varying concentrations of ATP, Aos1/Uba2
(SAE1/2), untagged RanGAP1, Ubc9 mutants and a demonstration of decon-
jugation by SenP1. The data is presented in unprocessed form and as the 527
nm / 485 nm ratio, but no advanced analysis such as Michaelis-Menten ﬁtting
was attempted. Figure 7.3 shows the initial results and data handling and
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includes the original ﬁgure caption. The ﬁrst graph shows the ﬂuorescence
data collected at 485 and 527 nm (ﬁlter bandpass width is not quoted) during
a conjugation reaction and a control reaction without ATP. In both cases the
ﬂuorescence at 485 nm decreases with time - however a decrease due to energy
transfer would only be expected in the active experiment with ATP. Indeed,
the decrease with ATP appears more prominent. However in the control - in
which the 527 nm emission decreases as well - this "is most likely due to pho-
tobleaching and/or denaturation of the recombinant proteins" [1]. This is a
surprising conclusion, since both ﬂuorescent proteins have proven very stable
both photophysically and structurally in our measurements. The changes in
ﬂuorescence presented here are more likely to be a result of increasing tempera-
ture and hence vibrational quenching. Since the experiments are performed at
elevated temperatures, this may reﬂect the equilibration of the well-plate. Fur-
thermore, the resulting wavelength ratio results in a zero gradient line, which
reinforces the theory that losses may be due to temperature, as a uniform loss
of signal across the spectrum will cancel when dividing the intensity of two
wavelengths.
According to Bossis et al, "the change in the emission ratio over time is
a direct readout for the rate of the conjugation reaction." This statement is
however neither veriﬁed nor referenced. While the ratio is a convenient way
of eliminating intensity changes across whole spectra (such as due to dilution
and temperature changes) and visualising spectral shifts, the division of two
ﬁltered readouts by no means represents a direct measure of the number of
molecules undergoing FRET and hence a readout of rates. In fact, if denatu-
ration and photobleaching were present as stated above this would deﬁnitely
not be true. In chapter 8 we experimentally validate the use of the acceptor
peak as a linearly proportional measure of molecules undergoing FRET. How-
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ever dividing this by the decreasing donor emission leads to an overestimation
of rates.
Figure 7.4: Emission spectra (excitation 400 nm) of ECFP-SUMO1 and EYFP-
RanGAP before (blue) and after (red) conjugation.
A further point to note about the ﬁrst graph is that the emission intensity
at 527 nm is about half that at 485 nm. Since details of the emission ﬁlters are
not disclosed, the spectral shape cannot be derived from the information given.
Moreover, ﬁlter-based well-plate readers allow for the separate adjustment of a
gain ("fudge") factor which is multiplied by the emission readout. The authors
state that YFP is not excited to signiﬁcant levels at 430 nm - it is clear from
our results in preceeding chapters that direct excitation indeed has to be born
in mind when using FRET data quantitatively. However, since the authors do
not attempt a rigorous analysis, this omission is not catastrophic. Figure 7.4
shows corrected spectra for a solution of ECFP-SUMO1 and EYFP-RanGAP1
before (blue) and after (red) conjugation, demonstrating the spectral change
due to FRET in this case, and the true relative peak emissions.
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7.4 Conclusion
The techniques most commonly used in the kinetic analysis of protein conju-
gation, such as the SUMOylation of substrates, require the manual removal of
sample from a reaction before fractionation on electrophoresis gels. This is a
labour-intensive process and the temporal resolution is clearly limited.
We demonstrated that these limitations can be overcome when using
FRET as a conjugation signal. The emission at 530 nm from an ECFP-SUMO1
and EYFP-RanGAP1 solution increases as a result of FRET during the conju-
gation of SUMO1 to RanGAP1, and closely follows gel data obtained in paral-
lel. A sensitive quantitative kinetic analysis of post-translational modiﬁcation
is achievable by this method. This is readily rolled out to high-throughput
screening format for diﬀerent substrates, potential ligases and inhibitors.
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FRET Detection of Protease Activity
Using Doubly-Tagged SUMO1
The protease SENP1 activates SUMO1 precursors by cleaving peptide bonds
during the initial maturation of SUMO1, and is involved again in the ﬁnal
stage of SUMOylation, where it deconjugates SUMO1 from modiﬁed substrates
by cleaving isopeptide bonds. As in the conjugation presented in chapter 7,
deconjugation is also usually quantiﬁed by immunoblotting or autoradiography
of samples fractionated by SDS electrophoresis. Reaction rates determined
from such experiments give valuable insights into the concentration-dependent
timescales of deconjugation and the speciﬁcity of a protease for a range of
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possible substrates.
In this chapter we present ﬂuorescently labelled substrates that enable
the kinetic analysis and detailed characterization of both the C-terminal hydro-
lase and the isopeptidase activities of SUMO1 proteases by FRET [117], as well
as measurement and analysis methods. In particular, SUMO1 doubly-tagged
with ECFP and EYFP is examined as a substrate for SenP1 which cleaves a
GG-HSTV motif on the C-terminus of SUMO1. This approach opens a vast
range of experimental possibilities for the study of proteases interacting with
ubiquitin-like proteins, some of which are presented here, and forms the basis
of subsequent research [127].
Materials used in this chapter were SUMO1, EYFP-SUMO1-ECFP, ECFP-
SUMO1-EYFP, EYFP-SUMO1-RanGAP1-ECFP, SenP1 (415−644) (kind gift from
L. Shen, University of Dundee)
8.1 Doubly-Tagged SUMO1
A doubly-tagged SUMO1 fusion protein was cloned, expressed and puriﬁed
with EYFP on the N-terminus and ECFP on the C-terminus. A ribbon di-
agram is shown in ﬁgure 8.1. In theory, a construct with two suitable tags
attached will display FRET, provided the size of the middle protein does not
generate a distance between the tags far beyond the Förster radius. Provided
the protein is also correctly folded and as active as its wild-type form, the pro-
tease activity can be monitored by a decrease in FRET signal upon cleaving
the peptide backbone.
In the following sections we examine the FRET signal and activity of
the construct and discuss the analysis of kinetic data from this assay using
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Figure 8.1: Ribbon diagram of EYFP-SUMO1-ECFP. This structure was as-
sembled from data for GFP and SUMO1 from the RCSB protein data bank
[82].
the SUMO1-speciﬁc protease SenP1. To determine the presence of FRET,
ﬂuorescence emission spectra from a quartz cuvette containing 1 ml of 2 µM
EYFP-SUMO1-ECFP were recorded on a Cary Eclipse Spectrophotometer
during an incubation with 0.4 nM SenP1(415−644). The sample was buﬀered
in 50 mM Tris/HCl pH 7.5, 20 mM NaCl, 1 mM β-mercaptoethanol. The
excitation wavelength was 400 nm, integration time 1 s and slit width 5 nm.
Figure 8.2 shows the initial and ﬁnal spectra of the 12 h incubation. The
ﬁnal products were analysed by mass spectrometry to conﬁrm their molecular
weights and hence the location of the cleaving site [117].
In a further experiment, we compared the kinetic rate of processing ac-
tivity of our tagged construct to that of the wild-type protein. For this, both
wild-type and EYFP-ECFP fused SUMO1 were incubated with 2 nM SENP1
at 25C in 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol.
The emission at 530 nm from the ﬂuorescent sample was monitored on a Cary
Eclipse Spectrophotometer throughout in intervals of 12 s to 5 min. Again,
the excitation wavelength was 400 nm, integration time 1 s and slit width 5
nm. Samples of 10 µl were withdrawn from both incubations at various times
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Figure 8.2: Emission spectra of EYFP-SUMO1-ECFP before (linked sub-
strate) and after processing by SenP1 (cleaved substrate).
from 1 min to 2 h - the exact timepoints are displayed in ﬁgure 8.3 - and
then fractionated by SDS polyacrylamide gel electrophoresis. The gels were
photographed under UV illumination, and again in white light transmission
after coomassie staining. The data was quantiﬁed by densitometry using Im-
age Gauge V3.45 software (performed by Mike Tatham). The data from both
gels and the ﬂuorescence emission was converted into the relative amount of
SUMO1 processed as a function of time and are compiled in ﬁgure 8.4.
The cleaving of the GG-motif of the SUMO1 C-terminus by SenP1 facil-
itates the deconjugation of SUMO1 from substrates. We compared our con-
struct which monitors C-terminal hydrolase activity (in absence of the sub-
strate) to a conjugated EYFP-SUMO1-RanGAP1-ECFP fusion protein, the
product from chapter 7, which monitors isopeptidase activity. Fluorescence
emission spectra from two quartz cuvettes containing 1 ml of 2 µM EYFP-
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SUMO1-ECFP and 1 ml of 2 µM EYFP-SUMO1-RanGAP1-ECFP respec-
tively were recorded on a Cary Eclipse Spectrophotometer during an incuba-
tion with 2 nM SENP1. The samples were buﬀered in 50 mM Tris/HCl pH
7.5, 20 mM NaCl, 1 mM β-mercaptoethanol. The excitation wavelength was
400 nm, integration time 1 s and slit width 5 nm.
The FRET-based SUMO1 processing assay is readily applied to multi-
well-plate format, which also faciliates the kinetic analysis of protease activity.
To demonstrate the initial rates analysis, a BMG Labtech Novostar Fluorime-
ter was used together with black, clear-bottom Greiner 384 well plates. Filters
chosen were 405-20 nm excitation and dual 480-10 nm and 530-10 nm emission.
Runs were prepared such that the automatic pipettor added 20 µl of ﬂuores-
cent SUMO1 protein to 10 µl protease-containing solution. Assays were hence
of 25-30 µl ﬁnal volume, buﬀered in 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 5
mM β-mercaptoethanol and 0.1 mg/ml BSA. Data were recoded through the
bottom of each well following mixing by the pipettor. After initial rate data
was measured, all reactions were read at 3 to 8 min intervals until completion.
8.2 Functionality of Substrates
Figure 8.2 shows the emission spectra before and after a 12 h incubation with
SENP1. The spectra initially show decreased ECFP emission at 475 and 500
nm and a large emission peak at 530 nm which, upon incubation, decreases
to a shoulder (attributed to the direct excitation of EYFP) while the ECFP
emission recovers. The double-tagged construct is hence displaying FRET
which decreases as the C-terminus of SUMO1 is split oﬀ by SenP1.
If these EYFP and ECFP tagged SUMO1 constructs are to be used as
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Figure 8.3: Photographs of SDS electrophoresis gels displaying various time-
points of SenP1 processing of SUMO1 (top, light transmission) and EYFP-
SUMO1-ECFP (bottom, UV illumination). Bands were analysed by mass
spectroscopy for identiﬁcation.
functional analogues of wild-type full-length SUMO1, it is important to de-
termine whether tagging with ﬂuorescent proteins aﬀects the processing of
SUMO1 by proteases. To check whether the SUMO1 fusion construct is cor-
rectly folded and active, it was processed in parallel with wild-type SUMO1
and samples removed at various times fractionated by SDS electrophoresis.
The gels are shown in ﬁgure 8.3.
Densitometric analysis of these gels revealed that SENP1 processed the
wild-type and ﬂuorescent SUMO1 at similar rates, as shown in ﬁgure 8.4.
The slightly higher cleavage rate of wildtype SUMO1 is more likely to be a
consequence of errors in the determination of wild-type SUMO1 concentration
rather than an inhibition caused by the ﬂuorescent proteins. Importantly, all
of the abundant ﬂuorescent protein was cleavable by SENP1, demonstrating
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that no fraction of the sample is protease resistant.
Figure 8.4: Densitometric analysis of the gels in ﬁgure 8.3 together with kinetic
FRET data based on the 530 nm peak.
Furthermore, if the ﬂuorescence signal is to be used as a proportional
representation of the number of processed SUMO1 molecules, the linear re-
lationship between signal change and cleaved protein has to be established.
Figure 8.4 shows the superposition of densitometric analysis and the 530 nm
peak decrease converted into % of processed SUMO1 by means of the initial
(0%) and ﬁnal (100%) measurements of the completed reaction. These results
prove two crucial points which are essential to all the FRET-based methods
presented here:
1. The use of tags, particularly the relatively large ﬂuorescent proteins,
raises concerns over potential denaturation, steric hindrance and al-
tered functionality of the labelled protein. The densitometric analysis of
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the parallel reactions shown in ﬁgure 8.4 clearly demonstrates that the
processing rate of SUMO1 is not decreased when sandwiched between
ﬂuorescent proteins. The similar functionality of tagged and untagged
SUMO1 demonstrates that the protein's behaviour is unaﬀected.
2. We have been using the 530 nm peak emission as a measure of the number
of molecules undergoing FRET. However this linear proportionality is by
no means a given relation since the acceptor peak appears as a shoul-
der on the donor emission and a more complex area-ﬁtting procedure
for example with Gaussian functions may be required for an accurate
estimation of energy transfer. Furthermore, the acceptor peak may itself
be quenched. The direct comparison of processing data based on FRET
with conventional densitometric analysis proves the linear relationship
we have so far only assumed.
8.3 Speciﬁcity of Substrates - RanGAP1
A great direct application of this assay with double-tagged proteins is the
sensitive comparison of diﬀerent substrates for a given protease or vice-versa.
SenP1 facilitates the deconjugation of SUMO1 from substrates by cleaving the
GG-HSTV of the SUMO1 C-terminus. The experiments so far involved assay-
ing for C-terminal hydrolase activity with the double-tagged SUMO1 without
a substrate present. In this section we examine a substrate as it occurs natu-
rally when SUMO1 is conjugated to RanGAP1 (see chapter 7) and compare it
to our construct. Thus for the same protease we can compare its C-terminal
hydrolase and isopeptidase activities.
A conjugated EYFP-SUMO1-RanGAP1-ECFP fusion protein was incu-
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Figure 8.5: Emission spectra of EYFP-SUMO1-ECFP and EYFP-SUMO1-
RanGAP1-ECFP, excited at 400 nm.
bated in parallel with the already examined EYFP-SUMO1-ECFP as described
in section 8.1, and emission spectra are recorded. The initial emission spec-
tra are shown in ﬁgure 8.5. Clearly the energy transfer is less eﬃcient in the
presence of RanGAP1 since it increases the distance between the two tags.
The processing rates calculated from the 530 nm emission are displayed
in ﬁgure 8.6. While they do not diﬀer dramatically for the two substrates,
we can note that the presence of RanGAP1 does not accelerate the reaction -
on the contrary, it may provide a steric hindrance to SenP1 binding SUMO1
and/or processing the GG site. Mass spectrometry results conﬁrmed that in
both cases cleavage occurs at the SUMO1 diglycine motif and at no further
points of the extended peptide chain.
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Figure 8.6: Processing time courses of 2 µM EYFP-SUMO1-ECFP and 2 µM
EYFP-SUMO1-RanGAP1-ECFP incubated by 2 nM SenP1 each.
8.4 Validation of the Analysis of FRET Data
While the ratio 530 nm / 480 nm gives a convenient representation of the
spectral changes caused by energy transfer, care has to be taken when using
spectral data quantitatively. If spectral shifts are solely due to decreasing
energy transfer, then monitoring either peak intensity will give a measure of
the rate of processing between the limits of the extrema of the peak intensities.
However dividing them will lead to an overestimation of the rate - if both
signals were to shift over the same dynamic range, this analysis would lead to
a doubling of the measured kinetic rate of the reaction. Furthermore, we have
avoided using the change in donor emission so far due to its limited dynamic
range.
In these experiments SenP1 is added once at the beginning of the re-
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Figure 8.7: Emission spectra of EYFP-SUMO1-ECFP recorded at various in-
tervals (30 s, 1 and 5 min) during processing by SenP1. Ten spectra are
displayed in each colour ranging from red (initial spectrum) to purple (last
spectrum).
action, so subsequent spectral changes are not due to quenching or dilution.
Figure 8.7 shows spectra recorded during the processing of EYFP-SUMO1-
ECFP by SenP1. The 530 nm peak intensity decreases as the ECFP is cleaved
oﬀ, while the double-peak at 475 and 500 nm increases slightly. This small
increase means that using the ratio in the analysis will lead to a slight over-
estimation - however if this is acknowledged and quantiﬁed, the ratio indeed
provides a measure of FRET that remains stable during long runs when tem-
perature stability may be an issue.
Figure 8.8 demonstrates the diﬀerence between the two analysis methods.
The spectral data from ﬁgure 8.7 are analysed once using the 530 nm / 475
nm ratio and again using the 530 nm peak. During the reaction, the ratio
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Figure 8.8: Initial rates of EYFP-SUMO1-ECFP processing using the the 530
nm / 480 nm ratio (blue) and the 530 nm acceptor peak (green). The initial
rates calculated by linear ﬁts are 1.22 %/min and 0.98 %/min respectively.
decreases from 1.96 to 0.73 while the peak emission intensity decreases from
326 to 157 units. Since the reaction completes, we can calculate the fraction
of SUMO1 processed at each timepoint using these 0% and 100% points.
The initial rates calculated by linear ﬁts to the ﬁrst 15 minutes are 1.22
%/min and 0.98 %/min respectively. We conclude that use of the ratio in
this case leads to an overestimation of initial rates by 25%. This excersise
demonstrates that caution regarding the source of the quantities measured is
worthwhile - while biochemical literature may state that optical signals are lin-
early proportional to the quantitites measured [128], this by no means ensures
that it has been investigated as discussed in chapter 7.3.
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8.5 Application in Kinetic Analysis
Multi-well plates, introduced in chapter 4 for repeat measurements of small-
volume sample provide a convenient assay format for the kinetic analysis of pro-
tease activity as well as tests for substrate speciﬁcity. While a gel-fractionation
technique typically requires 10 µl sample at 1 µM for each time point, a total
of just 20 µl at lower concentration analysed by FRET in a multi-well plate
will provide hours of kinetic data in up to 20 ms intervals.
Figure 8.9: The emission of ﬁve wells containing 2 - 10 µM EYFP-SUMO1-
ECFP during the injection of 2 nM SenP1 at t = 10 s.
Kinetic data is conventionally collected in two types of experiments: To
compare the substrate speciﬁcity of a speciﬁc protease, measurements can be
performed with a range of protease concentrations processing identical con-
centrations of the substrates to be tested. Alternatively, for a full Michaelis-
Menten analysis of the activity of a protease (determining the Km), a range
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of substrate concentrations is required together with a constant concentration
of protease. In either case the initial rates for each reaction are estimated and
plotted as a function of the concentration of the varying species. In the case
of the Michaelis-Menten analysis, the substrate concentrations must cover a
suﬃcient range either side of the Km value to generate a good ﬁt, similar to
that of the Kd described in chapter 4.
The assay was described and validated in this work, and research into
both types of analysis conducted. Subsequently Mike Tatham performed
experiments to compare the processing of SUMO1 and SUMO2 by SenP1
[117, 127].
Figure 8.10: Reaction time courses with varying EYFP-SUMO1-ECFP con-
centration (as indicated in µM) in multi-well plates.
Figure 8.9 shows the ﬁrst 50 s emission collected through the 530 nm
ﬁlter during the injection of 5 µl SenP1 into a selected range of concentrations
of EYFP-SUMO1-ECFP (as indicated in µM). In order to estimate potential
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Figure 8.11: Initial reaction rates determined from data in ﬁgure 8.10 as a
function of EYFP-SUMO1-ECFP concentration.
ﬂuctuations not due to energy transfer, the emission is monitored at both 480
± 5 nm and 530 ± 5 nm. The injection occurs by means of the automated
pipettor after 10 s, after which three mixing actions by aspiration and re-
injection of 5µl solution are performed. The injection results in an instant
decrease in emission due to dilution. A further short dip is observed as the
pipettor mixes close to the plate bottom and obscures the readings.
The time courses beyond the removal of the pipettor are converted into
% SUMO1 processed as described above and shown in ﬁgure 8.10. A number
of methods are used to determine initial reaction rates, ranging from using
"estimation by eye with ruler and pencil" [129] to computing a straight-line
ﬁt to the initial near-linear section of the curve. The density of data points
was found to be suﬃcient to use the linear ﬁt accurately. Figure 8.11 shows
the calculated initial rates as a function of EYFP-SUMO1-ECFP concentra-
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tion. The data ﬁts the line with an error of 6%, which is remarkably small
considering it is a function of the precision of dispensing both the substrate
and the protease in quantities as small as 5 µl, as well as reading data from 20
µl wells, as well as determining initial rates from these data. This sensitivity,
and the temporal resolution achievable in this FRET-based assay plug a hole
in the possibilities of kinetic analysis to date.
8.6 Further SUMO Processing Applications
Building on the proof of principle presented in this chapter, this processing
assay has been applied by Mike Tatham, Neil Hattersley and Anna Zagorska
and the results summarized below.
Using the basic well-plate format, the protease activity was tested on
two SUMO paralogs as a function of SenP1 concentration [117]. The raw data
for all runs and the data used for the analysis are shown in ﬁgure 8.12(a).
Similar measurements were repeated for SUMO2. An initial rates analysis was
performed as described above, and the resulting rates plotted as a function of
protease concentration for both SUMO1 and SUMO2 in ﬁgure 8.13(a). This
type of analysis is also readily extended to a more eﬃcient comparison of
protease mutants such as performed on SUMO proteases by Shen et al [127].
Another application which is ideally suited to analysis by FRET is the
testing of crude cell extract activity [117]. Gel fractionation is not ideal for
the detection of processed fragments, since contaminating proteins are likely
to obscure the bands of interest. As discussed previously in chapter 6, FRET
signals are not complicated by non-interacting proteins such as are present
in crude eukaryotic cell extracts. To investigate this application, a HeLa cell
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Figure 8.12: FRET-based time-course analysis of EYFP-SUMO1-ECFP and
EYFP-SUMO2-ECFP cleavage by a range of SENP1 concentrations. [117]
Figure 8.13: Comparison of the initial rates of EYFP-SUMO1-ECFP and
EYFP-SUMO2-ECFP processing as a function of SENP1 concentration. [117]
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lysate was added to EYFP-SUMO1-ECFP and EYFP-SUMO2-ECFP and con-
trasted with the activity of puriﬁed recombinant SenP1.
Figure 8.14: Analysis of SUMO processing activity in crude HeLa cell extract.
a. FRET was used to monitor the progress of SUMO protease assays containing
EYFP-SUMO1-ECFP and EYFP-SUMO2-ECFP with unpuriﬁed HeLa cell
extract. b. Comparison of the speciﬁc SUMO processing activity in crude
HeLa extract and puriﬁed recombinant SENP1.[117]
Figure 8.14 shows that processing activity can be detected in the crude
cell extract in a highly reproducible manner. On a biological level it also
shows that SUMO1 processing activity in the extract is far greater than that
for SUMO2. Mass spectrometry conﬁrmed that both processes yield the ex-
pected fragments, conﬁrming that speciﬁcally the SUMO protease activity of
the extracts is measured and no unrelated cleavage is occuring
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A full kinetic analysis of SUMO substrates was published in a study of
the mechanism of substrate recognition by SENP1 [127]. It was observed that
SENP1 preferentially processes SUMO1 over SUMO2, although the binding
aﬃnity of SenP1 to both SUMO1 and SUMO2 are similar. Initial rates from a
range of substrate concentrations were calculated and analysed by Michaelis-
Menten kinetics yielding the constants Km (half-maximal rate concentration)
and Kcat (the maximal rate per unit of protease). The data is shown in ﬁgure
8.15, a table of constants can be found in Shen et al [127].
Figure 8.15: Michaelis-Menten analysis from initial rates for full-length, and
RanGAP1 conjugated SUMO1 and SUMO2. 0.625 nM SenP1 was used in
all cases apart from full-length SUMO2, where the SenP1 concentration was
increased to 10 nM. [127]
The Km values were found to be similar for SUMO1 and SUMO2, the
maximal reaction rates Kcat however vary visibly. The diﬀerence is not a result
of preferential binding but due to more eﬃcient catalysis. This may result from
diﬀerences in the ability of SENP1 to bend and access the scissile bonds. On
the other hand, the processing rates are substantially increased when SUMO1
is conjugated to RanGAP1. This may be a result of the easier kinking of the
bond into the cis conﬁguration required for processing. The results suggest
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that residues on the C-terminal side of the diglycine motif aﬀect catalysis,
although SENP1 does not interact with the SUMOylated substrate. However
further unique regions of the protease may provide substrate speciﬁcity.
8.7 Binding-Induced Conformational Changes
Figure 8.16: Emission at 480 nm and 530 nm from 1 µM EYFP-SUMO1-
ECFP as a function of added dSenP1 in well plate format. Error bars denote
one standard deviation from the mean of readings from three wells.
Doubly tagged proteins are not only convenient substrates in processing
assays, but also for monitoring conformational changes in the tagged protein
as a result of binding [34, 93]. This is of particular interest in the study of
SUMO1 since the generation of the crystal structure of a catalytically deacti-
vated SenP1 mutant (dSenP1(415644)) bound to SUMO1 [127]. This shows a
conﬁgurational change at the SUMO1 C-terminus upon binding: the scissile
peptide bond is kinked at right angle to the C-terminal tail of SUMO1. This
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Figure 8.17: Schematic diagram of conformational changes in EYFP-SUMO1-
ECFP upon binding of dSenP1. Top: Doubly-tagged SUMO1 indicating the
mobility of C-terminal ECFP. Bottom left: binding of dSenP1 induces a right-
angle kink, expected to decrease the probe distance and increase FRET. Bot-
tom right: binding of dSenP1 provides a steric hindrance to ECFP, increase
the average probe distance, FRET decreases.
is thought to signiﬁcantly increase the rate of SUMO1 processing by SenP1,
since the processing rate of SUMO2, for which no such kink was detected, was
measured to be 50 times smaller.
The binding of dSenP1 to SUMO1 with ﬂuorescent proteins attached at
both N- and C-terminae may aﬀect the mean distance between tags and hence
result in a change in FRET. Such a signal change may then be used to calculate
the binding constant for the interaction of dSenP1 and SUMO1.
8.7.1 dSenP1 Binds EYFP-SUMO1-ECFP
A well plate was prepared to measure dSenP1 concentration dependent changes
in FRET. A dilution series of 20 µl dSenP1 was dispensed into wells in triplicate
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Figure 8.18: Binding curve of dSenP1 to EYFP-SUMO1-ECFP in well plate
format. Error bars arise from the combined reading errors shown in ﬁgure
8.16.
as indicated in ﬁgure 8.16. This was topped up with 5 µl EYFP-SUMO1-ECFP
to a ﬁnal concentration of 1 µM . The ﬁltered emission was measured on a well
plate reader (details in chapter 3.4).
The emission from EYFP-SUMO1-ECFP at 480 nm and 530 nm as a
function of added dSenP1 is shown in ﬁgure 8.16. A clear decrease in emission
at 530 nm coincides with an increase at 480 nm. This is attributed to a decrease
in FRET resulting in decreased acceptor and increased donor emission. At a
ﬁrst glance this result is counterintuitive: we may expect an induced 90 degree
kink in the peptide backbone of a terminus with an attached ﬂuorescent protein
to reduce the distance between ﬂuorescent probes and lead to an increase in
FRET, as depicted in ﬁgure 8.17. This result however cannot be attributed
to this speciﬁc conformational change, but instead to the steric hindrance
that dSenP1 poses to the C-terminal ECFP. The mean distance of the tags is
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eﬀectively increased, as ECFP is prevented from folding back on to SUMO1
in the presence of SenP1. The R−6 dependence of FRET on the distance
between ﬂuorophores is signiﬁcant in the signal changes detected here, since
a large fraction of the FRET signal results from the small number of tags at
close proximity.
The concentration-dependent FRET signal at 530 nm can be used as a
measure of binding, with an analysis similar to that in chapter 4. A crucial
diﬀerence is that the concentrations of ECFP and EYFP are constant and
equimolar throughout the experiment - hence no subtractions are required and
it is simply the initial point (Pi) and ﬁnal plateau (Pf ) data points that give
a measure of 1 µM free and 1 µM bound ECFP-SUMO1-EYFP respectively.
Using the data points in between (Pd), we determine the fraction of bound
protein (f) using the relation
f =
Pi − Pd
Pi − Pf (8.1)
.
The concentration of free dSenP1 is calculated by subtracting the bound
concentration from the total added for each data point. The binding curve of
bound versus free dSenP1 is displayed in ﬁgure 8.18. Fitting with the binding
hyperbola (equation 2.24 in chapter 2.4.2) gives Kd = 0.14 µM . However
this is associated with a large error as indicated by the error bars in ﬁgure
8.18, which turns the estimation of a binding constant from this signal into
merely a crude guess. The binding constant determined from ITC data is
0.787 ± 0.09 µM [127]. The errors arise from the relatively large errors in the
inital point and the ﬁnal plateau compared to the measured signal change. The
standard deviation from the triplicate measurement of the ﬁrst data point is 17
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% of the total subsequent signal change. While more sensitive measurements
may be achievable, the small change in FRET upon binding of dSenP1 to
EYFP-SUMO1-ECFP does not facilitate a precise measurement of the binding
constant of this interaction by this method.
8.8 Conclusion
Proteins that are doubly-tagged with FRET probes provide powerful tools for
investigating their cleavage as well as conformational changes. The construct
developed and investigated in this chapter, EYFP-SUMO1-ECFP, enables the
kinetic analysis of SUMO proteases, and the study of FRET changes upon
binding of inactive SenP1.The latter experiment interestingly results in a de-
crease in FRET, which we attribute to the steric hindrance that the protease
poses to the C-terminal ECFP. The protease-concentration-dependent signal
change was however found to be too small to provide as reliable a measure of
the binding constant as the method described in chapter 4.
Cleavage of the SUMO1 C-terminus by SenP1 results in a signiﬁcant
time-dependent decrease in FRET. A direct comparison to the processing rate
of unlabelled and doubly-labelled SUMO1 using electrophoresis gel fractiona-
tion revealed identical reaction rates. This is a crucial point, as it reinforces
results from previous chapter which suggest that the ﬂuorescent probes do not
inﬂuence the functionality of the labelled proteins in this work. Furthermore,
a comparison with the FRET signal measured as the emission intensity at 530
nm agrees well with data recovered from gels by densitometry, validating this
approach in the analysis of data in measurements throughout this work.
The FRET-based SUMO1 processing assay is particularly useful in the
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direct quantitative comparison of the processing rates of further SUMO sub-
strates, such as conjugated SUMO1-RanGAP1 or the paralog protein SUMO2.
Similarly, diﬀerent proteases are characterisable by the same method, and
even unknown samples can be screened for SUMO processing activity, such as
crude cell extracts. An exciting possibility arising from this work is the high-
throughput screen for SenP1 inhibitors and potential prostate tumor suppres-
sors described in the next chapter.
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FRET-Based High Throughput
Screening for Protease Inhibitors
A major advantage of FRET-based techniques is their compatibility with
small-volume and high throughput formats. In fact, the most exciting yet
simplest application of the FRET-based SUMO1 processing assay described in
chapter 8 is the development of a high-throughput screening system for pro-
tease inhibitors. The doubly-tagged SUMO1 construct EYFP-SUMO1-ECFP
is an ideal reporter of C-terminal hydrolase activity, as the initial FRET sig-
nal decreases as SUMO1 is processed by proteases. Naturally, this system can
also be used as a reporter of the inhibition of such activity. In fact, CFP/YFP
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FRET has been used in high-throughput systems, notably as an indicator of
apoptosis and caspase activity in cell assays [41]. In the following we establish
and validate a high-throughput screening method and use this for a ﬁrst screen
of the National Cancer Institute (NCI) diversity set library [130] for potential
inhibitors of the SUMO1-speciﬁc protease SenP1. The motivation for this is
two-fold: In order to use the doubly-tagged SUMO1 construct described in
chapter 8 in live cell studies, it must survive under attack by intracellular
proteases until the desired measurements are completed. The speciﬁc elimi-
nation of protease activity is essential to enable this research. Secondly, the
up-regulation of SenP1 activity has recently been linked to tumor growth in
prostate cancer [115, 116]. SenP1 inhibitors may suppress tumor growth and
hence provide anti-cancer medication.
9.1 High Throughput Screening Method
High-throughput screening methods facilitate the quantitative processing of
large sample numbers, ideally in small volumes. Several steps are required for
a comprehensive screen of compounds
1. Validation and determination of eﬃcacy of method
2. First screen of library compounds and identiﬁcation of initial set of hits
3. Further testing of hit compounds to determine the eﬃciency and speci-
ﬁcity of inhibition
In the following sections we present a method that facilitates a screen for
SUMO1 protease inhibitors and identify the hits from a ﬁrst screen of the NCI
diversity set [130]. All experiments were performed in Corning 3711 384 multi
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well plates read in a BMG Labtech Novostar ﬂuorimeter with ﬁlter settings of
405 nm for excitation and 480 nm and 530 nm for dual emission collection.
9.1.1 Proof of Principle and Validation
To demonstrate the method, a test-plate was set up with triplicate reactions.
Initially, 10 µl of 2 µM EYFP-SUMO1-ECFP (buﬀered in 50 mM Tris/HCl pH
7.5, 150 mM NaCl, 5 mM β-mercaptoethanol, 0.1 mg/ml bovine serum albu-
min) was distributed using the automated pipettor integrated in the Novostar
ﬂuorimeter. The even distribution was veriﬁed in a readout of ﬂuorescence at
both emission wavelengths, which gave E480 = 6547±114 and E530 = 4953±184
counts and hence an initial combined pipetting and measurement error of less
that 4%. To model inhibition, wells were topped up with 5 µl buﬀer, EDTA or
iodoacetamide of varying ﬁnal concentrations (0.1, 1, 10 and 50 mM). EDTA,
while a protease inhibitor, does not aﬀect the cysteine protease SenP1 since
its reaction does not depend on metal ions, and is hence a good model for a
potential candidate that does not inhibit this speciﬁc reaction. Iodoacetamide
on the other hand carboxymethylates the active cysteine in proteases and is
hence broadly destructive to protease activity. While it inhibits SenP1, its
reaction is clearly not speciﬁc to our purposes.
Fluorescence emission was monitored during and after 5 µl of 2.5 µM
SenP1 was automatically dispensed and mixed by aspiring 5 µl three times.
The ﬁnal volume was 20 µl and the ﬁnal concentrations 1 µM EYFP-SUMO1-
ECFP and 0.625 nM SenP1. The plate was subsequently read in 2 minute
intervals for a duration of four hours. Figure 9.1 shows timecourses for selected
series, while ﬁgure 9.2 displays the reactions' progress 30 minutes after the
dispensing of SenP1.
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Figure 9.1: Timecourses of the cleavage of 1 µM EYFP-SUMO1-ECFP by
0.625 nM SenP1 in the presence of indicated amounts of EDTA and iodoac-
etamide (IA). Note that the reaction with EDTA follows that without added
potential inhibitors, while iodoacetamide shows a dose-dependent response.
9.1.2 Statistical Parameters
Statistical analysis of the dynamic range and noise levels is required to deter-
mine the quality of a high-throughput screening technique. Z ′ has been deﬁned
as a simple parameter which combines the mean signal and background levels
µs and µb as well as the standard deviations of these measurements σs and σb
in one equation [131]:
Z ′ = 1− 3σs + 3σb|µs − µb| (9.1)
A high throughput screening method with Z ′ > 0.5 is considered an
excellent assay.
An initial calculation of the Z ′ value was determined with values from
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Figure 9.2: Proof of principle of the FRET-based SUMO1 protease inhibitor
screen: Reaction progress at t = 30 minutes. Error bars represent one standard
deviation from the mean based on triplicate reactions.
the measurements above. The ratio of the two emission wavelengths 530 nm
/ 480 nm is used in this analysis. Control wells with SenP1 but no inhibitor
provide the background (µb = 0.312, σb = 0.007), whereas wells with no SenP1
added provide the background measurement (µs = 0.733, σs = 0.006). The
resulting Z ′ = 0.905 demonstrates the high sensitivity of this FRET-based
screening method. Furthermore, the signal-to-background ratio µs/µb is 2.3
and signal-to-noise ratio (µs − µb)/σb is 58. In comparison to other screening
systems which state these parameters [46, 41], our signal-to-noise and Z ′ values
are excellent, in spite of the high background due to spectral bleed-through.
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9.2 Screen for SenP1 Inhibitors
Following the establishment and validation of the screening method, the proto-
col was adapted to the screening of the NIC diversity library. The compounds
are supplied in solution in DMSO at 2 mM in 96 well plates. The eﬀect of
DMSO on the assay was tested by adding 0.125 - 50 % DMSO to a set of wells
and measuring the activity of SenP1 as above (1 µM EYFP-SUMO1-ECFP,
0.625 nM SenP1). In small quantities (<20%), DMSO quenches ﬂuorescence
by 1.5% per increasing percentage, but has no eﬀect on the activity of SenP1.
Above 50% however the protein denatures and both ﬂuorescent proteins lose
their ﬂuorescence. For the compound screen a balance between compound
concentration and tolerable DMSO content was chosen at 5% DMSO and 100
µM compound.
9.2.1 Screening Strategy
10 rows of a 384 well plate were used to screen 2 library plates in parallel in
odd and even columns. Wells were ﬁlled with 23 µl buﬀer with the automated
pipettor and topped up with 2 µl of DMSO in control rows 1 and 10 and 2
µl from 2 compound library plates in rows 2 to 9 using a 12-fold multichannel
pipette. The plate was read to detect the ﬂuorescent compounds in this range
that will interfere with signals. Then, 5 µl of 8 µM EYFP-SUMO1-ECFP
was added to each well and the plate read again to pick up any aggregation,
denaturation or energy transfer between a compound and the ﬂuorescent pro-
teins. This reading also provides the reaction starting point. SenP1 (10 µl at
2.5 nM) was added to rows in 1 minute intervals (in two doses, 20 s apart),
however half of rows 1 and 10 were treated with 10 µl buﬀer instead as con-
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trols. The plate was then read in rows over a duration of 10 minutes , starting
10 (scan S1), 21 (S2), 32 (S3) and 45 (S4) minutes after the ﬁrst addition of
SenP1. This strategy leads to the parallel screening of 160 compounds in one
plate with dispensing and reading timings accurate to 1 minute. The readings
before the addition of SenP1 contrasted with readings after 45 minutes provide
a measure of SenP1 inhibition.
9.2.2 Identiﬁcation of Hits
Figure 9.3: Fluorescence emission at 480 nm and 530 nm for a representative
well plate row, indicating ﬂuorescing and quenching compounds.
Compound libraries contain highly reactive compounds that commonly
contain aromatic groups and are ﬂuorescent. A signiﬁcant number of com-
pounds were indeed found to be ﬂuorescent in the same range as ECFP and
EYFP. Similarly, several compounds were found to signiﬁcantly quench the
ﬂuorescence of either or both ﬂuorescent proteins. This was identiﬁed visually
by plotting the ﬂuorescence emission of the compounds and EYFP-SUMO1-
ECFP as shown in ﬁgure 9.3. To identify these compounds systematically,
a spreadsheet with logical functions was compiled that reports wells with an
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Figure 9.4: Emission ratio of a representative control well plate row (left) and
a compound well plate row (right). Grey data points show the initial emission,
blue denote active SenP1 and orange inhibited SenP1. Horizontal lines indicate
the mean control levels.
initial high or low emission at either wavelength. The mean emission from
control wells was computed for both wavelengths as a guideline. Data points
with emission 500 counts above or 1600 counts below the mean 530 nm sig-
nal and 500 counts above or 1300 counts below the mean 480 nm signal were
eliminated from the analysis. This necessary elimination of ﬂuorescent and
quenching compounds marks a disadvantage of using ﬂuorescence as a screen-
ing signal.
In order to detect inhibition, the 530 nm / 480 nm ratio of control wells
was plotted to determine the signals for SenP1 activity (SenP1 added but no
compound) and no SenP1 activity (buﬀer added instead of SenP1, no com-
pound). The results are plotted together with the initial ﬂuorescence ratio of
the wells prior to SenP1/buﬀer addition in ﬁgure 9.4. At t = 45 minutes the
wells including active SenP1 show a decrease in emission ratio, whereas the
wells with no added, or inhibited SenP1 demonstrate no change. These values
were averaged to give the levels for SenP1 activity (X1) and complete SenP1
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Figure 9.5: Mean control measurements at both wavelengths: compounds only,
EYFP-SUMO1-ECFP added, followed by scans S1, S2, S3 and S4 at 10, 21, 32
and 45 min after the addition of SenP1/Buﬀer as indicated. Error bars denote
one standard deviation from the mean.
inhibition (X2). Hits were deﬁned as points with 530 nm / 480 nm ratio larger
than (X1 +X2)/2.
Following this initial identiﬁcation of hits, the time point measurements
S1-4 for selected compounds were compared to control data. Control measure-
ments are summarized in ﬁgure 9.5, showing the clear distinction between the
presence and absence of SenP1 at both wavelengths. To illustrate the trends at
both wavelengths, ﬁgure 9.6 depicts a schematic of spectral changes following
the addition of active or inactive SenP1. The time point data for hits is plotted
in ﬁgure 9.7 as the ratio of emission intensity at each time point to the initial
emission at the ﬁrst measurement, which enables a clear visual comparison.
Only data for compounds that follow the trend expected for inhibitors is plot-
135
9.3. CONCLUSION
Figure 9.6: Schematic spectra of the FRET-based SUMO1 protease inhibitor
screen.
ted. The identiﬁed compounds are summarised in ﬁgure 9.8 which displays
the structures (where available), the NSC identiﬁcation number, the chemical
formulae and molecular weights. Interestingly, some compounds demonstrate
structural similarities.
9.3 Conclusion
In this chapter the suitability of doubly-tagged SUMO1 as a substrate for a
FRET-based hight throughput drug screen for SenP1 protease inhibitors was
demonstrated. The screening system was established and characterised prior
to a blind ﬁrst screen of the National Cancer Institute (NCI) diversity set
library.
The cysteine inhibitor iodoacetamide was used as a trial-inhibitor to
establish the method. While this does inhibit the processing of SUMO1 by
SenP1, it is clearly not a speciﬁc inhibitor. The signal-to-noise ratio was found
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Figure 9.7: Time point data of identiﬁed hits (see legend). The ratio of emis-
sion intensity at each of the measured time points S1-S4 to that of the ﬁrst
measurement S1 is plotted. SenP1 activity (blue trace) and inhibition (red
trace) is deﬁned with time points from control wells with either added SenP1
or buﬀer instead of SenP1. Error bars denote one standard deviation from the
mean, calculated from 144 control wells on 6 plates.
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Figure 9.8: Structures, NSC numbers, chemical formulae and molecular
weights of identiﬁed hits, as provided for the NCI diversity set.
138
9.3. CONCLUSION
to be excellent, and the signal-to-background level was comparable to other
screening systems based on double-tagged constructs. Several of the screened
compounds were found to be either highly ﬂuorescent or to strongly quench the
ﬂuorescence of ECFP and/or EYFP, and had to be excluded from the analysis.
In a screen of the 2500 compounds, we set out to ﬁnd inhibitors speciﬁc to the
SUMO1-SenP1 interaction.
Nine hits were identiﬁed systematically in the screen of 2500 compounds
and shown to signiﬁcantly inhibit processing. Some of the hits show structural
similarities, which may aid the synthesis of a highly speciﬁc inhibitor for SenP1.
Further investigations by biochemical methods will be necessary to char-
acterise the nature of inhibition. Speciﬁcally, the distinction between inhibition
at the active cysteine or of the binding interfaces can be made by comparing
dose-responses in normal and strongly reducing buﬀers. This occurs since
the cysteine activity will be reduced in a buﬀer containing high concentra-
tions of DTT or β-mercaptoethanol. This will identify inhibitors speciﬁc to
the SenP1-SUMO1 binding interface. The eﬃciency of inhibition can further
be determined from measurements of the processing activity at a range of
inhibitor concentrations. For their potential use as anti-cancer medication,
studies in cells and animal models will be required to determine their toxicity
and eﬀectiveness as tumor suppressors.
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Microinterferometric Detection of
SUMO1 and Ubc9
This work was carried out during a collaboration at the Bornhop Group at
Vanderbilt University, Nashville, Tennessee. This research group pioneers the
study of molecular interactions by observing small refractive index changes that
may occur upon binding of two species. Following the FRET-based work on
protein binding we test this alternative approach on SUMO1 and Ubc9, aiming
to expand work to a comparative study of labelled and unlabelled molecules.
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10.1 Refractive Index Measurements
Several strategies for the detection of biomolecules involve direct or indirect
measurements of refractive index changes close to a detection surface of immo-
bilized antibodies. The presence of a protein at an interface changes the local
refractive index, which can be monitored by surface plasmon resonance (SPR)
[132]. While SPR measurements are more sensitive than ITC, the requirement
for immobilization is a drawback due to both the laborious sample preparation
and its potentially modiﬁed functionality [133].
Theoretically however, binding in free solution may be measurable as
small bulk refractive index changes. This may occur if a solution of two proteins
displays diﬀerent bulk refractive indices when they are free to when they are
bound to each other. The origin of this eﬀect is not fully understood, although
an explanation based on solvent behaviour is plausible: water molecules align
around electropositive or negative regions of proteins, which leads to the forma-
tion of a distinct molecular dipole and hence the polarisability of a molecule
in a speciﬁc state. Upon binding of two proteins, solvent is excluded from
the binding interface and hence the polarisability of the sample may change.
Similarly, a conformational change in a protein upon binding may lead to a
signiﬁcant change in its hydration and its molecular dipole.
The ratio of the speed of an electromagnetic wave in vacuum c to that
in matter v gives the refractive index n [134].
n =
c
v
=
√
r
√
µr (10.1)
where n is the refractive index, r is the relative electric permittivity of
the sample and µr is its relative magnetic permeability. The latter is equal to
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1 in weakly magnetic materials at optical frequencies giving Maxwell's relation
[134]
n =
√
r (10.2)
The electric permittivity is wavelength-dependent and also depends strongly
on the polarisability of the sample. Refractive index measurements can hence
be used to measure changes in the polarisability of a sample. The refractive
index is a fundamental physical property of a material is hence used to identify
substances and conﬁrm their concentration and purity (such as of gemstones).
Just some examples of routine concentration measurements include that of the
sugar content of solutions in the food industry [135] or blood protein in vet-
erinary medicine [136]. Commercial refractometers enable measurements at a
range of wavelengths and achieve a precision of 10−5 − 10−6 RI units [135].
Our collaborators have pioneered the use of backscattering interferome-
try to detect small refractive index changes. In this approach a laser beam is
focussed on a microﬂuidic channel made of PDMS. Multiple reﬂections within
the sample-ﬁlled channel lead to a backscattered interference pattern, the anal-
ysis of which facilitates the detection of refractive index changes of the order of
10−7 [137]. The small detection volume coined the term microinterferometric
backscattering detection (MIDB) [138]. The advantage of MIDB over existing
free-solution methods of measuring protein aﬃnity such as microcalorimetry
is the detection limit of attomole quantities at sub-nanoliter volume, and its
technical suitability for a high-throughput conﬁguration. Applications devel-
oped by the same research group include solvent detection and ﬂow velocity
measurements in liquid chromatography (HPLC) [139, 140, 141], detection of
surface-immobilised binding events [142, 143], and most recently free-solution
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binding constant measurements [133].
In this collaboration we set out to detect refractive index changes upon
binding of SUMO1 and Ubc9 and to subsequently quantify their aﬃnity by
this method. Repeating measurements with the same but ﬂuorescently labelled
proteins, as used in chapter 4 for FRET measurements is hoped to give further
insight into whether their aﬃnity is aﬀected by the tags. The equipment
provided is based on a stably mounted glass chip channel, as opposed to silica
[144] or PDMS chips [143, 133] used in previous work. It is hoped that the use
of this chip will further increase the sensitivity of measurements.
10.2 The Stop-Flow Mixing Chip
At the heart of this setup lies a microﬂuidic stop-ﬂow channel, which pro-
vides both the solution mixing device as well as the optical interferometer
between its top and bottom boundaries. The channel was designed on a glass
chip so that solutions are introduced in a Y-shape geometry, followed by mix-
ing serpentines and the approximately semi-circular channel, as shown in ﬁg-
ure 10.1 (Micronit Microﬂuidics, Enschede, The Netherlands). The glass chip
was mounted on a temperature controlled stage (Thermistor, Omega; thermo-
electric cooler CP0.8-127-06L-1-W6 and Temperature controller MTCA-6040,
Melcor) and heat sink to maintain 25◦C ± 0.1◦C. Both chip and tempera-
ture control were mounted on a diﬀerential stage which enabled horizontal
displacement. Microtubes attached to the two introduction arms of the Y
channel allowed for solutions to be introduced directly from eppendorf tubes.
A further microtube linked the far end of the channel to a vacuum pump which
enables controlled ﬂow through the channel by the applied suction. Flow ve-
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locities where estimated by drawing water through the tubing and channel for
3 minutes and measuring the volume removed from an initial 50 µl volume for
a range of vacuum settings. The uptake from both channels was measured and
found to be identical. For binding measurements, the vacuum pump was set
to a low setting to avoid laminar ﬂow conditions and enhance mixing in the
spirals of the microﬂuidic channel.
Figure 10.1: Photograph of glass chip with Y-shaped channel including mixing
spirals.
10.3 The Backscattering Interferometer
The interferometer consisted of a HeNe laser coupled into a single-mode ﬁbre
(Laser-to-ﬁber coupler HPUC-23-633-S-6.2AS-2 and Fiber focusser LPF-04-
633-4/125-S-25-283-11AS-40-3S-1-0.5, Oz Optics) ﬁtted with a lens to produce
a focus at 28.3 cm. The beam was focussed vertically on the channel by means
of a 45◦ mirror 21.8 cm from the lens and 6.5 cm above the chip, as shown
in the schematic diagram in ﬁgure 10.2. The mirror was adjusted so that the
beam reﬂected back from the channel passed just above the optical ﬁbre, with
the aim to keep the incidence and reﬂection angles as close as possible to 90 ◦ to
the chip surface. The point measured on the channel was 1-2 mm downstream
from the last serpentine. This ensured that the measurements were taken at
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the earliest possible time after mixing in order to observe the binding kinetics
of the molecules of the two solutions combining.
Figure 10.2: Schematic diagram of the backscattering interferometer. The red
line demonstrates the laser beam path.
Figure 10.3: Fringe pattern photographed on white paper in front of the CCD.
The white box indicates the area of the pattern analysed for these measure-
ments.
The interference pattern created from the reﬂections from the top and
the bottom of the channel was initially observed using white card, before a
selection of fringes was picked up on a CCD detector (GARRY 3000 Detector
(280-1100nm), Melles Griot) at 81 cm optical path length from the channel.
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A photograph of the fringe pattern indicating the monitored fringes is shown
in ﬁgure 10.3.
The channel was centered under the beam while observing the illumi-
nation of the fringe pattern. Shifting the channel position left-right lead to
a left-right shift in the intensity of the fringe pattern to either side of the
main reﬂection. Accordingly, a symmetrical fringe pattern ensured a centrally
illuminated channel.
10.3.1 Data Collection and Analysis
The intensity versus position data recorded by the CCD camera was displayed
in a Labview program written for this setup [137]. The CCD was moved
into position 34 cm from channel so that ﬁve whole fringes (orders 7-11) were
observed. While part of a complex interference pattern, these fringes can be
approximated by a sine wave. A fourier transform of the pattern gives the
dominant frequency. The Labview program further displays the phase of this
sine wave as a function of time, which enables the sensitive detection of shifts
in the fringe pattern.
10.3.2 Detection Limits
The detection limits of the system was measured using glycerol solutions rang-
ing in concentration from 5 mM to 30 mM. These were made up from a 100 mM
stock solution of glycerol in ultrapure water. A 1 ml glass syringe was used to
ﬂush the channel in reverse ﬂow with ultrapure water between measurements.
The phase signal of the water-ﬁlled channel was recorded for 60 s, following
which a glycerol solution was introduced (with both ﬁlling tubes immersed in
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Figure 10.4: Phase signal changes recorded when replacing ultrapure water
in the channel with 5mM and 30mM glycerol. These are four representative
traces from quandruple measurements used to construct the calibration line in
ﬁgure 10.5.
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an eppendorf tube of sample). The phase was recorded continuously during
this introduction as well as for 60 s following it. A sharp change in phase was
observed during the introduction, the magnitude of which depended on the
glycerol concentration as shown in two examples in ﬁgure 10.4. Quadruple
runs were performed for each dilution. This enabled for a calculation of the
detection limit based not only on the signal-to-noise ratio, but also on the
reproducibility of sample introduction. The noise measurement was based on
the readings before and after the introduction of a glycerol sample, averaged
over 20 s.
Figure 10.5: Calibration line of phase signal as a function of increasing con-
centrations of aqueous glycerol.
The signal-to-noise ratio was improved over four calibration attempts
by centering the channel and aligning the interference fringes detected by the
CCD to give a clear Fourier transform peak corresponding to the dominant
sine wave. The repetition of this process eventually resulted in the phase
shifts plotted as a function of glycerol concentration in ﬁgure 10.5. Phase
readings were reproducible to 7 ·10−4 rad, based on quadruple measurements.
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The detection limit, a measure of the smallest resolvable phase change for this
particular setup, is given by
DL =
3σ
gl
(10.3)
where σ is the standard deviation of the data based the noise level and
gl is the gradient of the straight line ﬁt of the plot. This ﬁt revealed a gradient
gl = 5.49 radM
−1 with a correlation coeﬃcient of r2 = 0.999 which gives an
error on the gradient of 0.12 radM−1. The 3σ detection limits were calculated
for each data point and ranged from 76 nM to 152 nM glycerol, which corre-
sponds to 8.12·10−7−1.61·10−6 RI units (using the conversion factor of 0.0106
RIM−1 [145]). These results are an order of magnitude larger than published
results of 7.6·10−3 radM−1 error in the gradient and a detection limit of 7·10−8
RI units [137]. The main diﬀerence to our results is the quoted gradient of
53.2 radM−1, which is ten times our result (5.48 radM−1). Correspondingly
both their error and detection limit are an order of magnitude smaller.
10.3.3 Calibration
Following the alignment and detection limit determination, the setup was cali-
brated to ﬁnd the absolute refractive index corresponding to a measured phase
signal. This was performed by measuring the phase change upon introducing
a series of glycerol solutions with 30 µM concentration increments into the
channel. A plot of the resulting raw data is shown in ﬁgure 10.6 and the
concentration-dependent phase changes are presented in ﬁgure 10.7. We re-
scale the x-axis of the latter plot to display the refractive index which corre-
sponds to the glycerol concentrations, using the conversion factor 0.0106 M−1
[145] and the refractive index of water at 25◦C, nH2O = 1.33251 [146]. The
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Figure 10.6: Raw data of the phase signal as a function of time as the glycerol
concentration of the solution in the channel is varied in steps of 30 mM.
resulting graph shown in ﬁgure 10.8 gives the calibration of the detected phase
signal as a function of absolute refractive index.
This calibration displays a linear relationship between phase and refrac-
tive index over a 1.2 · 10−3RI range. This greatly simpliﬁes the analysis of
further measurements. Furthermore, n versus phase data can be ﬁtted by a
straight line of Y = −2.16·10−3X+1.34 which enables the accurate calculation
of the absolute refractive index for any phase signal within this range.
10.4 Detection of Protein-Protein Binding
The protocol for measuring binding by backscattering interferometry involves
the introduction of solutions of each binding partner into the channel via the
two arms of the Y-shaped channel. While suction is applied, the solutions are
drawn through both arms and are mixed in the mixing spirals before entering
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Figure 10.7: Phase signal versus glycerol concentration, ﬁtted with a straigt
line.
Figure 10.8: Phase signal as a function of absolute refractive index.
the detected section of the channel. While this may lead to perfect mixing,
binding apparently only occurs when the ﬂow is stopped. Binding upon ﬂow
stop may lead to a change in the interference pattern and hence a phase change
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of the monitored fringes. To date, this assumption is not based on microscopic
reasoning but is purely empirical, since non-binding solutions have been shown
not to generate a signal upon ﬂow stop [133].
Figure 10.9: Phase signal change upon applying and releasing suction, leading
to ﬂow and mixing of solutions of 10 µM ECFP-SUMO1 and 30 µM EYFP-
Ubc9. Measurements were repeated, two representative traces are shown.
Indeed, when we introduce 10 µM ECFP-SUMO1 and 30 µM EYFP-
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Figure 10.10: Repeat of above, with sample tube positions exchanged.
Ubc9 through the two sample channels into the measurement channel using
the vacuum pump for suction, a phase increase is observed over 10 seconds
following the release of the vacuum, as shown in ﬁgure 10.9. This signal could
be used as a data point of a binding curve, speciﬁc to these concentrations
of protein. Repeating this measurement with a range of EYFP-Ubc9 concen-
trations would enable the collection of a complete set of data. However upon
exchanging the position of the sample tubes and re-applying suction, we ob-
serve the signal shown in ﬁgure 10.10. Initially the phase decreases back to the
former level during suction - followed by an increase to double the former rise.
Upon releasing the vacuum, the phase signal now drops - down to the level
that it rose to in the previous conﬁguration. This signal change can clearly
not be attributed to binding, since it was the opposite of that detected in the
previous measurement of identical solutions. To convince ourselves that this
is not a binding eﬀect, the experiment was repeated, this time using buﬀer
instead of EYFP-Ubc9. The same pattern as in the ﬁrst set of experiments
153
10.4. DETECTION OF PROTEIN-PROTEIN BINDING
was observed, as shown in ﬁgures 10.11 and 10.12.
Figure 10.11: Phase signal change upon applying and releasing suction, leading
to ﬂow and mixing of solutions of 10 µM ECFP-SUMO1 and buﬀer.
Figure 10.12: Repeat of above, with tube positions exchanged.
A satisfactory explanation for this phenomenon is based on incomplete
mixing and asymmetric laminar ﬂow. It was found that upon introducing
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solutions of two distinct refractive indices, the signal during suction was very
close to that of the solution entering the top left Y-arm. Upon releasing
the vacuum, the signal rapidly moved toward the average of that of the two
solutions. The signal we observe upon stopping ﬂow is hence predominantly a
mixing eﬀect and can lead to a positive or negative change depending on the
sample positions.
Figure 10.13: Observed refractive index changes following ﬂow stop for the
mixing of protein buﬀer and ultrapure water as a function of the ﬂow rate.
The beam path of the laser is complicated due to multiple reﬂections
[138], hence it is conceivable that certain parts of the channel dominate the
measured signal. Laminar ﬂow conditions in the mixing spirals may indeed
lead to a subsequent parallel but asymmetric ﬂow of the two solutions in the
channel. We investigate this by varying the vacuum setting and measuring
the phase changes upon ﬂow stop using protein buﬀer and ultrapure water as
samples. The results are summarised in ﬁgure 10.13, which shows that there
there is a clear dependence of the ﬂow rate on the phase monitored after the
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ﬂow is stopped. This indicates that the measured signal is a mixing eﬀect, since
the mixing eﬀect of the spirals decreases with increased ﬂow rates as laminar
ﬂow conditions dominate the ﬂuid behaviour. It seems that we are monitoring
a two-phase solution that mixes upon ﬂow stop and gives an average n reading.
All further measurements were performed with the lowest vacuum setting that
resulted in ﬂuid ﬂow (100 mm Hg, 3.3 µl/min).
Figure 10.14: Phase signal of index-matched measurement: 10 µM ECFP-
SUMO1 and 8 µM EYFP-Ubc9 signal during three stop-ﬂow cycles.
Since we set out to measure protein-protein binding, we overcome this
limitation by index-matching the two solutions before repeating the exper-
iment. For this, the phase signal of a dilution series of EYFP-Ubc9 was
recorded. The concentration with the same refractive index as 10 µM ECFP-
SUMO1 was found to be 8 µM EYFP-Ubc9. The measurement was performed
as described above, repeating ﬂow-stop cycles several three times. The result-
ing phase signal is shown in ﬁgure 10.14. No signal change above the noise
level was observed in neither orientation of the samples.
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Figure 10.15: Refractive indices relative to that of buﬀer for a) 10 µM ECFP-
SUMO1, b) 30 µMEYFP-Ubc9, and c) a solution of 10 µMECFP-SUMO1 and
30 µM EYFP-Ubc9. Experiments were performed in triplicate, from which a
mean refractive index change (setting the buﬀer signal to be zero) and standard
deviation were calculated. The average of a) and b) is also displayed with
combined errors.
If a non-transient change in n occured in a solution of ECFP-SUMO1 and
EYFP-Ubc9 upon binding, we would expect the n of a solution of both proteins
to deviate from the average n of separate solutions of the same concentrations.
To verify this experimentally, we measured the phase diﬀerences between a)
buﬀer and 10 µM ECFP-SUMO1, b) buﬀer and 30 µM EYFP-Ubc9, and c)
buﬀer and a solution of 10 µM ECFP-SUMO1 and 30 µM EYFP-Ubc9. Ex-
periments were performed in triplicate, from which a mean refractive index
change (setting the buﬀer signal to be zero) and standard deviation were cal-
culated. These are displayed in ﬁgure 10.15 together with the average of a)
and b). The diﬀerence between measurement c) and the average is 2.89 · 10−7
RI, which is just above the noise level, but within the error bars based on the
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reproducibility of this measurement, and hence not signiﬁcant.
Figure 10.16: Refractive indices relative to that of buﬀer for a) 10 µM ECFP-
SUMO1 and b) a solution of 10 µM ECFP and 10 µM SUMO1.
Since protein-protein binding was not observed, the inﬂuence that tag-
ging proteins may have on their refractive index was measured. For this, a
solution of 10 µM ECFP and 10 µM SUMO1 was prepared and its n deter-
mined as in the previous experiment. This is contrasted with the n of 10 µM
ECFP-SUMO1 in ﬁgure 10.16. No signiﬁcant diﬀerence was detected.
10.5 Conclusion
In this collaboration we set out to detect refractive index changes upon binding
of SUMO1 and Ubc9 by backscattering interferometry. Careful alignment lead
to the best detection limit of our setup, 8.12 · 10−7− 1.61 · 10−6 RI units. This
is an order of magnitude larger than the best published results [137]. The
source of this diﬀerence is the calibration graph gradient. Their quoted result
is 53.2 radM−1, which is ten times our result (5.48 radM−1). The system was
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calibrated using glycerol solutions to enable the conversion from the measured
phase signal to absolute refractive index.
Following the protocol we monitored refractive index changes over 10
seconds following ﬂow stop, expecting to observe a binding signal from the
solutions exiting the chip's mixing spirals. Indeed, we monitored a signal
change consistent with the protocol in the form of an exponential rise as we
would expect from a kinetic binding signal. Upon closer examination, changes
were however found to be due to mixing of the two protein solutions and not
binding, as the swapping of sample tubes lead to the inverse signal. This eﬀect
was further examined, and found to be dependent on the ﬂow rate and the
diﬀerence in refractive index between the solutions. The same signal was also
observed in protein-buﬀer measurements.
Further attempts to detect binding signals were performed with index-
matched solutions and end-point data from pre-mixed solutions. Neither ap-
proach lead to a detectable signal. Finally the refractive index of tagged ECFP-
SUMO1 and a solution of untagged ECFP and SUMO1 was compared and no
diﬀerence found.
Backscattering interferometry is a promising technique for the detection
of small changes in refractive index, however care must be taken in the in-
terpretation of results and relevant control measurements must be performed
vigilantly to validate the source of signals.
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Autoﬂuorescence of Cervical Neoplasia
Models
This project was supervised by Professor Simon Herrington (Bute Medical
School) and organotypic rafts were cultured by 4th year student AndrewWood.
Andrew and I performed the ﬂuorescence measurements. He presented a ﬁrst
analysis of data in his 4th year project report, together with a comprehensive
literature review which forms the basis of the introduction to this chapter.
Subsequently I performed a rigorous analysis of data, the results of which are
presented here. A principal component analysis program written by Michael
Mazilu (School of Physics and Astronomy) provided wavelengths of best dis-
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crimination between raft types. The results were published in the International
Journal of Cancer [147].
11.1 Motivation
Cervical cancer is the second most common cancer in women, with an esti-
mated 500,000 new cases per year and 200,000 deaths [148]. Mass population
screening however has signiﬁcantly reduced its incidence as a result of detect-
ing and treating pre-malignant tissue. Screening has decreased the mortality
rate by 60% in women under 55 years of age in the UK. However the total cost
to the taxpayer of cervical screening programme is estimated to be 150 million
pounds per year in England, or 37.50 pounds per smear test [149].
The cervix connects the uterus to the vagina. The intravaginal part of the
cervix is covered by a stratiﬁed squamous epithelium [150]. Cervical cancer
is preceded by cervical intraepithelial neoplasia (CIN), which demonstrates
histological changes associated with malignancy. These include an increased
nuclear:cytoplasmic ratio and abnormalities of cellular organisation, but are
conﬁned to the epithelial layer [151].
Infection with certain genotypes of the sexually transmitted human papil-
lomavirus (HPV) is the principal cause of cervical cancer. A persistent viral in-
fection may result in the integration of the HPV genome in cells [152, 153, 154],
which is believed to generate DNA errors and the development of a malignant
phenotype.
Cervical screening involves taking a sample of cells from the surface of the
cervix of a woman every 3-5 years and testing it for preneoplastic cells which
may develop into malignant tumours. Each sample is examined visually by
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Figure 11.1: Histology photograph of normal cervical squamous epithelium on
the left and dysplastic squamous epithelium on the right side of the picture.
Dysplasia is a disorderly growth of epithelium which is still reversible. Image
from www-medlib.med.utah.edu.
a trained cytologist, making the process time-consuming and expensive. Test
results are typically returned within several weeks, however if preneoplastic or
even cancerous cells are found, a visual examination of the cervix is required.
Areas of neoplasia are highlighted by applying acetic acid, which turns regions
of high nucleic acid concentration white. For an accurate diagnosis however,
biopsy samples must be taken, ﬁxed, sliced and examined histologically, as
shown in ﬁgure 11.1.
The aim of this research project was to develop the use of ﬂuorescence
spectroscopy as a means of detecting the early signs of pre-malignancy in the
cervix without the need to remove tissue from the patient. The cell structure
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of the cervical epithelial layer suggest that an optical discrimination between
normal and neoplastic tissue may be possible: in neoplastic tissue, cells show
enlarged nuclei, are packed more densely and lose their regular packing struc-
ture, as is evident in ﬁgure 11.1. Furthermore, biochemical changes may occur
that are detectable in the autoﬂuorescence signature of the cells. Spectroscopic
approaches are currently limited by the substantial variation in the optical
properties of the cervix between patients, while changes in the spectroscopic
properties of cervical tissue speciﬁc to cancer have yet to be determined.
This work concentrates on establishing the use of organotypic epithelial
raft culture as an in vitro model of normal and neoplastic cervical tissue for
ﬂuorescence studies. Raft culture is a well established system used to recreate
the three-dimensional architecture of cervical tissue for investigating normal
[155, 156] and neoplastic [157, 158] stratiﬁed squamous epithelium tissue. A
type I collagen matrix containing J2 ﬁbroblasts forms the base of the artiﬁcial
tissue. On this, a thin layer of cells forms the epithelial layer. Primary human
keratinocytes (PHK) are known to form normal stratiﬁed epithelium, while the
SiHa cell line is cancer-derived and is used as a model for neoplastic cervical
tissue.
We explore ﬂuorescence excitation wavelengths between 250 nm and 330
nm, at which relatively little work is reported. The quantiﬁcation of a suc-
cessful model of normal and neoplastic cervical epithelium may help establish
spectroscopic diﬀerences that can be expected in vivo, as the variability of
parameters present in vivo is minimised. In the long term the discrimination
between normal and pre-cancerous neoplastic models may contribute to the
development of a simple, non-invasive technique, which provides instant, quan-
titative results. This could avoid both the cost and delay associated with the
163
11.2. THE DETECTION OF NEOPLASIA BY SPECTROSCOPY
existing screening procedure. In the short term the question to be addressed
was whether ﬂuorescence could distinguish between normal and pre-cancerous
cell culture raft models, and provide spectral regions of discrimination.
11.2 The Detection of Neoplasia by Spectroscopy
The ﬁrst attempt to detect neoplasia in vitro by spectroscopic methods dates
back to 1965 [159, 160]. The ﬁrst spectroscopic study of cervical cancer was in
1993, and biopsy samples were found to be signiﬁcantly less ﬂuorescent than
histologically normal tissue [161]. It was also found that at 330 nm excitation,
the slope of the emission spectrum between 420 and 440 nm emission is lower
for normal versus abnormal tissue. Following this, the eﬀect of excitation
at 337 nm, 380 nm and 460 nm was compared [162], and results analysed
by principal component analysis. Neoplastic and normal stratiﬁed epithelium
was best distinguished at 337 nm, with a quoted sensitivity of 84% and a
speciﬁcity of 65%, which is comparable to the current cervical smear. Further
work on biopsy samples has focussed on the excitation wavelength range from
300 nm to 470 nm [163]. However inter-patient variation in tissue ﬂuorescence
is currently a major hindrance to the clinical application of these results [164].
The ﬂuorescence of the cervix has also been found to vary signiﬁcantly with
age and menstrual status [165]. This makes a comprehensive characterisation
of spectral changes due to neoplastic progression based on in vivo and biopsy
samples problematic.
The biochemical basis of diﬀerences in ﬂuorescence between normal and
neoplastic tissue is not fully understood. Spectra of ﬂuorophores present in
tissues have been ﬁtted to spectra from patients in an attempt to determine
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changes in concentrations [166]. This and further studies [167] identify hypoxia
in tissue and particularly changes in Flavin Adenine Dinucleotide (FAD), the
reduced form of Nicotinamide Adenine Dinucleotide (NADH), and type 1 col-
lagen as potential variables for excitation wavelengths above 340 nm. Since
collagen cross-links are the principal source of stromal ﬂuorescence [160] their
disruption early in the course of neoplasia may lead to a decrease in emission.
The application of acetic acid has been shown to alter the optical proper-
ties of cervical neoplasia [168, 169, 170] and is used clinically to detect lesions
[171].
11.3 Cell Lines and Raft Culture
Cell and organotypic raft culture were performed by Andrew Wood under the
supervision of Michelle McRobbie.
Round collagen plugs (2.5 cm diameter, 2 mm thickness) containing J2
ﬁbroblast cells (a gift from Simon Broad, Cancer Research UK), a derivative
of the NIH-3T3 murine embryonic ﬁbroblast cell line (ATCC CRL-1658) [172]
were created on metal mesh supports to model the underlying skin structure.
Materials used were 2 ml rat tail type I collagen (Upstate, Serologicals
Cooperation, Norcross, U.S.) diluted to 4.0 g/l in glacial acetic acid, 0.25 ml
10x reconstitution buﬀer (2.2% sodium bicarbonate and 4.8% HEPES in milliQ
water) and 0.25 ml 10x DMEM solution per plug. Approximately 106 J2-cells
(cell culture described below) were added. Solutions were prepared on ice and
plugs prepared by pouring 2 ml of the mixture into a well of a six well plate
(Iwaki, Japan) and incubating overnight at 37◦C.
To model normal skin, primary human keratinocytes (PHK), normal hu-
165
11.3. CELL LINES AND RAFT CULTURE
Figure 11.2: Schematic top view and cross-section of cell rafts (not to scale).
The cross sections represent ideal cases of plain J2 rafts (top), rafts with normal
cells (middle) and rafts with neoplastic cells (bottom).
man epidermal keratinocytes isolated from foreskin (PromoCell GmbH, Hei-
delberg, Germany) were cultured in serum-free Keratinocyte Growth Medium
2 (KGM-2)(also from PromoCell GmbH, Heidelberg, Germany) before raft
culture. Neoplastic tissue was modelled using SiHa cells (ATCC HTB35), a
cervical cancer cell line containing 1 or 2 copies of the Human Papillomavirus
genotype 16 [173, 174]. SiHa and J2 were cultured in Dulbecco's Modiﬁed
Eagle Medium (DMEM) supplemented with 10% Fetal Calf Serum, 100 g/l
penicillin, 100 U/ml streptomycin and 2 mM glutamine.
All cell culture and rafting was carried out in aseptic conditions in a
class II laminar ﬂow cabinet. Reagents were supplied by Sigma-Aldrich and
Gibco, Invitrogen Ltd unless otherwise stated. Cell culture was performed
as described by Harrison and Rae [175]. Cells were cultured at 37◦C in an
atmosphere of 5% CO2, in separate T75 cell culture ﬂasks. Media were changed
166
11.4. FLUORESCENCE SPECTROSCOPY
three times a week and cells passaged when conﬂuent.
A schematic diagram of cultured rafts is shown in ﬁgure 11.3. Organ-
otypic raft culture of PHK and SiHa cells on collagen plugs is described
by Southern et al [157]. Rafting was carried out using FAD medium (75%
DMEM (supplemented with Penicillin, Streptomycin and Glutamine as de-
scribed above), 25% Ham's F12 medium) supplemented with 5% foetal calf
serum, 180 µ M adenine, 5 g/l insulin, 400 µ g/l hydrocortisone 5 mg/l apo-
transferase, 0.2mM tri-iodothyronine, 0.1nM Cholera toxin and 5 µ g/l Epi-
dermal Growth Factor (EGF). 2ml of FAD medium with 106 keratinocytes
(HaCaT, SiHa, CaSki or PHKs as required), were added to each of the plugs
in the 6-well plates. The plugs were incubated for 48 hours. The medium was
then removed from the plugs and each plug transferred to a circular stainless
steel wire mesh support using a sterile spatula, and placed in a 90 mm diameter
Petri dish. The mesh supports were made from circular stainless steel mesh
discs (78 mm in diameter, diameter of the mesh wire 0.26 mm) that was made
to order (Costacurta S.P.A., Milan, Italy) and autoclaved before use.
Up to 20 ml rafting medium was added to the Petri dish and the mesh
support used to suspend the raft just above the surface of the medium. Con-
tamination was prevented by placing the petri dishes in the incubator vented
plastic boxes. The medium was changed twice a week and ﬂuorescence mea-
surements were made twelve days after transfer to the Petri dishes.
11.4 Fluorescence Spectroscopy
All ﬂuorescence measurements were performed with a Cary Eclipse Fluo-
rescence Spectrophotometer (Varian Optical Spectroscopy Instruments, Mul-
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grave, Victoria, Australia). The ﬂuorimeter runs an autocalibration protocol
of both excitation and emission monochromators upon starting up. Further
calibrations were performed by analysing the Raman spectrum of water with
the Varian Validation software, and by comparing spectra of Fluorescein 27
and Rhodamine 6G to corrected spectra recorded on a calibrated Fluoromax
ﬂuorimeter. All data were corrected for the spectral response of the instru-
ment using the correction ﬁle supplied for the ﬂuorimeter. The ﬂuorescence of
diluted media was measured in 3.5 ml quartz cuvettes (Hellma Scientiﬁc).
Figure 11.3: Schematic diagram of the raft autoﬂuorescence setup showing
excitation and emission geometries in the Cary Eclipse Spectrophotometer
sample chamber from above [147].
A schematic diagram of the setup is shown in ﬁgure 11.3. The rafts were
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kept on the mesh they were grown on so as to prevent necrosis and structural
damage. Rafts were suspended vertically in the sample compartment of the
Cary Eclipse on a custom-built stand and measured at room temperature. The
plane of the raft was at 45◦ to both the incident source light and the direction
of the detector. Rafts were grown and measured in four separate batches at
diﬀerent dates.
A 10 mm x 2 mm section of each raft was excited with a range of wave-
lengths from 250 to 330 nm in 10 nm steps, using the "3D mode" step function
in the ﬂuorimeter software. The intensity of the excitation beam was measured
to be of the order of 10 µW over the beam area at all excitation wavelengths
(using a Coherence Fieldmaster power meter with UV head). Measurements
were repeated at all excitation wavelengths for selected rafts and no photo-
bleaching observed. Spectra were recorded in the emission range from 260
nm to 660 nm (1 nm resolution, 1 s averaging time, 5 nm slit width). These
settings enabled the collection of a complete data set from one raft within 20
minutes. Rafts did not show signs of dehydration during this time.
Background measurements of the wire mesh and collagen were made at
all wavelengths. Spectral data of the culturing media were also collected. A set
of background spectra at 290 nm excitation are shown in ﬁgure 11.4. The wire
mesh was found to be highly scattering at several angles of incident excitation
tested, all of which resulted in the collection of scattered excitation light due
to the weaved geometry of cylindrical wire.
Four sets of rafts, each comprising one J2 (control measurement), one
PHK (normal stratiﬁed epithelium) and one SiHa (neoplastic epithelium) raft,
were measured at diﬀerent dates but under the same conditions. These four
data sets were analysed together to quantify the inter-raft variation and deter-
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Figure 11.4: Emission spectra of the wire mesh, DMEM medium with and
without phenol red content and a collagen plug, all excited at 290 nm. Spectra
of media were recorded in cuvettes and are scaled down for comparison with
other spectra.
mine whether a signiﬁcant distinction between raft types is possible. Measure-
ments were repeated at several positions on each raft in order to determine the
intra-raft variation. Dehydration limited the number of repeat measurements
to a maximum of three on each raft.
Selected raw spectra of the wire mesh, collagen on mesh, as well as J2
(control measurement), PHK (normal stratiﬁed epithelium) and SiHa (neo-
plastic epithelium) rafts are shown in ﬁgure 11.5, all excited at 290 nm. The
emission around 340 nm from rafts with an epithelial cell layer on top (PHK
and SiHa) is signiﬁcantly higher than the background measurements. This is
important to note since a signal from the epithelial cells is essential to our
ability to go on to distinguish between normal and neoplastic surface layers.
Following a set of measurements of PHK and SiHa rafts, a 3% acetic acid
solution was applied to the rafts outside the sample chamber and measurements
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Figure 11.5: Raw emission spectra of wire mesh, collagen on wire mesh, a J2
raft (control measurement), a PHK raft (normal stratiﬁed epithelium and a
SiHa raft (neoplastic epithelium), excited at 290 nm.
repeated two minutes later at the same position of the raft. Visual inspection
after acetic acid application (VIA) is common in clinical practice with similar
concentrations and rapid changes in neoplastic epithelium [171, 176, 177, 178].
11.5 Data Analysis
The spectral range between λex+30nm and 2λex−50nm was used in analysis,
where λex is the excitation wavelength. This eliminates contributions from
excitation and scattering from data. Spectra were normalised by dividing each
data point by the sum of the intensities in the spectral range deﬁned above.
The normalised plots of ﬂuorescence spectra at each excitation wavelength
were then re-scaled to give the correct relative intensities and enable the di-
rect comparison of spectral diﬀerences at diﬀerent λex. This was achieved by
calculating the mean intensity of all spectra of one excitation wavelength and
171
11.6. AUTOFLUORESCENCE RESULTS
dividing spectral data by this mean intensity.
In order to determine the emission wavelengths that provide the best
discrimination between raft types, we used principal component analysis in
conjunction with the covariance matrix as described by Chatﬁeld and Collins
[179]. The algorithm was written for Mathematica software and returns the
ﬁrst principal component spectrum (PCS), which provides a measure of the
variance within analysed data sets. The absolute minimum and maximum
of the PCS hence give the two emission wavelengths of best discrimination
of the emission spectra of the diﬀerent raft types. The optimum excitation
wavelength can be deduced from the set of emission spectra that demonstrates
best discrimination.
The ﬁrst PCS was computed for data sets of each excitation wavelength.
The intensities corresponding to the two wavelengths of best discrimination
selected by PCA were plotted as 2D scatter plots. The peak at 425 nm was
not used as it is a possible instrumental contribution. Care was taken to
establish that peaks did not move with excitation wavelength, as would be
expected from scattered light.
11.6 Autoﬂuorescence Results
Figures 11.6-11.8 show normalised emission spectra of the four sets of mea-
surements of J2 (red), PHK (blue) and SiHa (green) rafts for the excitation
wavelengths 250 nm - 330 nm. Each graph displays four spectra of each raft
type at a diﬀerent excitation wavelength, and demonstrates the inter-raft con-
sistency between measurements. The intra-raft variation was found to be much
smaller. The ﬁgures up to 310 nm excitation are accompanied by the ﬁrst PCS
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Figure 11.6: Normalised ﬂuorescence spectra and ﬁrst principal component
spectrum from 4 sets of J2 (background, red), PHK (normal stratiﬁed epithe-
lium, blue) and SiHa (neoplastic epithelium, green) rafts, excited at 250 nm,
260 nm, 270nm and 280 nm.
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Figure 11.7: Normalised ﬂuorescence spectra and ﬁrst principal component
spectrum from 4 sets of J2 (background, red), PHK (normal stratiﬁed epithe-
lium, blue) and SiHa (neoplastic epithelium, green) rafts, excited at 290 nm
and 300 nm.
computed from this data in a separate graph below the corresponding ﬁgure.
A broad feature peaking at 334 nm - 340 nm dominates the spectra at
excitation wavelengths below 300 nm. Above 300 nm however, the emission
intensity is relatively low and spectra are dominated by noise at background
level. Excitation wavelengths below 310 nm result in emission spectra that are
distinguishable by visual inspection, as well as a deﬁned ﬁrst PCS. The extrema
of this spectrum help systematically identify regions of variation between the
diﬀerent raft types, and the results are summarised in table 11.1.
The entries 280, 290, 300, 510, 530 and 550 nm correspond to the edges of
the truncated spectrum and do not represent a physically signiﬁcant emission
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Figure 11.8: Normalised ﬂuorescence spectra from 4 sets of J2 (background,
red), PHK (normal stratiﬁed epithelium, blue) and SiHa (neoplastic epithe-
lium, green) rafts, excited at 310 nm, 320 nm and 330 nm. The ﬁrst principal
component spectrum (PCS) is shown for 310 nm excitation. The PCS at higher
excitation wavelengths were dominated by noise (data not shown).
wavelength. Normalised emission intensities of all rafts at wavelength y are
plotted against those at wavelength x. The resulting scatter plots are shown in
ﬁgure 11.9. Clustering of inter-raft results and distinction between raft types
is achieved at
Figure 11.10 shows scatter plots before and after the application of acetic
acid. An increase in relative emission intensity at 300 nm excitation / 340 nm
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Figure 11.9: Scatter plots based from data in ﬁgures 11.6-11.7 showing 4
sets of J2 (background, red squares), PHK (normal stratiﬁed epithelium, blue
diamonds) and SiHa (neoplastic epithelium, green triangles) rafts.
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Table 11.1: Emission wavelengths of best discrimination for each excitation
wavelength.
Excitation [nm] Wavelength x [nm] Wavelength y [nm]
250 280 336
260 290 334
270 300 334
280 334 510
290 335 530
300 340 550
310 352 566
320 N/A N/A
330 N/A N/A
emission was seen in PHK rafts whilst for the SiHa rafts a corresponding
decrease in ﬂuorescence intensity is visible. This trend was present at lower
excitation wavelengths but was most marked at 300 nm.
11.7 Discussion and Conclusion
The emission spectra in ﬁgures 11.6-11.8 show a large emission peak at 334
to 340 nm, which we attribute to tryptophan ﬂuorescence. This peak is also
the main feature of the emission spectra of DMEM culturing medium, which
clearly contributes to the ﬂuorescence from rafts. Rafts lined with cells show a
much higher emission intensity than collagen and J2 rafts, indicating that the
epithelial cell layer contributes signiﬁcantly to their ﬂuorescence. This enables
the clear identiﬁcation of the presence of epithelial cells on the collagen plug,
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Figure 11.10: Emission intensity scatter plots demonstrating the eﬀect of acetic
acid on the ﬂuorescence spectra of PHK and SiHa rafts at 300 nm excitation.
Filled data points denote the initial emission and outlined data points denote
the emission following the application of 3% acetic acid. Wavelengths were
chosen by PCA.
and is an essential step toward the discrimination between epithelial cell types.
Emission intensity scatter plots provide a simple, visual method for dis-
criminating between raft types. The spectral features that provide the best dis-
crimination were determined systematically by principal component analysis
(PCA). The two most suitable wavelengths were identiﬁed from the ﬁrst prin-
cipal component spectrum and the corresponding emission intensities plotted
in ﬁgure 11.9. The identiﬁcation of just two signiﬁcant emission wavelengths
for a given excitation could ultimately allow the detection of neoplastic tis-
sue with simple apparatus using two-point sampling. Discrimination between
PHK and SiHa rafts was identiﬁed at excitation wavelengths 250 nm to 300
nm. The discrimination at 300 nm improves following the application of acetic
acid, as spectral shifts increasing the diﬀerence between PHK and SiHa clus-
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ters are observed. This is in accordance with observations in clinical practice
and ﬂuorescence studies [180].
The emission region providing best discrimination was found to be the
main emission peak at 334 to 340 nm. The reason for this is not fully under-
stood, but a diﬀerential uptake of medium by the diﬀerent cell lines during raft
culture is conceivable. Similar arguments have been put forward for the dis-
crimination of neoplastic tissue in vivo at higher excitation wavelengths [167].
Here, diﬀerences in metabolic rate and blood supply become signiﬁcant since
they regulate the degree of tissue oxygenation. Our model however does not
model hypoxia in neoplastic tissue as it does not involve a limited blood sup-
ply. While this is a potential limitation of organotypic raft culture, hypoxia
is just one of several biochemical changes that may occur during neoplastic
progression. When using tissue models, it must be established they either ac-
curately mimic the structural and ﬂuorescence properties of biopsy samples,
or else that properties omitted from the model are acknowledged, as above.
Overall, raft culture has a number of important advantages over the
use of biopsy samples: rafts are relatively easy to produce, do not require
detailed ethical and legal consent and provide a system free from many of the
sources of variation in samples from patients (patient age, menstrual status or
inﬂammatory disease). Organotypic epithelial raft culture provides a model of
the cellular structure of normal and neoplastic stratiﬁed squamous epithelium.
This could however not be conﬁrmed for the speciﬁc rafts we measured since
they were damaged before the histology could be conﬁrmed microscopically.
The results of this study demonstrate a clear discrimination between
organotypic raft types modelling normal and pre-cancerous cervical tissue.
This is a useful step towards understanding the spectral properties of tissue
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and identifying speciﬁc changes in biopsy samples. Identiﬁcation of these dif-
ferences may in the long term aid the detection of cervical neoplasia in vivo.
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Summary and Conclusions
The central aim of this work was to develop assays for protein research based
on ﬂuorescence resonance energy transfer (FRET), contributing spectroscopic
methods and equipment, and a physicist's perspective. Aside from this I con-
tributed to a number of collaborative projects, two of which are also described
in this thesis.
The ﬁrst achievement was the development of a FRET-based protein-
protein binding assay, which provides an accurate and sensitive alternative
to conventional methods such as ITC. Furthermore, this approach enables
measurements of small sample volumes in well-plate format and hence repeat
measurements under varying conditions and in the presence of further inter-
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acting compounds. The choice of ﬂuorescent proteins as ﬂuorophores in this
assay provides a convenient labelling for molecular biologists preparing to ap-
ply these methods. Importantly, the presence of labels was shown not aﬀect the
behaviour of tagged proteins in control measurements. The well-characterised
proteins SUMO1 and Ubc9 were used as a model pair in this work. Measure-
ments were also performed on Ubc9 and RanBP2.
Steady-state measurements of ﬂuorescence intensity are the most com-
mon method of FRET detection, and indeed of biomolecular binding events.
However no explicit description of a steady-state protein-protein binding assay
such as presented here is published to our knowledge.
Furthermore we present the ﬁrst quantiﬁcation of binding by time-correlated
single photon counting measurements of the FRET donor lifetime. The results
agree well with the steady-state measurements, while fewer control measure-
ments were required. This makes time-resolved measurements an attractive
alternative.
With the protein-protein binding assays established, we utilised the fact
that FRET reports the proximity of two selected proteins within a complex
system to quantify interactions occuring in a biochemical cascade. The role
of the ligase RanBP2 in the SUMO1 pathway was not fully understood. Pre-
vious work showed that its presence signiﬁcantly enhanced the conjugation of
SUMO1 to target proteins, and that it contained a SUMO1 binding site. Our
work however shows that this site is not active when SUMO1 is not conju-
gated to Ubc9. FRET measurements show that Ubc9 binds both SUMO1 and
RanBP2 individually, but that no stable trimeric complex is formed. Ubc9 has
a strong aﬃnity for RanBP2 and it is thought that it facilitates the removal
of Ubc9 as SUMO1 is conjugated to the target protein. Using two RanBP2
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fragments, we develop a method of quantifying inhibition of protein-protein
binding by the determination of the inhibition constant.
Moving on from measurements of non-covalent interactions, we developed
a FRET-based assay to monitor the conjugation of SUMO1 to target proteins.
While we established this as a method to monitor SUMOylation rates and
validated it by comparison with gel electrophoresis results, it was published
by a competitor group. This emphasises the topical nature of this work with
regards to both SUMO and the development of FRET-based assays.
Our next achievement was the creation of a doubly-tagged SUMO1 con-
struct, which enables quantitative measurements of SUMO1 cleavage by pro-
teases as well as conformational changes upon protease binding. A variety
of applications using this FRET construct were developed, including substrate
and protease characterisation, and most importantly a high-throughput screen
for protease inhibitors. These assays have proven very popular, with numerous
plasmid requests following the publication of a set of applications.
The screening system was implemented in a screen of 2500 potential
anti-cancer drugs for inhibitors of the protease SenP1, which has been linked
to prostate tumour growth. Of these, nine hits demonstrated signiﬁcant inhi-
bition.
A collaboration initiated at the Biophotonics'05 summer school lead to
further interesting protein-protein binding work on SUMO1 and Ubc9, this
time using interferometry measurements of the refractive index of protein so-
lutions instead of FRET. Since this is pioneering work, we found that caution
was required to identify the source of signals. While binding may lead to re-
fractive index changes in a bulk solution, this was not found to be the case for
our two proteins. Instead, mixing eﬀects dominated the observed signals.
183
A further exciting project started as co-supervised undergraduate re-
search work on the detection of the ﬂuorescence signature of cervical pre-cancer
on cultured cell raft models. Initially a project on backscattering spectroscopy,
it was found that ﬂuorescence was a more promising method for identifying
diﬀerences between the near-transparent rafts. Indeed, following a rigorous
analysis by principal component analysis, raft types modelling normal and pre-
cancerous skin can be clearly diﬀerentiated from background measurements
and from each other. This is a promising step towards the discrimination
between healthy and abnormal tissue in vivo.
Several areas of investigation presented here merit further work:
While the protein-protein binding assays work well for the proteins ex-
amined in this work, they should be tested for a variety of proteins of diﬀerent
size, binding aﬃnity and solubility. This would establish how robust these as-
says are for application to other protein systems, and enable the deﬁnition of
upper and lower tolerance limits. In particular the study of binding partners
with a wide range of expected binding constants would be interesting.
While the proteins studied here were readily expressed as ﬂuorescent fu-
sions, this may not be as straightforward with other molecules. The addition
of ﬂexible N- and C-terminal extensions may encourage natural folding and
improve the probe mobility which is crucial in these assays. A range of ex-
pression vectors including the ﬂuorescent proteins as well as a ﬂexible linking
region and a comprehensive multiple cloning site would be a very useful toolkit
for molecular biologists.
Following the FRET-based screen for SenP1 inhibitors and the identi-
ﬁcation of nine hits, further work is required to characterise the nature and
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to quantify the eﬃciency of their inhibition. For this, dose-response measure-
ments should be performed in reducing buﬀers, which would separate general
cysteine inhibitors from compounds which act on the speciﬁc SUMO1/SenP1
binding interface and may hence be desirable anti-cancer medication. Clearly
this work leaves a wake of cellular and in vivo studies, ideally followed by
clinical trials.
Backscattering interferometry is a very sensitive refractive index mea-
surement. Further work is required on many levels in order to complete the
picture of what this technique may oﬀer to molecular biology. Firstly, a the-
oretical examination of the molecular nature of dipole formation and the re-
sulting dielectric properties of protein solutions is required. Work enabling
the projection of an expected refractive index change from protein structures
for example would be helpful in assessing the scale of the signal that can be
expected for a particular protein pair. On the experimental setup, the current
mixing channel on the glass chips is clearly inadequate. While this may have
been overcome in PDMS chips, a careful examination should be carried out
to conﬁrm this. Future work could be performed with index-matched solu-
tions, ideally using a non-interactive molecule to modify the refractive index
of protein solutions.
In vitro studies of tissue are only meaningful when the model is well-
established and shown to be true to nature in the characteristics to be studied.
Organotypic epithelial raft culture is a well-established model for cervical tis-
sue. Our work pioneered its use in ﬂuorescence studies, which merits further
work on the sources of ﬂuorophores, the nature of the changes between normal
and pre-cancerous models as well as, most importantly, a critical comparison
to in vivo data. This however is a sizeable undertaking due to large inter- and
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intra-patient variations in ﬂuorescence, and the reason why the tissue mod-
els were chosen in the ﬁrst place. Successful discrimination in vivo as well
as in vitro could lead to an instantaneous, reliable, cheap and comfortable
alternative to the current smear test.
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Sometimes, if you stand on the bottom rail of a bridge
and lean over to watch the river slipping slowly away beneath you,
you will suddenly know everything there is to be known.
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